Use: Labeled indications
- Treatment of active duodenal ulcer in adults
- Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults
- Treatment of active benign gastric ulcer in adults
- Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older
- Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older
- Pathologic hypersecretory conditions in adults
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Omeprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated for the: Treatment of active duodenal ulcer in adults (1.1) Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults (1.2) Treatment of active benign gastric ulcer in adults (1.3) Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older (1.4) Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older (1.6) Pathologic hypersecretory conditions in adults (1.7) 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks.
Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults.
Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy.
In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology sectio n]. 1.3 Treatment of Active Benign Gastric Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. 1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) Omeprazole delayed-release capsules are indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 2 years of age and older. 1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 2 Years of Age to Adults Omeprazole delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 2 years of age and older.
The efficacy of omeprazole delayed-release capsules used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole delayed-release capsules may be considered. 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD Omeprazole delayed-release capsules are indicated for the maintenance healing of EE due to acid-mediated GERD in patients 2 years of age and older.
Controlled studies do not extend beyond 12 months. 1.7 Pathological Hypersecretory Conditions Omeprazole delayed-release capsules are indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults.
Contraindications
4 CONTRAINDICATIONS Omeprazole delay-release capsules are contraindicated in patients with known hypersensitivity reactions including anaphylaxis to the formulation or any substituted benzimidazol. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions (5.2), Adverse Reactions (6)].
Proton pump inhibitors (PPIs), including omeprazole, are contraindicated in patients receiving rilpivirine-containing products [see Drug Interactions (7)]. For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with omeprazole, refer to the CONTRAINDICATIONS section of their package inserts.
Patients with known hypersensitivity to substituted benzimidazoles or any component of the formulation. (4) Patients receiving rilpivirine-containing products. (4, 7) Refer to the Contraindications section of the prescribing information for clarithromycin and amoxicillin, when administered in combination with omeprazole.
(4)
US FDA labelDosing: Adult
- Indication Recommended Adult (2.1)
- and Pediatric Dosage (2.2)
- Treatment of Active Duodenal Ulcer 20 mg once daily for 4 weeks; some patients may require an additional 4 weeks (2.1)
- H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Omeprazole 20 mg Each drug twice daily for 10 days (2.1)
- 1 Amoxicillin 1000 mg Clarithromycin 500 mg Dual Therapy: Omeprazole 40 mg once daily for 14 days 2 Clarithromycin 500 mg three times daily for 14 days (2.1)
- Active Benign Gastric Ulcer 40 mg once daily for 4 to 8 weeks (2.1)
- Symptomatic GERD 20 mg once daily for up to 4 weeks (2.1)
- See full prescribing information for weight based dosing in pediatric patients 2 years of age and older (2.2)
- EE due to Acid-Mediated GERD 20 mg once daily for 4 to 8 weeks (2.1)
- 3 See full prescribing information for weight based dosing in pediatric patients 2 years of age and older (2.2)
- Maintenance of Healing of EE due to Acid-Mediated GERD 20 mg once daily (2.1)
- 3 See full prescribing information for weight based dosing in pediatric patients 2 years of age and older (2.2)
- Pathological Hypersecretory Conditions Starting dose is 60 mg once daily (varies with individual patient, see full prescribing information) as long as clinically indicated (2.1)
- 1. if ulcer present, continue Omeprazole 20 mg once daily for an additional 18 days. 2. if ulcer present, continue Omeprazole 20 …
2.1 Recommended Adult Dosage Regimen by Indication
2.1 Recommended Adult Dosage Regimen by Indication Table 1 shows the recommended dosage of omeprazole in adult patients by indication. Table 1: Recommended Dosage Regimen of Omeprazole in Adults by Indication Indication Dosage of Omeprazole Treatment Duration Treatment of Active Duodenal Ulcer 20 mg once daily 4 weeks 1 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy Omeprazole 20 mg Amoxicillin 1000 mg Clarithromycin 500 mg Take all three drugs twice daily 10 days In patients with an ulcer present at the time of initiation of therapy, continue omeprazole 20 mg once daily for an additional 18 days for ulcer healing and symptom relief.
Dual Therapy Omeprazole 40 mg once daily Clarithromycin 500 mg three times daily 14 days In patients with an ulcer present at the time of initiation of therapy, an additional 14 days of omeprazole 20 mg once daily is recommended for ulcer healing and symptom relief. Active Benign Gastric Ulcer 40 mg once daily 4 to 8 weeks Treatment of Symptomatic GERD 20 mg once daily Up to 4 weeks Treatment of EE due to Acid-Mediated GERD 20 mg once daily 4 to 8 weeks 2 Maintenance of Healing of EE due to Acid-Mediated GERD 20 mg once daily 3 Controlled studies do not extend beyond 12 months.
Pathological Hypersecretory Conditions Starting dose is 60 mg once daily; adjust to patient needs Daily dosages of greater than 80 mg should be administered in divided doses. Dosages up to 120 mg three times daily have been administered. As long as clinically indicated. Some patients with Zollinger-Ellison syndrome have been treated continuously for more than 5 years. 1 Most patients heal within 4 weeks; some patients may require an additional 4 weeks of therapy to achieve healing 2 The efficacy of omeprazole used for longer than 8 weeks in patients with EE has not been established.
If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole may be considered. 3 Dosage reduction to 10 mg once daily is recommended for patients with hepatic impairment (Child-Pugh Class A, B or C) and Asian patients when used for the maintenance of healing of EE [see Use in Specific Populations (8.6, 8.7) and Clinical Pharmacology (12.3, 12.5)].
2.2 Recommended Pediatric Dosage Regimen by Indication
2.2 Recommended Pediatric Dosage Regimen by Indication Table 2 shows the recommended dosage of omeprazole in pediatric patients by indication. Table 2: Recommended Dosage Regimen of Omeprazole in Pediatric Patients by Indication Indication Omeprazole Dosage Regimen and Duration Patient Age Weight-Based Dose (mg) Regimen and Duration Treatment of Symptomatic GERD 2 to 16 years 10 to less than 20 kg: 10 mg Once daily for up to 4 weeks 20 kg and greater: 20 mg Treatment of EE due to Acid- Mediated GERD 2 to 16 years 10 to less than 20 kg: 10 mg Once daily for 4 to 8 weeks 1 20 kg and greater: 20 mg Maintenance of Healing of EE due to Acid-Mediated GERD 2 to 16 years 10 to less than 20 kg: 10 mg Once daily.
Controlled studies do not extend beyond 12 months 20 kg and greater: 20 mg 1 The efficacy of omeprazole used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole may be considered.
2.3 Administration Instructions
2.3 Administration Instructions Take omeprazole delayed-release capsules before meals. Antacids may be used concomitantly with omeprazole delayed-release capsules. Missed doses: If a dose is missed, administer as soon as possible. However, if the next scheduled dose is due, do not take the missed dose, and take the next dose on time.
Do not take two doses at one time to make up for a missed dose. Omeprazole Delayed-Release Capsules Swallow omeprazole delayed-release capsules whole; do not chew. For patients unable to swallow an intact capsule, omeprazole delayed-release capsules can be opened and administered as follows: Place one tablespoon of applesauce into a clean container (e.g., empty bowl).
The applesauce used should not be hot and should be soft enough to be swallowed without chewing. Open the capsule. Carefully empty all of the pellets inside the capsule on the applesauce. Mix the pellets with the applesauce. Swallow applesauce and pellets immediately with a glass of cool water to ensure complete swallowing of the pellets.
Do not chew or crush the pellets. Do not save the applesauce and pellets for future use.
Dosing: Altered kidney function
Renal Impairment In patients with chronic renal impairment (creatinine clearance between 10 and 62 mL/min/1.73 m²), the disposition of omeprazole was very similar to that in healthy subjects, although there was a slight increase in bioavailability. Because urinary excretion is a primary route of excretion of omeprazole metabolites, their elimination slowed in proportion to the decreased creatinine clearance. This increase in bioavailability is not considered to be clinically meaningful.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.6 Hepatic Impairment In patients with hepatic impairment (Child-Pugh Class A, B, or C) exposure to omeprazole substantially increased compared to healthy subjects. Dosage reduction of omeprazole to 10 mg once daily is recommended for patients with hepatic impairment for maintenance of healing of EE [see Dosage and Administration (2.1), Clinical Pharmacology (12.3)].
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of omeprazole have been established in pediatric patients 2 to 16 years for the treatment of symptomatic GERD, treatment of EE due to acid-mediated GERD, and maintenance of healing of EE due to acid-mediated GERD. Use of omeprazole in this age group is supported by adequate and well-controlled studies in adults and uncontrolled safety, efficacy and pharmacokinetic studies performed in pediatric and adolescent patients [see Clinical Pharmacology (12.3), Clinical Studies (14.8)].
In the pediatric population, adverse reactions of the respiratory system were frequently reported in the entire (2 to 16 year) age group. Accidental injuries were frequently reported in the 2 to 16 year age group [see Adverse Reactions (6.1)]. The safety and effectiveness of omeprazole delayed-release capsules have not been established in: patients less than 1 year of age for: Treatment of symptomatic GERD Maintenance of healing of EE due to acid-mediated GERD pediatric patients for: Treatment of active duodenal ulcer H. pylori eradication to reduce the risk of duodenal ulcer recurrence Treatment of active benign gastric ulcer Pathological hypersecretory conditions patients less than 1 month of age for any indication.
Juvenile Animal Data Esomeprazole, an enantiomer of omeprazole, was shown to decrease body weight, body weight gain, femur weight, femur length, and overall growth at oral doses about 34 to 68 times a daily human dose of 40 mg esomeprazole or 40 mg omeprazole based on body surface area in a juvenile rat toxicity study. The animal to human dose multiples are based on the assumption of equal systemic exposure to esomeprazole in humans following oral administration of either 40 mg esomeprazole or 40 mg omeprazole.
A 28-day toxicity study with a 14-day recovery phase was conducted in juvenile rats with esomeprazole magnesium at doses of 70 to 280 mg/kg/day (about 17 to 68 times a daily oral human dose of 40 mg esomeprazole or 40 mg omeprazole on a body surface area basis). An increase in the number of deaths at the high dose of 280 mg/kg/day was observed when juvenile rats were administered esomeprazole magnesium from postnatal day 7 through postnatal day 35.
In addition, doses equal to or greater than 140 mg/kg/day (about 34 times a daily oral human dose of 40 mg esomeprazole or 40 mg omeprazole on a body surface area basis), produced treatment-related decreases in body weight (approximately 14%) and body weight gain, decreases in femur weight and femur length, and affected overall growth. Comparable findings described above have also been observed in this study with another esomeprazole salt, esomeprazole strontium, at equimolar doses of esomeprazole.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Omeprazole was administered to over 2000 elderly individuals (≥ 65 years of age) in clinical trials in the U.S. and Europe. There were no differences in safety and effectiveness between the elderly and younger subjects. Other reported clinical experience has not identified differences in response between the elderly and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.
Pharmacokinetic studies have shown the elimination rate was somewhat decreased in the elderly and bioavailability was increased. The plasma clearance of omeprazole was 250 mL/min (about half that of young volunteers) and its plasma half-life averaged one hour, about twice that of young healthy volunteers. However, no dosage adjustment is necessary in the elderly [see Clinical Pharmacology (12.3)].
Administration
2.3 Administration Instructions Take omeprazole delayed-release capsules before meals. Antacids may be used concomitantly with omeprazole delayed-release capsules. Missed doses: If a dose is missed, administer as soon as possible. However, if the next scheduled dose is due, do not take the missed dose, and take the next dose on time. Do not take two doses at one time to make up for a missed dose. Omeprazole Delayed-Release Capsules Swallow omeprazole delayed-release capsules whole; do not chew. For patients unable to swallow an intact capsule, omeprazole delayed-release capsules can be opened and administered as follows: Place one tablespoon of applesauce into a clean container (e.g., empty bowl). The applesauce used should not be hot and should be soft enough to be swallowed without chewing. Open the capsule. Carefully empty all of the pellets inside the capsule on the applesauce. Mix the pellets with the applesauce. Swallow applesauce and pellets immediately with a glass of cool water to ensure complete swallowing of the pellets. Do not chew or crush the pellets. Do not save the applesauce and pellets for future use.
US FDA labelDosage forms
Philippines
- Lyophilized powder for injection: 40 mg
- Delayed-release capsule: 10 mg, 20 mg, 40 mg
- Capsule: 10 mg, 20 mg, 40 mg
- Powder for injection: 40 mg
- Lyophilized powder for iv injection: 40 mg
- Powder for solution for injection: 40 mg
- Lyophilized powder for i.v. injection: 40 mg
- Lyophilized powder for intravenous injection/infusion: 20 mg, 40 mg
- Lyophilized powder for iv injection/infusion: 40 mg
- Enteric-coated capsule: 20 mg, 40 mg
and 18 more forms; see the products table.
Registered products in the Philippines
524 products registered with the Food and Drug Administration (FDA) Philippines list Omeprazole as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Omeprazol (1 product). Products registered under these spellings are included in the table and marked.
All registered products524
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AbacidOmeprazole | 20 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 100’s) | Rx | XL Laboratories Pvt. Ltd.India | Marti-Lian Pharma LinkImporter: Ambica International Corporation | DRP-5736 | Sep 22, 2030 | |
AcetorOmeprazole (as sodium monohydrate) | 40 mg Lyophilized Powder for Injection (IV)10 mL amber and transparent USP Type II glass tubular vials sealed with gray butyl rubber stopper and blue aluminum plastic cap + 10 mL USP Type I glass transparent colorless ampoule (Water for Injection as diluent) (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Pharma King DistributorImporter: GPC GEO Pharma Corporation | DRP-12424-02 | Aug 4, 2027 | |
AcidemOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)10 ml Type I Amber Glass Vial Sealed with Grey Bromobutyl Rubber Stopper and Magenta Aluminum Flip-Off Seal Cap x 1's (Box 1's) | Rx | Nitin Lifesciences Ltd. (Unit III)India | Medarruz Pharmaceuticals Philippines Inc.Importer: Pharmakon Biotec Inc. | DRP-13514-02 | Mar 2, 2028 | |
AcifluxOmeprazole (as sodium monohydrate) | 40mg Lyophilized Powder for Injection (IV)10 mL amber and transparent USP Type II glass tubular vials sealed with gray butyl rubber stopper and blue aluminum plastic cap + 10mL USP Type I glass transparent colorless ampoule (Water for Injection as .diluent) [Box of 1’s] | Rx | Reyoung Pharmaceutical Co., Ltd.China | GPC Geo Pharma Corporation | DRP-12424 | Aug 4, 2027 | |
AcifreOmeprazole | 40 mg CapsuleAlu/Alu Blister pack x 8's (Box of 24's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: GX International, Inc. | DR-XY42726 | Oct 2, 2028 | |
AcifreOmeprazole Sodium | 40 mg Lyophilized Powder for InjectionUSP Type I Clear Glass Vial x 10 mL (Box of 1's); USP Type I Clear Glass Vial x 10 mL with 10 mL USP Type I Glass Ampoule containing Sterile Water for Injection (as diluent) in a box | Rx | Furen Pharmaceutical Group Co., LtdChina | Gx International, Inc.Importer: Aglobal Care, Inc. | DRP-5930-09 | Dec 5, 2028 | |
AcifreOmeprazole (as Sodium) | 40 mg Powder for Injection (IV)10 mL colorless USP Type III vial & diluent 10 mL Sterile Water for Injection in plastic FFS Not Applicable | Rx | Gufic Biosciences LimitedIndia | GX International, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-1570-11 | Jul 30, 2031 | |
AcimedOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV injectionOne (1) box contains: USP Type 1 amber glass vial (as active)+ USP Type I Colorless Glass ampoule x 10mL (net content as diluent) | Rx | Alwin DMD PharmaceuticalsIndia | Sigma Pharma Int'l Phils Inc. | DRP-6717 | Jun 2, 2031 | |
AciprazOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Tubular Glass Vial with Gray Bromobutyl Rubber Stopper and Purple Aluminum Flip-Off Seal Cap x 10 mL + 10 mL Sterile Water for Injection in White Polyethylene (PE) Plastic Form-Fill-Seal (FFS) Ampoule (Box of 1's) | Rx | Jodas Expoim Pvt. Ltd.India | Labmate Pharma Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-11492-01 | Mar 17, 2027 | |
AciprazOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP Type I amber glass vial with grey bromobutyl tubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | OM Biomedic Pvt. Ltd.India | Labmate Pharma Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15496-15 | Jul 26, 2029 | |
AciprazOmeprazole (as Sodium) | 40 mg Powder for Injection (I.V.)10 mL colorless USP Type III Vial and Diluent 10 mL Sterile Water for Injection in plastic FFS | Rx | Gufic Biosciences LimitedIndia | Labmate Pharma, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-1570-04 | Jul 31, 2031 | |
AdveprazoleOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl rubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | Om Biomedic Pvt. Ltd.India | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15495-11 | Jul 26, 2029 | |
AeprazoleOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection10 mL-capacity USP Type II amber glass vial with gray butyl rubber stopper and blue aluminum plastic caps + USP Type I transparent glass ampoule x 10 mL water for injection (diluent) [Box of 1's] | Rx | Reyoung Pharmaceutical Co. Ltd.China | Dynasty PharmaceuticalsImporter: Ambicare Pharmaceuticals Inc. | DRP-13236-07 | Jan 6, 2028 | |
AeprazoleOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent (Box of 1 vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Dynasty PharmaceuticalsImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-10 | Dec 27, 2028 | |
Aeprazole 20Omeprazole | 20 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's Box of 30's and 100's | Rx | Stallion Laboratories Pvt. Ltd.India | Dynasty PharmaceuticalsImporter: Ambica International Corporation | DRP-3047-09 | Jun 15, 2029 | |
AezecOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection10mL Amber Tubular Glass Vial Sealed with Butyl Rubber Stopper and Aluminum Flip-off Cap x 1's (Box of 1's); 10mL Amber Tubular Glass Vial Sealed with Butyl Rubber Stopper and Aluminum Flip-off Cap x 1's (Box of 10's) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | Dynasty Pharmaceuticals | DRP-13511 | Feb 1, 2028 | |
AezecOmeprazole (As Sodium) | 40mg Lyophilized Powder for Injection (IV)10 mL Amber Tubular Glass Vial Sealed with Butyl Rubber Stopper and Aluminum Flip-Off Cap x 1's (Box of 1's and 10's) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | Dynasty Pharmaceuticals | DR-XY48594 | Feb 1, 2028 | |
AfreemepOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)Type I Clerar Tubular Glas Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 10 mL + 10 mL Sterile Water for Injection in White Polyethylene (PE) Plastic Form-Fill-Seal (FFS) Ampoule (Box of 1's) | Rx | Jodas Expoim Pvt. Ltd.India | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-11492-10 | Mar 17, 2027 | |
AfreemepOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl tubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | Om Biomedic Pvt. Ltd.India | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15495-05 | Jul 26, 2029 | |
AfreeprazoleOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl tubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | OM Biomedic Pvt. Ltd.India | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15496-10 | Jul 26, 2029 | |
AfricidOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl rubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | Om Biomedic Pvt. Ltd.India | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15496-01 | Jul 26, 2029 | |
AltoprazoleOmeprazole (as Sodium) | 40 mg Powder for Injection (IV)10 mL Colorless USP Type III Vial + Diluent 10 mL Sterile Water for Injection in plastic FFS | Rx | Gufic Biosciences LimitedIndia | Altomed Pharmaceuticals, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-1570-14 | Jul 16, 2031 | |
AltoprazoleOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with Pink Flip-off Seal + 10 mL Sterile Water for Injection as Diluent (Box of 1 Vial + Diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Altomed Pharmaceuticals, Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-36 | Dec 27, 2028 | |
AmbrazoleOmeprazole (As Sodium) | 40 mg Powder For Injection (Iv)Borosilicate Tube Vial with Rubber Stopper and Blue Flip-Off Seal | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-3590 | Jul 14, 2028 | |
AmepzivOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)10 mL-capacity USP Type II amber glass vial with gray butyl rubber stopper and blue aluminum plastic caps + USP Type I transparent glass ampoule x 10 mL water for injection (diluent) (Box of 1's) | Rx | Reyoung Pharmaceutical Co. Ltd.China | Ambica International CorporationImporter: Ambicare Pharmaceuticals Inc. | DRP-13236-01 | Jan 6, 2028 | |
AmfrazoleOmeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10’s (Box of 100’s) | Rx | Jiangxi Xierkangtai Pharmaceutical Co., Ltd.China | Maraki Pharma Co.Importer: Philrx Pharma Inc. | DRP-9420-03 | Dec 5, 2028 | |
AmikaOmeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Curemed Healthcare Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-4887-04 | Nov 4, 2028 | |
AmkomepOmeprazole (as sodium monohydrate) | 40 mg Lyophilized Powder for Injection (I.V.)10 mL amber and transparent USP Type II glass tubular vials sealed with gray butyl rubber stopper and blue aluminum plastic cap + 10 mL USP Type I glass transparent colorless ampoule (Water for Injection as diluent) [Box of 1's] | Rx | Reyoung Pharmaceutical Co., Ltd.China | AMK Pharma International TradingImporter: GPC Geo Pharma Corporation | DRP-12424-06 | Aug 4, 2027 | |
AmprazpOmeprazole (As Sodium) | 40 mg Lyophilized Powder for Injection (IV)10 mL Type I Amber Tubular Glass Vial Sealed with Grey Bromobutyl Rubber Stopper and Blue Flip-Off Seal Cap x 1's (Box 1's and 10's) | Rx | Lyka Labs LimitedIndia | Hexagon Pharmaceuticals | DRP-13446 | Feb 20, 2028 | |
AmsomepOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (I.V.)10 mL USP Type I clear and colorless glass vial + 10 mL USP Type I clear and colorless glass ampoule (0.9 % sodium chloride as solvent) (Box of 1's) | Rx | Aristopharma Ltd.Bangladesh | Amson PharmaceuticalsImporter: Sahar International Trading Inc. | DRP-5041-03 | Jun 27, 2028 | |
AtomezoleOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)10 mL Type I Amber Glass Vial Sealed with Grey Bromobutyl Rubber Stopper and Magenta Aluminum Flip-Off Seal Cap x 1's (Box 1's) | Rx | Nitin Lifesciences Ltd. (Unit III)India | Aton PharmaImporter: Pharmakon Biotec Inc. | DRP-13514-05 | Mar 2, 2028 | |
AvegnirOmeprazole (As Sodium) | 40 mg Lyophilized Powder For IV InjectionUsp Type I Amber Glass Vial With Pink Flip-Off Seal (Box of 1's and 10's) | Rx | Lyka Labs, Ltd.India | Remker Drug, Inc.Importer: Arvincare Pharma Inc. | DRP-2116-01 | Mar 15, 2031 | |
AziblocOmeprazole | 20 mg CapsuleAlu-Alu Strip Foil x 10's (Box of 100''s) | Rx | Bal Pharma Ltd.India | Endure Medical, Inc.Importer: Singapore Genebio, Inc, | DR-XY40198 | Oct 18, 2027 | |
BestpromepOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent (Box of 1 vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Alpace Pharmaceutical DistributorImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-24 | Dec 27, 2028 | |
BlicidOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey amber bromobutyl tubber stopper, aluminum seal and white seal and white flip-off cap (Box of 1's) | Rx | Om Biomedic Pvt. Ltd.India | Bliss Pharma Distribution and Consultancy Corp. | DRP-15496 | Jul 26, 2029 | |
BlissprazoleOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl tubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | OM Biomedic Pvt. Ltd.India | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15495-08 | Jul 26, 2029 | |
BlissprazoleOmeprazole (as sodium) | 40mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Tubular Glass Vial with Gray Bromobutyl Rubber Stopper and Purple Aluminum Flip-Off Seal Cap x 10mL + 10mL Sterile Water for Injection in White Polyethylene (PE) Plastic Form-Fill-Seal (FFS) Ampoule (Box of 1's) | Rx | Jodas Expoim Pvt. Ltd.India | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-11492-02 | Mar 17, 2027 | |
BlomesOmeprazole (as sodium) | 40 mg Lyophilized Powder For Injection (IV Infusion)Type I Clear Tubular Glass Vial with Gray Bromobutyl Rubber Stopper and Purple Aluminum Flip-Off Seal Cap x 10 mL + 10 mL Sterile Water for Injection in White Polyethylene (PE) Plastic Form-Fill-Seal (FFS) Ampoule (Box of 1's) | Rx | Jodas Expoim Pvt. Ltd.India | Bliss Pharma Distribution and Consultancy Corp. | DRP-11492 | Mar 17, 2027 | |
BloxidOmeprazole (as Sodium) | 40 mg Lyophilized Powder for InjectionUSP Type I Amber Glass Vial + USP Type I Clear Glass Ampoule containing 10 mL Sterile Water for Injection (as diluent) in a box | Rx | Gufic Biosciences Ltd.India | SRS Life Sciences Inc. | DRP-5576 | Jun 13, 2028 | |
BlueprazoleOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)10 mL Type II Amber Glass Vial Sealed with Gray Butyl Rubber Stopper and Blue Aluminum Plastic Cap + 10 mL Sterile Water for Injection in Type I Colorless and Transparent Glass Ampoule (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Bluecore Philipppines Inc.Importer: Euro-Care Products Philippines | DRP-12583-02 | Sep 8, 2027 | |
BMEPOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type 1 amber vial with grey bromobutyl rubber stopper, aluminum seal and flip-off cap (as finished product) + polypropylene ampuole of Sterile Water for Injection x 10mL (as diluent) (Box of 1 finished product + 1 diluent) | Rx | Swiss Parenterals Ltd. (Block-B)India | Basicmed Pharma And Medical Supplies TradingImporter: GPC GEO PHARMA CORPORATION | DRP-15591-01 | Aug 7, 2029 | |
BosecOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I Clear and Colorless Glass Vial (for the lyophilized powder) + 10 mL USP Type I Clear and Colorless Glass Ampoule [Diluent 0.9% Sodium Chloride)] in Aluminum PVC Blister Pack (Box of 1's) | Rx | Drug International LimitedBangladesh | Bio Erixx Pharma DisrtributionImporter: Jazmark Pharmaceutical | DRP-6422-05 | Apr 1, 2031 | |
BriandazoleOmeprazole (as sodium monohydrate) | 40 mg Lyophilized Powder for Injection (I.V.)10 mL amber and transparent USP Type II glass tubular vials sealed with gray butyl rubber stopper and blue aluminum plastic cap + 10 mL USP Type I glass transparent colorless ampoule (Water for Injection as diluent) [Box of 1's] | Rx | Reyoung Pharmaceutical Co., Ltd.China | PBD Pharmaceutical Product DistributionImporter: GPC Geo Pharma Corporation | DRP-12424-04 | Aug 4, 2027 | |
BrizolOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I Clear and Colorless Glass Vial (for the lyophilized powder) + 10 mL USP Type I Clear and Colorless Glass Ampoule [Diluent (0.9% Sodium Chloride)] in Aluminum PVC Blister Pack (Box of 1's) | Rx | Drug International LimitedBangladesh | Medko Pharmaceuticals DistributorImporter: Jazmark Pharmaceutical | DRP-6422-08 | Mar 31, 2031 | |
CabxolOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl tubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | OM Biomedic Pvt. Ltd.India | Cabcare PharmaImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-15496-12 | Jul 26, 2029 | |
CaploprazOmeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 100's) | Rx | XL Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-4887 | Nov 4, 2028 | |
CerolOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (I.V.)10 mL USP Type I Amber Glass Vial + Water for Injection (Diluent) in 10 mL Flint ampoule with yellow band snap off Box of 1 vial + 1 ampoule | Rx | Neon Laboratories LtdIndia | Ambica International Corporation | DRP-3684 | Mar 21, 2032 | |
CezoleOmeprazole | 40mg Lyophilized Powder for Injection (IV)10mL USP Type I Amber vial with rubber stopper & Blue flip-off seal + 10mL clear Ampoule Sterile water for injection (Box of 1's) | Rx | Celon Laboratories Private LimitedIndia | I.E. Medica, Inc. | DRP-1499 | Apr 23, 2030 | |
CleazoleOmeprazole | 20 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Clearvue PharmaceuticalImporter: Ambica International Corporation | DRP-3047-01 | Jun 15, 2029 | |
CleazoleOmeprazole (as Sodium) | 40 mg Powder for Injection (I.V.)10 mL colorless USP Type III Vial and Diluent 10 mL Sterile Water for Injection in plastic FFS | Rx | Gufic Biosciences LimitedIndia | Clearvue PharmaceuticalImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-1570-13 | Jul 30, 2031 | |
Cosec 40Omeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I Clear and Colorless Glass Vial (for the lyophilized powder) + 10 mL USP Type I Clear and Colorless Glass Ampoule [Diluent (0.9% Sodium Chloride)] in Aluminum PVC Blister Pack (Box of 1's) | Rx | Drug International LimitedBangladesh | Jazmark Pharmaceutical | DRP-6422 | Mar 4, 2031 | |
Cosec-40Omeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 7's (Box of 28's) | Rx | DRUG INTERNATIONAL LTD.Bangladesh | JAZMARK PHARMACEUTICAL | DRP-5603 | Oct 14, 2028 | |
CyclicOmeprazole (as Sodium) | 40 mg Powder for Injection (I.V.)10 mL Colorless USP Type III Vial & Diluent 10 mL Sterile Water for Injection in Plastic FFS | Rx | Gufic Biosciences LimitedIndia | Ellebasy Medicale TradingImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-1570-05 | Jul 30, 2037 | |
CylicOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with Pink Flip-off Seal + 10 mL Sterile Water for Injection as Diluent (Box of 1 Vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | JJJ Pharmaceutical Marketing Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-19 | Dec 27, 2028 | |
DiaprazOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent Box of 1 vial + diluent | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Titanium PharmaImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-12 | Dec 27, 2028 | |
Diapraz 40Omeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | Titanium PharmaImporter: Ambica International Corporation | DRP-2725-13 | Jan 17, 2028 | |
DonprazoleOmeprazole Sodium | 40 mg Lyophilized Powder for InjectionUSP Type I Clear Glass Vial x 10 mL with 10 mL USP Type I Glass Ampoule containing Sterile Water for Injection (as diluent) in a box (Box of 1's and 10's) | Rx | FUREN PHARMACEUTICAL GROUP CO., LTD.China | DONDESS PHARMA AND MEDICAL SUPPLIES TRADINGImporter: AGLOBAL CARE, INC. | DRP-5930-04 | Dec 5, 2028 | |
EastprazolOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent Box of 1 vial + diluent | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | 228 Pharma TradingImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-11 | Dec 27, 2028 | |
EffeprazOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV InjectionUSP Type I Glass Vial (Box of 1's) | Rx | Harbin Pharmaceutical Group Bioengineering Co., Ltd.China | Sahar Pharmaceuticals DistributionImporter: Sahar International Trading, Inc. | DRP-3943-01 | Apr 15, 2029 | |
ElbazoleOmeprazole | 20 mg Delayed Release CapsuleAlu/Alu Strip Foil x 10’s (Box of 100’s) | Rx | Kopran LimitedIndia | Ellebasy Medicale TradingImporter: Triple Tact Import & Export Corp. | DRP-6949-01 | Dec 14, 2031 | |
ElovianOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Tubular Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cal x 10 mL + 10 mL Sterile Water for Injection in White Polyethylene (PE) Plastic Form-Fill-Seal (FFS) Ampoule (Box of 1's) | Rx | Jodas Expoim Pvt. Ltd.India | Greencore Pharma Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-11492-15 | Mar 17, 2027 | |
EmproOmeprazole | 20 mg capsuleAlu/Alu Blister Pack x 6's Box of 48's | Rx | Biopharma Laboratories LimitedBangladesh | Importer: JF Draf Pharmaceuticals Corp. | DRP-1978 | Dec 1, 2029 | |
EmproOmeprazole | 40 mg capsuleAlu/Alu Blister Pack x 4's (Box of 40's) | Rx | Biopharma Laboratories LimitedBangladesh | Importer: JF Draf Pharmaceuticals Corp. | DRP-1977 | Dec 1, 2029 | |
Emzol 40Omeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection/Infusion10 mL USP Type 1 Amber Glass Vial + 10 mL USP Type 1 Clear and Colorless Glass Ampoule containing Sterile Water for Injection (as Diluent) Box of 1's | Rx | Gufic Biosciences LimitedIndia | Ellebasy Medicale TradingImporter: Suhitas Pharmaceuticals Inc. | DRP-5882-01 | Dec 9, 2027 | |
EnomOmeprazole | 20 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's Box of 100's | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-5904 | Dec 17, 2029 | |
EprozOmeprazole (as Sodium) | 40 mg Lyophilized Powder For Injection (IV)10 mL Type I Amber Glass Vial Sealed with Grey Bromobutyl Rubber Stopper and Magenta Aluminum Flip-Off Seal Cap x 1's (Box 1's) | Rx | Nitin Lifesciences Ltd. (Unit III)India | Pharmakon Biotec, Inc. | DRP-13514 | Mar 2, 2028 | |
EsprazoleOmeprazole Sodium | 40 mg Lyophilized Powder for InjectionUSP Type I Clear Glass Vial x 10 mL with 10 mL USP Type I Glass Ampoule containing Sterile Water for Injection (as diluent) in a Box | Rx | Furen Pharmaceutical Group Co., Ltd.China | Medicamenta Inc.Importer: Aglobal Care, Inc. | DRP-5930-13 | Dec 5, 2028 | |
EzrazoleOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent (Box of 1 vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Biotechnica Medical EnterprisesImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-09 | Dec 27, 2028 | |
FADZfluxOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent (Box of 1 vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Fadz Pharma Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-43 | Dec 27, 2028 | |
FADZoleOmeprazole (as Sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with Pink Flip-Off Seal + 10 mL Sterile Water for Injection as Diluent (Box of 1 vial + Diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Fadz Pharma Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-42 | Dec 27, 2028 | |
FarmazoleOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection/Infusion10 mL USP Type 1 Amber Glass Vial + 10 mL USP Type 1 Clear and Colorless Glass Ampoule containing Sterile Water for Injection (as diluent) Box of 1's | Rx | Gufic Biosciences LimitedIndia | Ellebasy Medicale TradingImporter: Suhitas Pharmaceuticals Inc. | DRP-5882 | Dec 9, 2027 | |
FerazolOmeprazole | 20 mg CapsuleFoil Strip x 10's (Box of 100's) | Rx | J.M. Tolmann Laboratories, Inc.Philippines | HEI Gruppo Pharmaceutica, Inc.Trader: Interhealthcare Pharmaceuticals, Inc. | DRP-1623-01 | Mar 10, 2028 | |
Ferazol ForteOmeprazole | 40 mg CapsuleAlu/Alu Blister Pack x 8's (Box of 24's) | Rx | Lloyd Laboratories, Inc.Philippines | HEI Gruppo Pharmaceutica, Inc.Trader: Vitalink Health Products, Inc. | DRP-6378-07 | Sep 23, 2028 | |
FgzoleOmeprazole | 40 mg Powder for Injection (IV)Amber-colored Glass Vial Box of 10's | Rx | CSPC OUYI PHARMACEUTICALS CO., LTD.China | FIRST GLOBAL TRADING CORPORATION | DR-XY41462 | Dec 12, 2029 | |
FicuzoleOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent Box of 1 vial + diluent | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Euparex Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-15 | Dec 27, 2028 | |
FlazomelOmeprazole | 20 mg CapsuleAlu/Alu blister pack x 10’s Box of 100’s | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DRP-413 | Nov 13, 2027 | |
FlazomelOmeprazole (As Sodium) | 40 mg Lyophilized Powder for IV Injection.10 mL USP Type I Amber Colored Tubular Glass Vial with Grey Bromobutyl Rubber Stopper and Flip-off Seal (Box of 1's and 10's) | Rx | Lyka Labs Limited.India | Hexagon Pharmaceuticals | DRP-13388 | Feb 15, 2028 | |
FluxzolOmeprazole (as sodium monohydrate). | 40 mg Lyophilized Powder for Intravenous InjectionProtect 10 mL-capacity USP Type II Amber glass vial sealed. with grey bromobutyl rubber stopper and aluminum seal with blue flip-off cap in an individual box (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Liforce Industrial Co., Ltd. | DR-XY 48778 | Jun 22, 2028 | |
FrazoleOmeprazole | 20 mg CapsuleAluminum Foil Strip x 10’s (Box of 30’s) | Rx | Zim Laboratories LimitedIndia | Starpharm, Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-526-04 | Nov 17, 2028 | |
Frazole ForteOmeprazole | 40 mg CapsuleAlu/Alu Blister Pack x 4's (Box of 40's) | Rx | Biopharma Laboratories LimitedBangladesh | Biopharma Laboratories LimitedTrader: JF Draf Pharmaceuticals Corp. | DRP-1977-01 | Dec 1, 2029 | |
Frazole-20Omeprazole | 20 mg CapsuleAlu/Alu Blister Pack x 6's (Box of 48's) | Rx | Biopharma Laboratories LimitedBangladesh | Starpharm, Inc.Importer: JF Draf Pharmaceuticals Corporation | DRP-1978-03 | Dec 1, 2029 | |
Furecid IVOmeprazole (As Sodium) | 40 mg Lyophilized Powder for Injection (I.V.)Type I clear colorless vial with blue aluminum flip off seal and rubber stopper (Box of l’s) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Pharmakon Biotech Inc. | DRP-12118 | Jun 14, 2027 | |
G-PrazOmeprazole | 40 mg CapsuleAlu/Alu Blister Pack x 4's (Box of 40's) | Rx | Biopharma Laboratories LimitedBangladesh | Pharmasilv TradingImporter: Jf Draf Pharmaceuticals Corp. | DRP-1977-06 | Dec 1, 2029 | |
GaspizolOmeprazole Sodium | 40 mg Lyophilized Powder for InjectionUSP Type I Clear Glass Vial x 10 mL (Box of 1's and 10's); USP Type I Clear Glass Vial x 10mL with 10 mL USP Type 1 Glass Ampoule containing Sterile Water for Injection (as diluent) in a Box (Box of 1's and 10's) | Rx | FUREN PHARMACEUTICAL GROUP CO., LTD.China | MEDGEN M5 PHARMACEUTICAL, INC.Importer: AGLOBAL CARE, INC. | DRP-5930-07 | Dec 5, 2028 | |
GastomeOmeprazole | 20 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Zim Laboratories Limited441501 India | Medethix, Inc.Importer: I.E. Medica, Inc. | DRP-9652 | Apr 26, 2031 | |
Gastrec 20Omeprazole | 20 mg Delayed-Release CapsuleAluminum Strip Foil x 10’s (Box of 50’s) | Rx | Hizon Laboratories, Inc.Philippines | Trader: S.V. MORE PHARMA CORPORATION | DRP-7916 | Jan 5, 2031 | |
Gastrec 40Omeprazole | 40 mg Delayed-Release CapsuleStrip Foil x 10’s (Box of 50’s) | Rx | Hizon Laboratories, Inc.Philippines | Trader: S.V. MORE PHARMA CORPORATION | DRP-8118 | Jan 5, 2031 | |
Gastri-XOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)10 mL Type II Transparent Amber color Tubular Glass Vial Sealed with Grey Butyl Rubber Stopper and Flip-Off Seal Cap x 1's (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | H & B Pharma International Inc.Importer: Pharmaessence, Inc. | DRP-13545-02 | Mar 8, 2028 | |
GastrivOmeprazole | 40 mg Delayed Release CapsuleStrip Foil of 10’s (Box of 50’s) | Rx | Hizon Laboratories, Inc.Philippines | Crisdy-Na Drug CorporationTrader: S.V. More Pharma Corporation | DRP-8118-02 | Dec 8, 2031 | |
GastrothekOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with bromobutyl tubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | Om Biomedic Pvt. Ltd.India | RH Pharma and Medical Supplies DistributionImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-15495-09 | Jul 26, 2029 | |
GastrovaineOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Tubular Glass Vial with Gray Bromobutyl Rubber Stopper and Purple Aluminum Flip-Off Seal Cap x 10 mL + 10 mL Sterile Water for Injection in White Polyethylene (PE) Plastic Form-Fill-Seal (FFS) Ampoule (Box of 1's) | Rx | Jodas Expoim Pvt. Ltd.India | Pharmaine Pharmaceutical Products DistributionImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-11492-06 | Mar 17, 2027 | |
GazoOmeprazole (as sodium) | 20 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Harmann Pharmaceutical Laboratories (Pvt) Ltd.Pakistan | Raquel Abbas Pharmaceuticals and General Merchandise | DR-XY41443 | Dec 7, 2027 | |
GazoOmeprazole (as sodium) | 20 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Harmann Pharmaceutical Laboratories (Pvt) Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-17064 | Dec 7, 2027 | |
GemzoleOmeprazole Sodium | 40 mg Lyophilized Powder for InjectionUSP Type I Clear Glass Vial x 10 mL (Box of 1's and 10's); USP Type I Clear Glass Vial x 10 mL with 10 mL USP Type I Glass Ampoule containing Sterile Water for Injection (as diluent) in a Box | Rx | FUREN PHARMACEUTICAL GROUP CO., LTD.China | EURO-CARE PRODUCTS PHILIPPINESImporter: AGLOBAL CARE, INC. | DRP-5930-01 | Dec 5, 2028 | |
Gemzole PlusOmeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 7's (Box of 70's) | Rx | Medisure Laboratories Pakistan (Pvt.) LimitedPakistan | Euro-Care Products PhilippinesImporter: Accesspoint International Trading Inc. | DRP-6027-06 | Feb 27, 2030 | |
Gemzole-20Omeprazole | 20 mg Delayed Release CapsuleAlu/Alu strip foil x 10’s (Box of 100’s) | Rx | Kopran LimitedIndia | Euro-Care Products PhilippinesImporter: Triple Tact Import & Export Corp. | DRP-6949-03 | Dec 14, 2031 | |
GenpramepOmeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's Box of 30's | Rx | Curemed Healthcare Pvt. Ltd.India | Generics Pharmacal Phils. Inc.Importer: Ambica International Corporation | DRP-4887-01 | Nov 4, 2028 | |
GenzoleOmeprazole | 20 mg CapsuleFoil Strip x 10's (Box of 100's) | Rx | J.M. Tolmann Laboratories, Inc.Philippines | Basic Pharmaceutical CorporationTrader: Interhealthcare Pharmaceuticals Inc. | DRP-1623-09 | Mar 10, 2028 | |
GenzoleOmeprazole Sodium | 40 mg Lyophilized Powder for InjectionUSP Type I Clear Glass Vial x 10 mL (Box of 1's and 10's); USP Type I Clear Glass Vial x 10 mL with 10 mL USP Type I Glass Ampoule containing Sterile Water for Injection (as diluent) in a Box | Rx | Furen Pharmaceutical Group Co., Ltd.China | Basic Pharmaceutical CorporationImporter: Aglobal Care, Inc. | DRP-5930-16 | Dec 5, 2028 | |
GenzoleOmeprazole (as Sodium) | 40 mg Powder for Injection (I.V.)Colorless USP Type III vial x 10 mL & Sterile Water for Injection as diluent in Plastic FFS x 10 mL (Box of 1's) | Rx | Gufic Biosciences LimitedIndia | Basic Pharmaceutical CorporationImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-1570-20 | Jul 16, 2031 | |
GeoprazoleOmeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | GPC Geo Pharma CorporationImporter: Ambica International Corporation | DRP-2725-12 | Jan 17, 2028 | |
GeoprazoleOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent (Box of 1 vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | GPC Geo Pharma CorporationImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-03 | Dec 27, 2028 | |
Gezole 40Omeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | Pharmasilv TradingImporter: Ambica International Corporation | DRP-2725-14 | Jan 17, 2028 | |
GiozoleOmeprazole (As Sodium) | 40mg Lyophilized Powder for Injection (IV Infusion)10 mL Type II Amber Glass Vial Sealed with Gray Butyl Rubber Stopper and Blue Aluminum Plastic Cap + 10 mL Sterile Water for Injection in Type I Colorless and Transparent Glass Ampoule (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Euro-Care Products Philippines | DRP-12583 | Sep 8, 2027 | |
GiprazoleOmeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Sapphire Lifesciences Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc. | DRP-12788-04 | Oct 7, 2027 | |
GizolOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I Clear and Colorless Glass Vial (for the Lyophilized Powder) + 10 mL USP Type I Clear and Colorless Glass Ampoule [Diluent (0.9% Sodium Chloride)] in Aluminum PVC Blister Pack (Box of 1's) | Rx | Drug International LimitedBangladesh | Gijun Trading Inc.Importer: Jazmark Pharmaceutical | DRP-6422-06 | Apr 5, 2031 | |
GizolOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent (Box of 1 vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Gijun Trading Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-47 | Dec 27, 2028 | |
Go-mepOmeprazole (as Sodium) | 40 mg Powder for Injection (IV)10 mL USP Type I clear glass vial with rubber stopper and blue flip off seal with Water for Injection (Type I Clear Colorless Glass Ampoule x 10 mL) (Box of 1’s and 10’s) | Rx | Cspc Ouyi Pharmaceutical Co. Ltd.China | Applied Pharmaceutical Distribution IncImporter: Amb HK Enterprises Inc. | DRP-8396-10 | Nov 19, 2028 | |
Gom-EPOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)10 mL Type I Clear Glass Vial sealed with gray bromobutyl rubber stopper and blue aluminum Flip-Off seal cap x 1's (Box of 1's) + 10 mL Sterile Water for Injection in USP Type I Colorless and Transparent Glass Ampoule (diluent) | Rx | Reyoung Pharmaceutical Co., LtdChina | Applied Pharmaceutical Distribution Inc.Importer: PhilRx Pharma Inc. | DRP-13351-01 | Feb 2, 2028 | |
Gomep IVOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)10 mL Type II Amber Glass Vial Sealed with Gray Butyl Rubber Stopper and Blue Aluminum Plastic Cap + 10 mL Sterile Water for Injection in Type I Colorless and Transparent Glass Ampoule (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Go Healthcare Pharmaceutical DistributionImporter: Euro-Care Products Philippines | DRP-12583-07 | Sep 8, 2027 | |
Gomep IVOmeprazole (as sodium) | 40mg Powder for Injection (I.V.)10 mL capacity USP Type II amber colored Clear Glass Vial with Gray Butyl Rubber stopper and blue aluminum plastic cap x 10mL (Box of 1's) | Rx | Reyoung Pharmaceutical Co. Ltd.China | Go Healthcare Pharmaceutical DistributionImporter: Medinova Pharmaceutical Inc. | DRP-12554-01 | Sep 1, 2027 | |
GomeprazoleOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent (Box of 1 vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-17 | Dec 27, 2028 | |
GOMEZOLEOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type 1 tubular glass vial with rubber stopper and flip off cap (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Applied Pharmaceutical Distribution Inc.Importer: AMB HK Enterprises Inc. | DRP-9122-02 | Oct 20, 2031 | |
GomezoleOmeprazole (as Sodium) | 40 mg Powder for Injection (IV)Borosilicate Tube Vial with Rubber Stopper and Blue Flip-Off Seal (Box of 10's) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | Applied Pharmaceutical Distribution Inc.Importer: AMB HK Enterprises Inc. | DRP-3590-07 | Jul 14, 2028 | |
GopracidOmeprazole (as sodium) | 40mg Lyophilized Powder for Injection (I.V.)USP Type I amber vial with grey bromobutyl rubber stopper, aluminum seal and flip off-cap (as finished product) polypropylene ampoule of Sterile Water + for Injection x 10 mL (as diluent) (Box of 1 finished product + 1 diluent) | Rx | Swiss Parenterals Ltd. (Block B)India | GPC Geo Pharma Corporation. | DRP-15591 | Aug 7, 2029 | |
Gopraz IVOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent Box of 1 Vial + Diluent | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-26 | Dec 27, 2028 | |
GoprazoleOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent (Box of 1 vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | JJJ Pharmaceutical Marketing Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-04 | Dec 27, 2028 | |
Gozol IVOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with Pink Flip-off Seal + 10 mL Sterile Water for Injection as Diluent (Box of 1 Vial + Diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-27 | Dec 27, 2028 | |
GrexoleOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)10 mL Type I Amber Glass Vial Sealed with Grey Bromobutyl Rubber Stopper and Magenta Aluminum Flip-Off Seal Cap x 1's (Box 1's) | Rx | Nitin Lifesciences Ltd. (Unit III)India | Greentech Life Sciences Inc.Importer: Pharmakon Biotec Inc. | DRP-13514-03 | Mar 2, 2028 | |
GrozoleOmeprazole (as sodium) | 40 mg Powder for Injection (I.V.)10 mL-capacity USP Type II amber glass vial with gray butyl rubber stopper and aluminum seal with blue plastic flip-off cap + USP Type I clear and colorless glass ampoule containing 10 mL Sterile Water for Injection as diluent (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Go-Life PharmaImporter: Dreamax Incorporated | DRP-14850-03 | Jan 24, 2029 | |
HaizoleOmeprazole | 20 mg Delayed Release CapsuleAlu/Alu Strip Foil x 10’s (Box of 100's) | Rx | Kopran LimitedIndia | JJJ Pharmaceutical Marketing Inc.Importer: Triple Tact Import & Export Corp | DRP-6949-06 | Dec 14, 2031 | |
HaizoleOmeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 7's (Box of 70's) | Rx | Medisure Laboratories Pakistan (Pvt.) LimitedPakistan | Greencore Pharma Inc.Importer: Accesspoint International Trading, Inc. | DRP-6027-01 | Feb 27, 2030 | |
HelizolOmeprazole | 20 mg CapsuleFoil Strip x 10's (Box of 100's) | Rx | J.M. Tolmann Laboratories Inc.Philippines | Medirich Pharma Distribution Corp.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1623-06 | Mar 10, 2028 | |
HovizolOmeprazole | 20 mg CapsuleAlu-Alu Blister Pack x 7's Box of 28's | Rx | Hovid Bhd.Malaysia | Hovid, Inc. | DRP-1219 | Feb 21, 2028 | |
Hycid-20Omeprazole | 20 mg CapsuleAlu/Alu Blister Pack x 10's Box of 30's | Rx | XL Laboratories Pvt. Ltd.India | Rilem Pharma Corp.Importer: Ambica International Corporation | DRP-1313 | Oct 20, 2030 | |
Hycid-40Omeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | XL Laboratories Pvt. Ltd.India | Rilem Pharma Corp.Importer: Ambica International Corporation | DRP-2725 | Jan 17, 2028 | |
HyperzolOmeprazole | 40 mg Delayed-Release Capsule2 Alu/PVC Blister Pack x 7's Enclosed in PET/Alu/PE Pouch (2 Pouches per Box of 28's) | Rx | Jiangsu Pengyao Pharmaceutical Co., Ltd.China | Global PharmatradeTrader: Mecechem (Wuxi) Co., Ltd. | DR-XY44636 | Jun 23, 2030 | |
HyperzolOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I Clear Glass Vial + 10mL LDPE Vial (Water for Injection as Diluent) in a Box (Box of 1’s) | Rx | Jiangsu Kingsley Pharmaceutical Co., Ltd.China | Global PharmatradeTrader: Mecechem (Wuxi) Co., Ltd. | DRP-5071 | Sep 21, 2032 | |
HyzolOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I Tubular Glass Vial with Butyl Rubber Stopper and Flip-Off Cap (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Sanimed Pharmaceuticals Inc. | DRP-8747 | Feb 21, 2030 | |
InhibitaOmeprazole | 40 mg Enteric Coated CapsuleAlu/Alu Blister Pack x 4's (Box of 20's and 100's) | Rx | Delta Pharma Ltd.Bangladesh | Biomed Pharma, Inc. | DR-XY39212 | Mar 23, 2029 | |
InobyOmeprazole (as Sodium) | 40 mg Powder for Injection (I.V.)10 mL colorless USP Type III Vial and Diluent 10 mL Sterile Water for Injection in plastic FFS Not Applicable | Rx | Gufic Biosciences LimitedIndia | Clearvue PharmaceuticalImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-1570-07 | Jul 30, 2031 | |
InobyOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent (Box of 1 vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | CV Clearvue Pharma, Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-44 | Dec 27, 2028 | |
JaczoleOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Tubular Glass Vial with Gray Bromobutyl Rubber Stopper and Purple Aluminum Flip-Off Seal Cap x 10mL + 10mL Sterile Water for Injection in White Polyethylene (PE) Plastic Form - Fill - Seal (FFS) Ampoule (Box of 1's) | Rx | Jodas Expoim Pvt. Ltd.India | Jackson Pharmaceuticals Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-11492-03 | Mar 17, 2027 | |
JaczoleOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV injection10 mL USP Type I amber glass vial with grey bromobutyl tubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | Om Biomedic Pvt. Ltd.India | Jackson Pharmaceuticals Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15495-01 | Jul 26, 2029 | |
JiaaprazoleOmeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Jiangxi Xierkangtai Pharmaceutical Co., Ltd.China | Jiaa PharmaImporter: PhilRx Pharma Inc. | DRP-9420-02 | Dec 5, 2028 | |
JumepOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I Clear and Colorless Glass Vial (for the lyophilized powder) + 10 mL USP Type I Clear and Colorless Glass Ampoule [Diluent (0.9% Sodium Chloride)] in Aluminum PVC Blister Pack (Box of 1's) | Rx | Drug International LimitedBangladesh | Jusan Pharmaceuticals Distributor & SupplyImporter: Jazmark Pharmaceutical | DRP-6422-16 | Apr 5, 2031 | |
KairozolOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent Box of 1 vial + diluent | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Pharmacom DistributionImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-05 | Dec 27, 2028 | |
KinmeprazoleOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Tubular Glass Vial with Gray Bromobutyl Rubber Stopper and Purple Aluminum Flip-Off Seal Cap x 10 mL + 10 mL Sterile Water for Injection in White Polyethylene (PE) Plastic Form-Fill-Seal (FFS) Ampoule (Box of 1's) | Rx | Jodas Expoim Pvt. Ltd.India | Kinmed Healthcare Trading Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-11492-04 | Mar 17, 2027 | |
KinmeprazoleOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Tubular Glass Vial with Gray Bromobutyl Rubber Stopper and Purple Aluminum Flip-Off Seal Cap x 10 mL + 10 mL Sterile Water for Injection in White Polyethylene (PE) Plastic Form-Fill-Seal (FFS) Ampoule (Box of 1's) | Rx | Jodas Expoim Pvt. Ltd.India | Kinmed Healthcare Trading Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-11492-05 | Mar 17, 2027 | |
KinmeprazoleOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromomobutyl tubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | Om Biomedic Pvt. Ltd.India | Kinmed Healthcare Trading Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15495-04 | Jul 26, 2029 | |
KodazolOmeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 70's and 100's) | Rx | Medisure Laboratories Pakistan (Pvt.) LimitedPakistan | Kodapharm Med Corp.Importer: Accesspoint International Trading Inc. | DRP-6027-07 | Feb 27, 2030 | |
KomprazOmeprazole | 10 mg Delayed-release CapsuleAlu/Alu Blister Pack x 8's (Box of 16's, 24's and 80's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Konzept Convenience And Drug Store Corp. | DRP-6638-01 | Apr 12, 2031 | |
KomprazOmeprazole | 20 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 8's (Box of 16's, 24's and 80's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Konzept Convenience and Drug Store Corp. | DRP-6639-01 | Apr 12, 2031 | |
Ladazol 40Omeprazole | 40 mg CapsuleAlu Strip Foil x 10's (Box of 100's) | Rx | Windlas Biotech LimitedIndia | Grovic Pharma Inc. | DRP-3016 | Jun 2, 2028 | |
LeveprazOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I amber vial with grey bromobutyl rubber stopper, aluminum seal and flip off - cap (as finished product) + polypropylene ampoule of Sterile Water for Injection x 10 mL (as diluent) (Box of 1 finished product + 1 diluent) | Rx | Swiss Parenterals Ltd. (Block-B)India | HLM Pharmaceutical Inc.Importer: GPC Geo Pharma Corporation | DRP-15591-07 | Aug 7, 2029 | |
LeveprazoleOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with Pink Flip-off Seal + 10 mL Sterile Water for Injection as Diluent (Box of 1 Vial + Diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | HLM Pharmaceutical Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-37 | Dec 27, 2028 | |
Leveprazole-40Omeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | HLM Pharmaceutical Inc.Importer: Ambica International Corporation | DRP-2725-19 | Jan 17, 2028 | |
Life-ZolOmeprazole (as Sodium) | 40 mg Powder for Injection (IV)Borosilicate Tube Vial with Rubber Stopper and Blue Flip-Off Seal (Box of 10's) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | Life and Health Source Pharmaceutical Distribution Co.Importer: AMB HK Enterprises Inc. | DRP-3590-08 | Jul 14, 2028 | |
LosecOmeprazole | 10 mg CapsuleAlu/Alu blister pack x 7's (Box of 14's) | Rx | Astrazeneca ABSweden | ZUELLIG PHARMA CORPORATION | DR-XY18046 | Feb 15, 2029 | |
LourzoleOmeprazole | 40mg Lyophilized Powder for Injection (IV)10 mL-capacity USP type I amber glass vial with bromo butyl rubber stopper and aluminum flip-off seal and FFS ampoule x 10 mL for sterile water for injection (diluent) [in one box] (Box of 1's) | Rx | Med Biopharm Pvt. Ltd.India | Lourbon Pharma DistributorImporter: Pors Pharma Trading | DRP-17355-02 | Oct 24, 2031 | |
Malprazole PlusOmeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 7's Box of 70's | Rx | Medisure Laboratories Pakistan (Pvt.) LimitedPakistan | Malyka International Trading Corp.Importer: Accesspoint International Trading Inc. | DRP-6027-03 | Feb 26, 2030 | |
MarprazoleOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with Pink Flip-off Seal + 10 mL Sterile Water for Injection as Diluent (Box of 1 Vial + Diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Sanoviz Pharmaceutical Products TradingImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-21 | Dec 27, 2028 | |
MarzoleOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I Clear and Colorless Glass Vial (for the lyophilized powder) + 10 mL USP Type I Clear and Colorless Glass Ampoule [Diluent (0.9% Sodium Chloride)] in Aluminum PVC Blister Pack (Box of 1's) | Rx | Drug International LimitedBangladesh | Jhisreh Medica Co., Ltd.Importer: Jazmark Pharmaceutical | DRP-6422-04 | Apr 1, 2031 | |
MazoleOmeprazole | 20 mg CapsuleFoil Strip x 10's (Box of 20's) | Rx | Lloyd Laboratories, Inc.Philippines | Metz Pharmaceuticals, Inc.Trader: Vitalink Health Products, Inc. | DRP-716-03 | Dec 13, 2029 | |
MediprazoleOmeprazole | 20mg Delayed-Release CapsuleAlu/Alu Foil Strip Pack x 10's (Box of 100's) | Rx | ACME Formulation Pvt. Ltd.India | Medinova Pharmaceutical, Inc. | DRP-10810 | Nov 26, 2026 | |
MedizolOmeprazole | 40 mg Lyophilized Powder for Injection (IV)USP Type I Amber Vial w/ Rubber Stopper & Blue Flip-Off Seal x 10 mL Clear Ampoule Sterile Water for Injection (Box of 1's) | Rx | Celon Laboratories Private LimitedIndia | Euro-Health Care Exponents, Inc.Importer: I.E. Medica, Inc. | DRP-1499-13 | Jan 14, 2032 | |
MEDIZOLOmeprazole (as sodium) | 40mg Powder for Solution for injection (IV)10mL USP Type I Amber glass vial + 10ml Ampoule diluent (Box of 1's) | Rx | Scott Edil Pharmacia Ltd.India | Euro-Health Care Exponents, Inc.Importer: I.E. Medica, Inc.Trader: I-Care Formulations | DRP-8557-06 | Oct 6, 2027 | |
Medprazol IVOmeprazole (Sodium) | 40mg Powder For Injection (IV)10 mL-capacity USP Type II amber colored Clear Glass Vial with Gray Butyl Rubber stopper and blue aluminum plastic cap x 10 mL(Box of 1's) | Rx | Reyoung Pharmaceutical Co. Ltd.China | Medinova Pharmaceutical Inc. | DRP-12554 | Sep 1, 2027 | |
MedruszoleOmeprazole ( as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)10 mL Type II Amber Glass Vial Sealed with Gray Butyl Rubber Stopper and Blue Aluminum Plastic Cap + 10 mL Sterile Water for Injection in Type I Colorless and Transparent Glass Ampoule (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Med R Us Pharma and Medical Supplies DistributionImporter: Euro-Care Products Philippines | DRP-12583-06 | Sep 8, 2027 | |
MegaprazOmeprazole | 20 mg CapsuleFoil Strip x 4's (Box of 4's); Foil Strip x 6's (Box of 30's) | Rx | Drugmaker's Laboratories, Inc.Philippines | Terramedic, Inc. | DRP-570-02 | Dec 7, 2027 | |
MeolifeOmeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack Of 10's (Box of 30's) | Rx | Innovative HealthcareIndia | Biophil Medical Equipment And Supplies Trading | DRP-18435 | Jul 9, 2031 | |
Mep-40Omeprazole | 40 mg CapsuleAluminum Foil Strip x 6's (Box of 30's) | Rx | Hizon Laboratories, Inc.Philippines | Pharma Dynamic, Inc. | DRP-4769-01 | Jul 29, 2029 | |
MepazoleOmeprazole | 20 mg CapsuleAluminum Foil Strip x 10’s (Box of 100’s) | Rx | Unique Pharmaceutical Laboratories (A Division of J.B. Chemicals & Pharmaceuticals Limited)India | Qualifirst Health IncImporter: Ambica International Corporation | DRP-843-04 | Feb 5, 2029 | |
MepracidOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)10ml-capacity amber tubular vial with flip-off cap and butyl rubber stopper (Box of 1's) | Rx | Reyoung Pharmaceutical Co. Ltd.China | EuroAsia Pharmaceuticals Inc. | DRP-12538 | Aug 31, 2037 | |
Mepracid 40Omeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30’s) | Rx | Mediwin PharmaceuticalsIndia | EuroAsia Pharmaceuticals, Inc.Trader: Tunic Healthcare | DRP-11713 | Apr 20, 2032 | |
Mepral 20Omeprazole | 20 mg CapsuleFoil Strip x 10’s (Box of 100’s) | Rx | Nabros Pharma Pvt. Ltd.India | PH Phil Asia Medica Co.Importer: Ambica International Corporation | DRP-6303-02 | Dec 14, 2031 | |
MepranexOmeprazole (as sodium) | 40 mg Lyophilized Powder for Intravenous Injection/Infusion10 mL Type I glass vial with rubber stopper and flip-off seal (drug product) + 10 mL Type I glass ampoule (Sterile water for injection as diluent) (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | D'Conner PharmaImporter: Sanimed Pharmaceuticals Inc. | DRP-11700-03 | Apr 25, 2027 | |
MeprarichOmeprazole Sodium | 40 mg Lyophilized Powder for InjectionUSP Type I Clear Glass Vial x 10 mL (Box of 1's and 10's); USP Type I Clear Glass Vial x 10 mL with 10 mL USP Type I Glass Ampoule containing Sterile Water for Injection (as diluent) in Box | Rx | Furen Pharmaceutical Group Co., Ltd.China | Medirich Pharma Distribution Corp.Importer: AGlobal Care, Inc. | DRP-5930-15 | Dec 5, 2028 | |
MeprazOmeprazole | 20 mg Delayed Release CapsuleAluminum Strip Foil of 10’s (Box of 50’s) | Rx | Hizon Laboratories, Inc.Philippines | The Cathay Drug Co., Inc.Trader: S.V. More Pharma Corporation | DRP-7916-01 | Nov 9, 2031 | |
MeprazOmeprazole | 40 mg Delayed Release CapsuleStrip Foil of 10’s (Box of 50’s) | Rx | Hizon Laboratories, Inc.Philippines | The Cathay Drug Co., Inc.Trader: S.V. More Pharma Corporation | DRP-8118-01 | Dec 8, 2031 | |
Mepraz IVOmeprazole (as Sodium) | 40mg Powder for injection (I.V.)10ml-Capacity USP Type II Amber Glass Vial with gray butyl rubber stopper and aluminum seal with blue plastic flip-off cap + USP Type I clear and colorless glass ampoule containing 10ml Sterile Water for Injection as diluent (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | The Cathay Drug Co., Inc.Importer: Dreamax Incorporated | DRP-14850-04 | Jan 24, 2029 | |
MeprazolOmeprazole | 20 mg CapsuleAlu/White PVC Blister Pack of 7's Box of 14's | Rx | The United Drug (1996) Co., Ltd.Thailand | Endure Medical, Inc.Importer: Singapore Genebio, Inc. | DR-XY41002 | Jun 29, 2027 | |
MepzocapOmeprazole | 20 mg CapsuleAluminum Foil Strip x 10’s (Box of 100's) | Rx | Unique Pharmaceutical Laboratories (A Division of J.B. Chemicals & Pharmaceuticals Limited)India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-843-02 | Feb 5, 2029 | |
MepzolOmeprazole | 20 mg CapsuleFoil Strip x 10's (Box of 100's) | Rx | J.M. Tolmann Laboratories, Inc.Philippines | Altomed Pharmaceuticals, Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1623-07 | Mar 10, 2028 | |
MepzolOmeprazole | 40 mg CapsuleAlu/Alu Blister Pack x 8's (Box of 24's) | Rx | Lloyd Laboratories, Inc.Philippines | Altomed Pharmaceuticals, Inc.Trader: Vitalink Health Products, Inc. | DRP-6378-05 | Sep 30, 2028 | |
MepzoprazOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with Pink Flip-off Seal + 10 mL Sterile Water for Injection as Diluent (Box of 1 Vial + Diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Decano Drug Distribution ServicesImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-20 | Dec 27, 2028 | |
Merazol 40Omeprazole (as Sodium) | 40 mg Lyophilized Powder For I.V. InjectionUSP Type I Amber Glass Vial with Pink Flip-Off Seal (Box of 1's and 10's) | Rx | Lyka Labs LimitedIndia | Arvincare Pharma Inc. | DRP-2116 | Feb 11, 2030 | |
MerkprazOmeprazole (as sodium) | 40 mg Lyophilized Powder for I.V. InjectionUSP Type I Glass Vial (Box of 1's) | Rx | Harbin Pharmaceutical Group Bioengineering Co., Ltd.China | Merkchem Pharma, Inc.Importer: Sahar International Trading, Inc. | DRP-3943-02 | Apr 15, 2029 | |
MexxOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent Box of 1 vial + diluent | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Sanitas PharmaceuticalsImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-40 | Dec 27, 2028 | |
MizzoleOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)20 mL Type I Amber Glass Vial Sealed with Gray Butyl Rubber Stopper and Blue Flip-Off Cap and Aluminum Seal x 1's (Box of 1's) | Rx | Sanjar Pharma LLPIndia | Aglobal Care, Inc. | DRP-13293 | Jan 18, 2028 | |
Ml-GacidOmeprazole | 20 mg Delayed-Release CapsuleAlu/Alu Foil Strip Pack x 10's (Box of 100's) | Rx | Milan Laboratories Private LimitedIndia | Khriz Pharma Trading, Inc. | DR-XY47949 | Apr 20, 2027 | |
Morzole-40Omeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)Type III Clear Glass Vial Sealed with Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal Cap x l's (Box of 1's) | Rx | Mason PharmaIndia | Finstad, Inc. | DRP-11022 | Apr 29, 2027 | |
NahazoleOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (I.V.)10 mL USP Type I clear and colorless glass vial + 10 mL USP Type I clear and colorless glass ampoule (0.9% sodium chloride as diluent) (Box of 1's) | Rx | Aristopharma Ltd.Bangladesh | Nahal PharmaceuticalImporter: Sahar International Trading Inc. | DRP-5041-02 | Jun 27, 2028 | |
NeoverzolOmeprazole (as Sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with Pink Flip-off Seal + 10 mL Sterile Water for Injection as Diluent Box of 1 Vial + Diluent | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Neo-Care PhilippinesImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-25 | Dec 27, 2028 | |
NewpronOmeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | United Pharma Plus (Unipharma),Inc.Importer: Ambica International Corporation | DRP-2725-10 | Jan 17, 2028 | |
Newpron 40Omeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I amber vial with grey bromobutyl rubber stopper, aluminum seal and flip off-cap (as finished product) + polypropylene ampoule of Sterile Water for Injection x 10 mL (as diluent) (Box of 1 finished product + 1 diluent) | Rx | Swiss Parenterals Ltd. (Block-B)India | United Pharma Plus (UNIPHARMA) Inc.Importer: GPC Geo Pharma Corporation | DRP-15591-05 | Aug 7, 2029 | |
NicoproOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent [Box of 1 vial + diluent] | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Thymed EnterprisesImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-48 | Dec 27, 2028 | |
NjectzoleOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I Clear and Colorless Glass Vial (for the lyophilized powder) + 10 mL USP Type I Clear and Colorless Glass Ampoule [Diluent (0.9% Sodium Chloride)] in Aluminum PVC Blister Pack (Box of 1's) | Rx | Drug International LimitedBangladesh | NJT EnterprisesImporter: Jazmark Pharmaceutical | DRP-6422-15 | Mar 30, 2031 | |
NoneOmeprazole | 10 mg Delayed Release CapsulePET/Alu/PE Foil Strip x 4's (Box of 100's) | Rx | Interphil Laboratories, Inc.Philippines | Neodrug Inc. | DRP-4934-01 | Nov 20, 2028 | |
NoneOmeprazole | 20 mg CapsuleAlu/Alu Strip Pack x 10's (Box of 30's and 100's) | Rx | Micro Labs LimitedIndia | RiteMED Phils., Inc. | DR-XY39278 | Apr 6, 2031 | |
NoneOmeprazole | 20 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | RiteMED Phils., Inc.Importer: Ambica International Corporation | DRP-1313-03 | Oct 20, 2030 | |
NoneOmeprazole | 20 mg CapsuleAluminum Flex Foil x 10's (Box of 30s) | OTC | STANDARD CHEM. & PHARM. CO., LTD.China | RITEMED PHILS., INC. | DRP-3071 | Nov 23, 2029 | |
NoneOmeprazole | 20 mg CapsuleAluminum Foil Strip x 10’s Box 100’s | Rx | Agio Pharmaceuticals Ltd.India | International Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-4950-01 | Apr 29, 2029 | |
NoneOmeprazole | 20 mg CapsuleAluminum Foil Strip x 10’s (Box of 100's) | Rx | Agio Pharmaceuticals Ltd.India | Westpoint Pharma Inc.Importer: Ambica International Corporation | DRP-4950-02 | Apr 29, 2029 | |
NoneOmeprazole | 20 mg CapsuleFoil Strip x 4's (Box of 4's); Foil Strip x 6's (Box of 30's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-570 | Dec 7, 2027 | |
NoneOmeprazole | 20 mg CapsuleFoil Strip x 6's (Box of 30's) | Rx | Drugmaker's Laboratories, Inc.Philippines | TGP Pharma Inc. | DRP-570-04 | Dec 7, 2027 | |
NoneOmeprazole | 20 mg CapsuleFoil Strip x 10’s (Box of 30’s and 100’s) | Rx | Nabros Pharma Pvt. Ltd.India | PharmaVital Corp.Importer: Ambica International Corporation | DRP-6303-01 | Dec 14, 2031 | |
NoneOmeprazole | 20 mg CapsuleAluminum Foil Strip x 10’s (Box of 100’s) | Rx | Unique Pharmaceutical Laboratories (A Division of J.B. Chemicals & Pharmaceuticals Limited)India | Pharex Health CorporationImporter: Ambica International Corporation | DRP-843 | Feb 5, 2029 | |
NoneOmeprazole | 20 mg CapsuleAluminum Foil Strip x 10’s Box of 100’s | Rx | Unique Pharmaceutical Laboratories (A Division of J.B. Chemicals & Pharmaceuticals Limited)India | Actimed, Inc.Importer: Ambica International Corporation | DRP-843-03 | Feb 5, 2029 | |
NoneOmeprazole | 20 mg CapsuleWhite PVDC/Aluminum Blister Pack x 10’s (Box of 20’s and 50’s) | Rx | Hizon Laboratories, Inc.Philippines | — | DRP-946 | Jul 5, 2031 | |
NoneOmeprazole | 20 mg Delayed Release CapsulePET/Alu/PE Foil Strip x 4's (Box of 100's) | Rx | Interphil Laboratories, Inc.Philippines | Rose Pharmacy, Incorporated | DRP-4935-01 | Nov 18, 2028 | |
NoneOmeprazole | 20 mg Delayed Release CapsulePET/Alu/PE Foil Strip x 4's (Box of 100's) | Rx | Interphil Laboratories, Inc.Philippines | St. Joseph Drugstore | DRP-4935-02 | Nov 18, 2028 | |
NoneOmeprazole | 20 mg Delayed Release CapsulePET/Alu/PE Foil Strip x 4's (Box of 100's) | Rx | Interphil Laboratories, Inc.Philippines | Neodrug Inc. | DRP-4935-03 | Nov 18, 2028 | |
NoneOmeprazole | 20 mg Delayed Release CapsulePET/Alu/PE Foil Strip x 4's (Box of 100's) | Rx | Interphil Laboratories, IncPhilippines | South Star Drug | DRP-4935-04 | Nov 18, 2028 | |
NoneOmeprazole | 20 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Zim Laboratories LimitedIndia | I.E. Medica, Inc. | DR-XY47242 | Apr 26, 2031 | |
NoneOmeprazole | 20 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's Box of 30's | Rx | Stallion Laboratories Pvt. Ltd.India | Alkem Laboratories CorporationImporter: Ambica International Corporation | DRP-3047-12 | Jun 15, 2029 | |
NoneOmeprazole | 20 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Ltd. | DRP-5904-01 | Dec 17, 2029 | |
NoneOmeprazole | 20 mg Delayed-Release CapsuleAlu/Alu Strip Foil x 10’s (Box of 100’s) | Rx | Kopran LimitedIndia | TGP Pharma Inc.Importer: Triple Tact Import & Export Cor. | DRP-6949-04 | Dec 14, 2026 | |
NoneOmeprazole (as Sodium) | 20 mg Lyophilized Powder for Intravenous Injection/Infusion10 mL Low Borosilicate Clear Glass Vial with Bromobutyl Rubber stopper, Aluminum Flip-Off Seal and Plastic Cap. (Box of 1's) | Rx | Shandong Yuxin Pharmaceutical Co., Ltd.China | Luoxin Pharmaceuticals (PH) Corp. | DRP-12754 | Apr 25, 2027 | |
NoneOmeprazole | 40 mg CapsuleAlu/Alu Blister Pack x 8's (Box of 24's) | Rx | Lloyd Laboratories, Inc.Philippines | South Star DrugTrader: Innogen Pharmaceuticals, Inc. | DRP-11761-03 | Nov 21, 2026 | |
NoneOmeprazole | 40 mg CapsuleAlu Strip Foil x 10's (Box of 100's) | Rx | Windlas Biotech LimitedIndia | Actimed, Inc.Importer: Grovic Pharma Inc. | DRP-3016-02 | Jun 2, 2028 | |
NoneOmeprazole | 40 mg CapsuleAlu/Alu Blister Pack x 8's (Box of 24's) | Rx | Lloyd Laboratories, Inc.Philippines | Foramen Products CorporationTrader: Vitalink Health Products, Inc. | DRP-6378-04 | Sep 23, 2028 | |
NoneOmeprazole | 40 mg CapsuleAlu/Alu Blister Pack x 8's (Box of 24's) | Rx | Lloyd Laboratories, Inc.Philippines | Gamot Philippines, Inc.Trader: Vitalink Health Products, Inc. | DRP-6378-06 | Sep 23, 2028 | |
NoneOmeprazole | 40 mg CapsuleAlu/Alu Blister Pack x 8's (Box of 24's) | Rx | Lloyd Laboratories Inc.Philippines | Transcend Phils., Inc.Trader: Vitalink Health Products, Inc. | DRP-6378-08 | Sep 23, 2028 | |
NoneOmeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | Pharex Health CorporationImporter: Ambica International Corporation | DRP-2725-04 | Jan 17, 2028 | |
NoneOmeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | RiteMED Phils., Inc.Importer: Ambica International Corporation | DRP-2725-08 | Jan 17, 2028 | |
NoneOmeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | International Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-2725-15 | Jan 17, 2028 | |
NoneOmeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-2725-18 | Jan 17, 2028 | |
NoneOmeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | Alkem Laboratories CorporationImporter: Ambica International Corporation | DRP-4887-06 | Nov 4, 2028 | |
NoneOmeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister pack x 10’s (Box of 30’s) | Rx | Sapphire Lifesciences Pvt. Ltd.India | Watsons Personal Care Store (Philippines), Inc.Importer: Nelpa Lifesciences, Inc. | DRP-12788-02 | Oct 7, 2027 | |
NoneOmeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister pack x 10’s (Box of 30’s); Alu/Alu Blister pack x 10’s (Box of 100’s) | Rx | Sapphire Lifesciences Pvt. Ltd.India | Watsons Personal Care Stores (Philippines), Inc.Importer: Nelpa Lifesciences, Inc. | DRP-12788-03 | Oct 7, 2027 | |
NoneOmeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 7's (Box of 70's) | Rx | Medisure Laboratories Pakistan (Pvt.) Ltd.Pakistan | TGP Pharma Inc.Importer: Accesspoint International Trading Inc. | DRP-6027-02 | Feb 27, 2030 | |
NoneOmeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 70's and 100's) | Rx | Medisure Laboratories Pakistan (Pvt.) LimitedPakistan | Reta DrugImporter: Accesspoint International Trading Inc. | DRP-6027-8 | Feb 26, 2030 | |
NoneOmeprazole (as sodium monohydrate) | 40 mg Lyophilized Powder for Injection (I.V.)10 mL amber and transparent USP Type II glass tubular vials sealed with gray butyl rubber stopper and blue aluminum plastic cap + 10 mL USP Type I glass transparent colorless ampoule (Water for Injection as diluent) [Box of 1's] | Rx | Reyoung Pharmaceutical Co., Ltd.China | VGV Medispec IncorporatedImporter: GPC Geo Pharma Corporation | DRP-12424-08 | Aug 4, 2027 | |
NoneOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I amber vial with grey bromobutyl rubber stopper, aluminum seal and flip-off cap (as finished product) + polypropylene ampoule containing Sterile Water for Injection x 10 mL (as diluent) (Box of 1 finished product +1 diluent) | Rx | Swiss Parenterals Ltd. (Block-B)India | HLM Pharmaceutical, Inc.Importer: GPC Geo Pharma Corporation | DRP-15591-06 | Aug 7, 2029 | |
NoneOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Tubular Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 10 mL + 10 mL Sterile Water for Injection in White Polyethylene (PE) Plastic Form-Fill-Seal (FFS) Ampoule (Box of 1's) | Rx | Jodas Expoim Pvt. Ltd.India | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-11492-13 | Mar 17, 2027 | |
NoneOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Tubular Glass Vial with Gray Bromobutyl Rubber Stopper and Purple Aluminum Flip-Off Seal Cap x 10 mL + 10 mL Sterile Water for Injection in White Polyethylene (PE) Plastic Form-Fill-Seal (FFS) Ampoule (Box of 1's) | Rx | Jodas Expoim Pvt. Ltd.India | Marcburg Philippines Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-11492-14 | Mar 17, 2027 | |
NONEOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Tubular Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 10 mL + 10 mL Sterile Water for Injection in White Polyethylene (PE) Plastic Form-Fill-Seal (FFS) Ampoule (Box of 1's) | Rx | Jodas Expoim Pvt. Ltd.India | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-11492-16 | Mar 17, 2027 | |
NoneOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Intravenous Injection/Infusion10 mL Low Borosilicate Clear Glass Vial with Bromobutyl Rubber Stopper, Aluminum Flip-Off Seal and Plastic Cap. (Box of 1's) | Rx | Shandong Yuxin Pharmaceuitcal Co., Ltd.China | Luoxin Pharmaceuticals (PH) Corp. | DRP-12757 | Apr 25, 2027 | |
NoneOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl rubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | Bliss Pharma Distribution and Consultancy Corp.Philippines | Providencia Medica Inc. | DRP-15496-04 | Jul 26, 2029 | |
NoneOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl rubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | Om Biomedic Pvt. Ltd.India | Sonchel Pharma DistributorsImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-15496-05 | Jul 26, 2029 | |
NoneOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl tubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | OM Biomedic Pvt. Ltd.India | Marcburg Philippines Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15496-07 | Jul 26, 2029 | |
NoneOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl tubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | Om Biomedic Pvt. Ltd.India | Triple Tact Import & ExportImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-15496-08 | Jul 26, 2029 | |
NoneOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl tubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | Om Biomedic Pvt. Ltd.India | Jackson Pharmaceuticals Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15496-09 | Jul 26, 2029 | |
NoneOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl tubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | Om Biomedic Pvt. Ltd.India | Afree Pharmaceutical Distribution Corp.Importer: Bliss Phar ma Distribution and Consultancy Corp. | DRP-15496-11 | Jul 26, 2029 | |
NoneOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl tubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | Om Biomedic Pvt. Ltd.India | Loriel PharmaceuticareImporter: Bliss Pharma Distribution And Consultancy Corp. | DRP-15496-16 | Jul 26, 2029 | |
NoneOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent (Box of 1 vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-08 | Dec 27, 2028 | |
NoneOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent (Box of 1 vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-49 | Dec 27, 2028 | |
NoneOmeprazole (as sodium) | 40mg Lyophilized Powder for Injection (I.V.)USP Type I amber vial with grey bromobutyl rubber stopper, aluminum seal and flip off-cap (as finished product) + polypropylene ampoule of Sterile Water for Injection x 10 mL (as diluent) (Box of 1 vial + diluent) | Rx | Swiss Parenterals Ltd. (Block-B)India | HLM Pharmaceutical Inc.Importer: GPC Geo Pharma Corporation | DRP-15591-04 | Aug 7, 2029 | |
NoneOMEPRAZOLE (as sodium) | 40mg Powder for solution for injection (I.V.)10mL USP Type I Amber glass vial + 10mL Ampoule Diluent Box of 1's | Rx | SCOTT EDIL PHARMACIA Ltd.India | MEDETHIX INC.Importer: I.E. MEDICA, INC.Trader: ADI SOLUTIONS Pty. Ltd. | DRP-8557-02 | Oct 6, 2027 | |
O-Gold 20Omeprazole | 20 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | JVZEA Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-5904-03 | Dec 17, 2029 | |
O-Gold 40Omeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | JVZEA Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-4887-05 | Nov 4, 2028 | |
ObaxOmeprazole | 20 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | Kaufmann Pharma Inc.Importer: Ambica International Corporation | DRP-1313-02 | Oct 20, 2030 | |
ObaxOmeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | Kaufmann Pharma Inc.Importer: Ambica International Corporation | DRP-2725-11 | Jan 17, 2028 | |
OhmepviaOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent (Box of 1 vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Madecs Pharma CorporationImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-41 | Dec 27, 2028 | |
OmacareOmeprazole (as Sodium) | 40 mg Powder for Injection (IV)10 mL USP Type I clear glass vial with rubber stopper and blue flip off seal with Water for Injection (Type I Clear Colorless Glass Ampoule x 10 mL) (Box of 1's and 10's) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | MSF Pharmaceutical DistributionImporter: AMB HK Enterprises Inc. | DRP-8396-06 | Nov 19, 2028 | |
OMBESTOmeprazole (as sodium) | 40 mg Powder for Injection (I.V.)10 mL-capacity USP Type II amber colored Clear Glass Vial with Gray Butyl Rubber stopper and blue aluminum plastic cap x 10 mL (Box of 1's) | Rx | Reyoung Pharmaceutical Co. Ltd.China | Best ClearImporter: Medinova Pharmaceutical Inc. | DRP-12554-05 | Sep 1, 2027 | |
OmcareOmeprazole Sodium | 40 mg Lyophilized Powder for InjectionUSP Type I Clear Glass Vial x 10 mL (Box of 1's and 10's); USP Type I Clear Glass Vial x 10 mL with 10 mL USP Type I Glass Ampoule containing Sterile Water for Injection (as diluent) in a Box | Rx | FUREN PHARMACEUTICAL GROUP CO., LTD.China | AGLOBAL CARE, INC. | DRP-5930 | Dec 5, 2028 | |
OmcidOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey mber bromobutyl tubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | Om Biomedic Pvt. Ltd.India | Bliss Pharma Distribution and Consultancy Corp. | DRP-15495 | Jul 26, 2029 | |
Ome-40Omeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation | DRP-2725-02 | Jan 17, 2028 | |
Ome-BOP40Omeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | Better Option Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-2725-09 | Jan 17, 2028 | |
Ome-MOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent (Box of 1 vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Vigorous Health Pharma and Medical Supplies TradingImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025 | Dec 27, 2028 | |
Ome-WestOmeprazole (as sodium) | 40 mg Powder for Injection (I.V.)10 mL capacity USP Type 1 amber glass vial (Box of 1's) | Rx | Swiss Parenterals Ltd.India | Central West Medicale Inc.Importer: Ambica International Corporation | DRP-7385 | Oct 9, 2027 | |
OmebelOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey mber bromobutyl tubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | Om Biomedic Pvt. Ltd.India | Bliss Pharma Distribution and Consultancy Corp. | DRP-15497 | Jul 26, 2029 | |
OmeblocOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (I.V)10 mL-capacity USP Type I Amber Glass Vial with Grey rubber stopper and Aluminum Flip-Off Seal (Box of 1's) | Rx | Zee Laboratories LimitedHimachal Pradesh India | Eon Pharmatek Inc. | DR-XY48206 | Jul 20, 2032 | |
Omebloc-20Omeprazole | 20mg Delayed-Release CapsuleStrip Foil x 10's Box of 100's | Rx | Zee Laboratories, Inc.India | Eon Pharmatek Inc. | DR-XY35831 | May 14, 2029 | |
OmecareOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Tubular Glass Vial with Gray Bromobutyl Rubbert Stoppert and Blue Aluminum Flip-off Seal Cap x 10 mL + 10 mL Sterile Water for Injection in White Polyethylene (PE) Plastic Form-Fill-Seal (FFS) Ampoule (Box of 1's) | Rx | Jodas Expoim Pvt, Ltd.India | Onicare Pharma Trading & General MerchandiseImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-11492-09 | Mar 17, 2027 | |
OmecareOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Infusion10 mL USP type I amber glass vial with grey bromobutyl rubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | OM Biomedic Pvt. Ltd.India | Onicare Pharma Trading & General MerchandiseImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-15495-03 | Jul 26, 2029 | |
OmecomOmeprazole (as sodium) | 40 mg Lyophilized Powder for Intravenous Injection / Infusion10 mL Type I glass vial, with rubber stopper and flip off seal (drug product) +10 mL Type I glass ampoule (Sterile Water for Injection as diluent) (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Hillcross Prime, Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-11700-06 | Apr 25, 2027 | |
OmecoreOmeprazole | 20 mg Delayed Release CapsuleAlu/Alu Strip Foil x 10’s (Box of 100's) | Rx | Kopran LimitedIndia | Greencore Pharma Inc.Importer: Triple Tact Import & Export Corp. | DRP-6949-02 | Dec 14, 2031 | |
40 mg Lyophilized Powder for Injection (IV)USP Type I Amber Vial w/ Rubber Stopper & Blue Flip-Off Seal x 10 mL + Clear Ampoule x 10 mL Sterile Water for Injection (Box of 1's) | Rx | Celon Laboratories Private LimitedIndia | Medhaus Pharma IncorporatedImporter: I.E. Medica, Inc. | DRP-1499-12 | Feb 4, 2032 | ||
Omed 20Omeprazole | 20 mg CapsuleAlu/Alu Blister Pack x 8's (Box of 24's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma, Incorporated | DR-XY34421 | Mar 25, 2028 | |
OmedazOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (I.V.)10 mL-capacity USP Type I clear and colorless glass vial lorles with grey bromobutyl rubber stopper and aluminum seal with polypropylene flip-off cap (Box of 1's) | Rx | Indasi Lifescience Private LimitedIndia | Aglobal Care, Inc.Trader: Veiovis Lifescience Private Limited | DRP-14932 | Feb 15, 2029 | |
OmedecOmeprazole (as sodium) | 40 mg Lyophilized Powder for Intravenous Injection/Infusion10 mL Type I glass vial, with rubber stopper and flip-off seal (drug product) + 10 mL Type I glass ampoule (Sterile Water for Injection as diluent) (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Deca Pharmaceutical and Trading Corp.Importer: Sanimed Pharmaceuticals Inc. | DRP-11700-5 | Apr 25, 2027 | |
OmedecOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent (Box of 1 vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Deca Med Pharmaceutical Trading Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-50 | Dec 27, 2028 | |
OmedenOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type 1 tubular glass vial with rubber stopper and flip off cap (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Cyden Medical Trading Inc.Importer: AMB HK Enterprises Inc. | DRP-9122-01 | Sep 22, 2031 | |
OmedimeOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I Clear and Colorless Glass Vial (for the lyophilized powder) + 10 mL USP Type I Clear and Colorless Ampoule [Diluent (0.9% Sodium Chloride)] in Aluminum PVC Blister Pack (Box of 1's) | Rx | Drug International LimitedBangladesh | Pharmadyme Philippines, Inc.Importer: Jazmark Pharmaceutical | DRP-6422-18 | Apr 5, 2031 | |
OmedimeOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection/Infusion10 mL USP Type 1 Amber Glass Vial + 10 mL USP Type 1 Clear and Colorless Glass Ampoule containing Sterile Water for Injection (as Diluent) (Box of 1's) | Rx | Gufic Biosciences LimitedIndia | Pharmadyme Philippines, Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-5882-02 | Dec 9, 2027 | |
OmeeOmeprazole Sodium | 40 mg Lyophilized Powder for InjectionUSP Type I Clear Glass Vial x 10 mL (Box of 1's and 10's); USP Type I Clear Glass Vial x 10 mL with 10 mL USP Type I Glass Ampoule containing Sterile Water for Injection (as diluent) in a Box | Rx | Furen Pharmaceutical Group Co., Ltd.China | Alkem Laboratories CorporationImporter: Aglobal Care, Inc. | DRP-5930-11 | Dec 5, 2028 | |
OmeeOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection/Infusion10 mL USP Type I Amber Glass Vial + 10 mL USP Type 1 Clear and Colorless Glass Ampoule containing Sterile Water for Injection (as Diluent) Box of 1's | Rx | Gufic Biosciences LimitedIndia | Alkem Laboratories CorporationImporter: Suhitas Pharmaceuticals Inc. | DRP-5882-04 | Dec 9, 2027 | |
OmefbicaOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)10 mL- capacity USP Type II amber glass vial with gray butyl rubber stopper and blue aluminum plastic caps + USP Type I transparent glass ampoule x 10 mL water for injection (diluent) [Box of 1's] | Rx | Reyoung Pharmaceutical Co. Ltd.China | Ambitech Biopharmaceuticals Inc.Importer: Ambicare Pharmaceuticals Inc. | DRP-13236-05 | Jan 6, 2028 | |
OmefhaloxOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent Box of 1 vial + diluent | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-38 | Dec 27, 2028 | |
Omefil WFIOmeprazole (as Sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with Pink Flip-off Seal + 10 mL Sterile Water for Injection as Diluent Box of 1 vial + Diluent | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Filadams Pharma, Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-22 | Dec 27, 2028 | |
OMEFIRSTOmeprazole | 20 mg CapsuleFoil Strip x 10's (Box of 60's and 100's) | Rx | J.M. Tolmann Laboratories Inc.Philippines | Firstmed Theraconcept Inc. | DRP-3136 | Apr 11, 2031 | |
OmegerdOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)10 mL Type II Amber Glass Vial Sealed with Gray Butyl Rubber Stopper and Blue Aluminum Plastic Cap + 10 mL Sterile Water for Injection in Type I Colorless and Transparent Glass Ampoule (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Asianmeds, Inc.Importer: Euro-Care Products Philippines | DRP-12583-05 | Sep 8, 2027 | |
Omegrand 20Omeprazole | 20 mg Delayed-Release CapsuleAluminum Foil Strip x 10’s (Box of 100’s) | Rx | Brawn Laboratories LimitedIndia | Grandis Pharma IncorporatedImporter: Sbrg Exim Philippines Inc. | DRP-4149-03 | Dec 18, 2027 | |
OmegrazoleOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)10 mL Type II Transparent Amber color Tubular Glass Vial Sealed with Grey Butyl Rubber Stopper and Flip-Off Seal Cap x 1's (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Grabernoll Pharmaceutical CorporationImporter: Pharmaessence, Inc. | DRP-13545-03 | Mar 8, 2028 | |
OmegutOmeprazole | 40 mg Powder for Injection (IV)USP Type 1 Clear Glass Vial +10 mL diluent in Alu/PVC Combipack (Box of 1's) | Rx | POPULAR PHARMACEUTICALS LTD.Bangladesh | HEKA HEALTH INTERNATIONAL CORP. | DR-XY43410 | May 13, 2029 | |
OMEHILOmeprazole (as sodium) | 40 mg Lyophilized Powder for Intravenous Injection / Infusion10 mL Type I glass vial, with rubber stopper and flip off seal (drug product)+10 mL Type I glass ampoule (Sterile Water for Injection as diluent) (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Hillcross Prime, Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-11700-02 | Apr 25, 2027 | |
Omejys-40Omeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | JJYSRINN Trading Inc.Importer: Ambica International Corporation | DRP-2725-07 | Jan 17, 2028 | |
Omekhriz 40Omeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)10 mL Type II Amber Glass Vial Sealed with Gray Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1's (Box of 1's, 5's and 10's) | Rx | Reyoung Pharmaceutical Co., Ltd..China | Khriz Pharma Trading, Inc. | DR-XY47900 | Apr 5, 2027 | |
OMELIFEOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I tubular glass vial with rubber stopper and flip-off cap (Box of 10’s) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Life And Health Source Pharmaceutical Distribution Co.Importer: Philrx Pharma Inc. | DRP-9122-03 | Sep 4, 2030 | |
OmelineOmeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | RSG Pharma TradingImporter: Ambica International Corporation | DRP-2725-17 | Jan 17, 2028 | |
OmelineOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent Box of 1 vial + diluent | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | RSG Pharma TradingImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-14 | Dec 27, 2028 | |
OmeloveOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)10 mL Type II Transparent Amber color Tubular Glass Vial Sealed with Grey Butyl Rubber Stopper and Flip-off Seal Cap x 1's (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | One That Love TradingImporter: Pharmaessence Inc. | DRP-13545-04 | Mar 8, 2028 | |
Omemac-GerdOmeprazole | 20 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Speed Cure PharmaImporter: Ambica International Corporation | DRP-3047-03 | Jun 15, 2029 | |
Omemac-GERDOmeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | Speed Cure Pharma | DRP-2725-16 | Jan 17, 2028 | |
Omemac-GerdOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with Pink Flip-off Seal + 10 mL Sterile Water for Injection as Diluent (Box of 1 Vial + Diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Speed Cure PharmaImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-29 | Dec 27, 2028 | |
OmenixOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I Clear and Colorless Glass Vial (for the lyophilized powder) + 10 mL USP Type I Clear and Colorless Glass Ampoule [Diluent (0.9% Sodium Chloride)] in Aluminum PVC Blister Pack (Box of 1's) | Rx | Drug International LimitedBangladesh | Ranixx PharmaceuticalsImporter: Jazmark Pharmaceutical | DRP-6422-17 | Apr 5, 2031 | |
OmenixOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection/Infusion10 mL USP Type I Amber Glass Vial + 10 mL USP Type I Clear and Colorless Glass Ampoule containing Sterile Water for Injection (as Diluent) Box of 1's | Rx | Gufic Biosciences LimitedIndia | Ranixx PharmaceuticalsImporter: Suhitas Pharmaceuticals Inc. | DRP-5882-03 | Dec 9, 2027 | |
OmenoleOmeprazole (as sodium) | 40 mg Powder for Injection (I.V.)10 mL colorless USP Type III Vial and Diluent 10 mL Sterile Water for Injection in plastic FFS | Rx | Gufic Biosciences LimitedIndia | Pharmalife DistributionImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-1570-02 | Jul 14, 2031 | |
OmenoleOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent Box of 1 vial + diluent | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Pharmalife DistributionImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-30 | Dec 27, 2028 | |
OmepOmeprazole (as Sodium) | 40mg Lyophilized Powder for Injection (I.V)10mL USP Type I clear and colorless glass vial + 10mL USP Type I clear and colorless glass ampoule (0.9% sodium chloride as diluent) (Box of 1's) | Rx | Aristopharma Ltd.Bangladesh | SAHAR INTERNATIONAL TRADING INC. | DRP-5041 | Jun 27, 2028 | |
Omep-zOmeprazole (as sodium monohydrate) | 40 mg Lyophilized Powder for Injection (I.V.)10 mL amber and transparent USP Type II glass tubular vials sealed with gray butyl rubber stopper and blue aluminum plastic cap + 10 mL USP Type I glass transparent colorless ampoule (Water for Injection as. diluent) [Box of 1's] | Rx | Reyoung Pharmaceutical Co., Ltd.China | Zion Pharmaceutical Product DistributionImporter: GPC Geo Pharma Corporation | DRP-12424-07 | Aug 4, 2027 | |
OmepaceOmeprazole (as sodium monohydrate) | 40 mg Lyophilized Powder for Injection (I.V.)10 mL amber and transparent USP Type II glass tubular vials sealed with gray butyl rubber stopper and blue aluminum plastic cap + 10 mL USP Type I glass transparent colorless ampoule (Water for Injection as diluent) (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | QLap Endoscopics Inc.Importer: GPC Geo Pharma Corporation | DRP-12424-03 | Aug 4, 2027 | |
OmepaceOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I amber vial with grey bromobutyl rubber stopper, aluminum seal and flip off-cap (as finished product) + polypropylene ampoule of Sterile Water for Injection x 10 mL (as diluent) (Box of 1 finished product + 1 diluent) | Rx | Swiss Parenterals Ltd. (Block-B)India | QLap Endoscopics Inc.Importer: GPC Geo Pharma Corporation | DRP-15591-03 | Aug 7, 2029 | |
Omepfast-40Omeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Flourish PharmaIndia | Speed Med Pharmaceuticals IncImporter: Biophil Medical Equipment and Supplies Trading | DRP-16568 | Apr 29, 2030 | |
OmepfindOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent Box of 1 vial + diluent | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Sonchel Pharma DistributorsImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-16 | Dec 27, 2028 | |
OmepfreeOmeprazole (as Sodium) | 40 mg Powder for Injection (IV)10 mL colorless USP Type III Vial & diluent 10 mL Sterile Water for Injection in plastic FFS | Rx | Gufic Biosciences LimitedIndia | Diafarm Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-1570-19 | Aug 6, 2031 | |
OmepharOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)10 mL-capacity USP Type II amber glass vial with gray butyl rubber stopper and blue aluminum plastic caps USP Type I transparent glass ampoule x 10 mL water for injection (diluent) (Box of 1's) | Rx | Reyoung Pharmaceutical Co. Ltd.China | Pharma King DistributorImporter: Ambicare Pharmaceuticals Inc. | DRP-13236-09 | Jan 6, 2028 | |
OmepharOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent Box of 1 vial + diluent | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Pharma King DistributorImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-18 | Dec 27, 2028 | |
Omephil 40Omeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Fredun Pharmaceuticals LimitedIndia | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-14809-01 | Feb 26, 2029 | |
Omephil-20Omeprazole | 20 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-5870 | Sep 6, 2027 | |
OmeporsOmeprazole | 40 mg Lyophilized Powder for Injection (IV)10 mL-capacity USP type I amber glass vial with bromo butyl rubber stopper and aluminum flip-off seal and FFS ampoule x 10 mL for sterile water for injection (diluent) (in one box) | Rx | Med Biopharm Pvt. Ltd.India | Pors Pharma Trading | DR-XY49560 | Oct 24, 2031 | |
OmeporsOmeprazole | 40 mg Lyophilized Powder for Injection (IV)10 mL-capacity USP type I amber glass vial with bromo butyl rubber stopper and aluminum flip-off seal and FFS ampoule x 10 mL for sterile water for injection (diluent) [in one box] | Rx | Med Biopharm Pvt. Ltd.India | Pors Pharma Trading | DRP-17355 | Oct 24, 2031 | |
Omepra-BrillOmeprazole Sodium | 40 mg Lyophilized Powder for InjectionUSP Type I Clear Glass Vial x 10 mL (Box of 1's and 10's); USP Type I Clear Glass Vial x 10 mL with 10 mL USP Type I Glass Ampoule containing Sterile Water for Injection (as diluent) in a Box (Box of 1's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Rcbrilliant Pharma And Medical Supplies TradingImporter: Aglobal Care, Inc. | DRP-5930-14 | Dec 5, 2028 | |
OmeprablesOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl rubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | Om Biomedic Pvt. Ltd.India | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15496-02 | Jul 26, 2029 | |
OmepracentOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)10 mL-capacity USP Type II amber glass vial with gray butyl rubber stopper and blue aluminum plastic caps + USP Type I transparent glass ampoule x 10 mL water for injection (diluent) [Box of 1's] | Rx | Reyoung Pharmaceutical Co. Ltd.China | Central West Medicale Inc.Importer: Ambicare Pharmaceuticals Inc. | DRP-13236-02 | Jan 6, 2028 | |
Omepracent 40Omeprazole | 40 mg CapsuleAlu Strip Foil x 10's (Box of 100's) | Rx | Windlas Biotech LimitedIndia | Central West Medicale Inc.Importer: Grovic Pharma Inc. | DRP-3016-03 | Jun 2, 2028 | |
Omepracent-ProOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl rubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | Om Biomedic Pvt. Ltd.India | Central West Medicale, Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15495-10 | Jul 26, 2029 | |
OmepracircOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I amber vial with grey bromobutyl rubber stopper, aluminum seal and flip off -cap (as finished product) + polypropylene ampoule of Sterile Water for Injection x 10 mL (as diluent) (Box of 1 finished product + 1 diluent) | Rx | Swiss Parenterals Ltd. (Block -B)India | PharmaCircle Enterprise CorporationImporter: GPC Geo Pharma Corporation | DRP-15591-02 | Aug 7, 2029 | |
OmepramOmeprazole (as sodium) | 40 mg Powder for Injection (IV)Boxed Borosilicate Tube Vial with Rubber Stopper and Blue Flip-Off Seal (Box of 10's) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | Marilz Pharmaceuticals CorporationImporter: AMB HK Enterprises Inc. | DRP-3590-03 | Jul 14, 2028 | |
OmepramarcOmeprazole (as sodium) | 40mg Lyophilized Powder for Injection (I.V.)10 mL Type I amber glass vial with rubber stopper, aluminum seal and flip-off cap (as finished product) + USP Type I clear glass ampoule Sterile Water for Injection x 10 mL (as diluent) (Box of 1 finished product + 1 diluent) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Marcburg Philippines Inc | DR-XY49485 | Sep 2, 2030 | |
OmepranavOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent (Box of 1 vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | JN Carlo Pharmaceuticals DistributorImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-45 | Dec 27, 2028 | |
OmeprasaphOmeprazole | 20 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's & 100's) | Rx | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-12932 | Jun 8, 2031 | |
OmeprasaphOmeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-12788 | Jan 23, 2031 | |
OmeprasaphOmeprazole (As Sodium) | 40 mg Lyophilized Powder for Injection (IV)USP Type I clear glass vial with grey bromobutyl rubber stopper, aluminum seal, and light blue flip-off cap (drug) and USP Type I clear colorless glass ampoule x 10 mL (Sterile Water for Injection diluent) (Box of 1 drug product and 1 diluent) | Rx | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences, Inc. | DRP-12165 | Jun 27, 2027 | |
OmepraseaOmeprazole | 40mg (equivalent to 44.63mg Omperazole Sodium) Lyophilized Powder for Injection (IV)USP Type II Amber Tubular Vial x 10mL with Butyl Rubber Stopper and Flip-off Aluminum Seal (Box of 10's) (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Seapharma International, Inc.Importer: Pharma-Surrey International, Inc. | DRP-11407-01 | Mar 9, 2027 | |
Omeprastar-20Omeprazole | 20 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Sapphire Lifesciences Pvt. Ltd.India | Pharmastar Int'l Trading CorpImporter: Nelpa Lifesciences, Inc. | DRP-12932-01 | Nov 4, 2027 | |
Omeprastar-40Omeprazole | 40 mg Delayed-Release CapsuleAlu/Alu blister pack of 10's (Box of 30's) | Rx | Sapphire Lifesciences Pvt. Ltd.India | Pharmastar Int'l Trading Corp.Importer: Nelpa Lifesciences, Inc. | DRP-12788-01 | Oct 7, 2027 | |
OmepratelOmeprazole Sodium | 40 mg Lyophilized Powder for InjectionUSP Type I Clear Glass Vial x 10 mL (Box of 1's and 10's); USP Type I Clear Glass Vial x 10 mL with 10 mL USP Type I Glass Ampoule containing Sterile Water for Injection (as diluent) in a Box | Rx | FUREN PHARMACEUTICAL GROUP CO., LTD.China | GCMED PHARMACEUTICAL DISTRIBUTORImporter: AGLOBAL CARE, INC. | DRP-5930-05 | Dec 5, 2028 | |
OmepravinOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)Type III Clear Glass Vial Sealed with Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Mason PharmaIndia | MDB Pharma TradingImporter: Finstad, Inc. | DRP-11022-02 | Apr 29, 2027 | |
Omeprazole (as sodium)Omeprazole (as sodium) | 40 mg Powder for Solution for Injection (IV)In a box, 10 mL-capacity amber glass vial with rubber stopper and aluminum white flip-off seal and LDPE plastic ampoule x 10 mL for sterile water for injection (as diluent) | Rx | Skymap Healthcare Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-18569 | Jul 30, 2031 | |
OmeprexOmeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 7's (Box of 70's) | Rx | Medisure Laboratories Pakistan (Pvt.) LimitedPakistan | Rexmed Pharmaceutical SalesImporter: Accesspoint International Trading Inc. | DRP-6027-04 | Feb 27, 2030 | |
OmeprexOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent (Box of 1 vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Rexmed Pharmaceuticals SalesImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-51 | Dec 27, 2028 | |
Omeprim-40Omeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | XL Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-2725-01 | Jan 17, 2028 | |
OmeprobOmeprazole (as Sodium) | 40 mg Powder for Injection (IV)10 mL USP Type I clear glass vial with rubber stopper and blue flip off seal with Water for Injection (Type I Clear Colorless Glass Ampoule x 10 mL) (Box of 10’s) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | AGCC MarketingImporter: AMB HK Enterprises Inc. | DRP-8396-08 | Nov 19, 2028 | |
Omeprollen B20Omeprazole | 20 mg Enteric Coated CapsuleAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Belco PharmaIndia | Ollen Pharma Trading Inc. | DRP-17139 | Oct 20, 2030 | |
Omeprollen-B40Omeprazole | 40 mg Enteric Coated CapsuleAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Belco PharmaIndia | Ollen Pharma Trading Inc. | DRP-17140 | Oct 20, 2030 | |
OmepronOmeprazole | 20 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | UNILAB, Inc.Importer: Ambica International Corporation | DRP-1313-04 | Oct 20, 2030 | |
OmepronOmeprazole | 20 mg CapsuleAluminum Flex Foil (Alu/Alu) x 10's Box of 30's | OTC | Standard Chem. & Pharm. Co., Ltd.China | UNILAB, Inc. | DRP-3071-01 | Nov 22, 2029 | |
OmepronOmeprazole | 40 mg Delayed-Release CapsuleAlu-Alu Blister x 7's (Box of 28's) | Rx | Ajanta Pharma LimitedIndia | UNILAB, Inc. | DRP-9983 | Sep 6, 2031 | |
OmepronOmeprazole (as sodium) | 40 mg Powder for Injection (I.V.)Clear and colorless glass vial with green flip-off seal + clear and colorless ampoule (Diluent: Polyethylene glycol, citric acid and Water for Injection) x 10 mL per box (Box of 1's) | Rx | Standard Chem & Pharm. Co., Ltd.China | UNILAB, INC. | DR-XY30333 | Jan 21, 2031 | |
OmepronOmeprazole Sodium | 40mg/ 10mL Powder for IV Injection10 mL-capacity USP Type I clear and colorless glass vial with gray brmobutyl rubber stopper and aluminum seal with blue-colored plastic flip-off cap + 10 mL solvent in USP Type I clear and colorless glass ampoule (Box of 1 vial + solvent ampoule) in plastic tray | Rx | Pt. Darya - Varia Laboratoria, Tbk.Indonesia | — | DRP-11754 | Apr 26, 2027 | |
OmeprovivOmeprazole (as Sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent Box of 1 vial + diluent | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Jaydee Care MarketingImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-32 | Dec 27, 2028 | |
OmeproxOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)10 mL-capacity USP Type II amber glass vial with gray butyl rubber stopper and blue aluminum plastic caps + USP Type I transparent glass ampoule x 10 mL water for injection (diluent) (Box of 1's) | Rx | Reyoung Pharmaceutical Co. Ltd.China | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambicare Pharmaceuticals Inc. | DRP-13236-04 | Jan 6, 2028 | |
OMEPROZONEOmeprazole Sodium | 40 mg Lyophilized Powder for InjectionUSP Type I Clear Glass Vial x 10 mL (Box of 1's) | Rx | FUREN PHARMACEUTICAL GROUP CO., LTD.China | ELISET PHARMACEUTICAL, INC.Importer: AGLOBAL CARE, INC. | DRP-5930-02 | Dec 5, 2028 | |
OmepsolOmeprazole | 20 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Centurion Laboratories Pvt. Ltd.India | 777 Red Pharma Inc.Importer: Philgen Pharmaceuticals, Inc. | DRP-1421-05 | Jul 10, 2028 | |
OmeptamOmeprazole (as sodium) | 40 mg Powder for Injection (I.V.)10 mL-capacity USP Type II amber colored Clear Glass Vial with Gray Butyl Rubber stopper and blue aluminum plastic cap x 10 mL (Box of 1's; Box of 10's) | Rx | Reyoung Pharmaceutical Co. Ltd.China | Tamiga Pharmaceutical SupplyImporter: Medinova Pharmaceutical Inc. | DRP-12554-02 | Sep 1, 2027 | |
OmeptasOmeprazole | 20 mg CapsuleAluminum Foil Strip x 10’s (Box of 30’s) | Rx | Zim Laboratories LimitedIndia | Better Option Pharmaceuticals, Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-526-01 | Nov 17, 2028 | |
OmepureOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Tubular Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 10 mL + 10 mL Sterile Water for Injection in White Polyethylene (PE) Plastic Form-Fill-Seal (FFS) Ampoule (Box of 1's) | Rx | Jodas Expoim Pvt. Ltd.India | MedPure Pharmaceutical Company Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-11492-12 | Mar 17, 2027 | |
OmepureOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl tubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | Om Biomedic Pvt. Ltd.India | MedPure Pharmaceutical Company Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15495-07 | Jul 26, 2029 | |
OmepzinOmeprazole | 40 mg Lyophilized Powder for Injection (IV)10 mL-capacity USP type I amber glass vial with bromo butyl rubber stopper and aluminum flip-off seal and FFS ampoule x 10 mL for sterile water for injection (diluent) in one box (Box of 1's) | Rx | Med Biopharm Pvt. Ltd.India | Mandamed Pharma and Medical Supplies TradingImporter: Pors Pharma Trading | DRP-17355-03 | Oct 24, 2031 | |
OmeraOmeprazole | 40 mg CapsuleAlu/Alu Blister Pack x 4's (Box of 40’s) | Rx | Biopharma Laboratories Ltd.Bangladesh | All-Bio Pharma, Inc.Importer: JF Draf Pharmaceuticals Corp. | DRP-1977-03 | Dec 1, 2029 | |
OmeraOmeprazole | 40 mg Lyophilized Powder for Injection (IV)10mL USP Type I Amber vial with rubber stopper & Blue flip off seal + 10mL clear Ampoule Sterile water for injection [Box of 1's] | Rx | Celon Laboratories Private LimitedIndia | All-Bio Pharma, Inc.Importer: I.E. Medica, Inc. | DRP-1499-04 | Apr 23, 2031 | |
OmeraOmeprazole (as sodium) | 40 mg Powder for Solution for injection (IV)10 mL USP Type I Amber Glass Vial + 10 ml Ampoule Diluent (Box of 1's) | Rx | Scott Edil Pharmacia Ltd.India | All-Bio Pharma, Inc.Importer: I.E. Medica, Inc.Trader: I-Care Formulations | DRP-8557-05 | Oct 6, 2027 | |
OmerazOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I Tubular Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Medwise, Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-8747-02 | Mar 2, 2031 | |
OmerecidOmeprazole (As Sodium) | 40 mg Lyophilized Powder For Injection (IV)10 mL Type I Clear Glass Vial Sealed with Gray. lass Via Bromobutyl Rubber Stopper and Blue Aluminum Flip- Off Seal Cap x 1's (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | FSPC Pharmaceuticals, Inc. | DRP-13351 | Feb 2, 2028 | |
OmerichOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)10 mL-capacity USP Type II amber glass vial with gray butyl rubber stopper and blue aluminum plastic caps + USP Type I transparent glass ampoule x 10 mL water for injection (diluent) [Box of 1's] | Rx | Reyoung Pharmaceutical Co. Ltd.China | Applied Pharmaceutical Distribution Inc.Importer: Ambicare Pharmaceuticals Inc. | DRP-13236-03 | Jan 6, 2028 | |
OmerifeOmeprazole Sodium | 40 mg Lyophilized Powder for InjectionUSP Type I Clear Glass Vial x 10 mL (Box of 1's and 10's); USP Type I Clear Glass Vial x 10 mL with 10 mL USP Type I Glass Ampoule containing Sterile Water for Injection (as diluent) in a Box | Rx | FUREN PHARMACEUTICAL GROUP CO., LTD.China | RIFEMEDICA CORPORATIONImporter: AGLOBAL CARE, INC. | DRP-5930-06 | Dec 5, 2028 | |
OmerilzOmeprazole | 20 mg CapsuleFoil Strip x 10's (Box of 100's) | Rx | J.M. Tolmann Laboratories Inc.Philippines | Marilz Pharmaceuticals CorporationTrader: Interhealthcare Pharmaceuticals Inc. | DRP-1623-04 | Mar 10, 2028 | |
Omerk-40Omeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (I.V.)10 mL USP Type I Clear and Colorless Glass Vial + 10 mL USP Type I Clear and Colorless Glass Ampoule (0.9 % Sodium Chloride as Diluent) (Box of 1's) | Rx | Aristopharma Ltd.Bangladesh | Merkchem Pharma, Inc.Importer: Sahar International Trading, Inc. | DRP-5041-04 | Jun 27, 2028 | |
OmeroseOmeprazole | 40mg (equivalent to 42.6mg Omeprazole sodium) Sterile Powder for Injection (I.V.)Brown Glass Vial x 10mL with Rubber Stopper and Aluminum-Plastic Cap (Box of 10's) | Rx | CSPC Ouyi Pharmaceutical Co. Ltd.China | AMB HK Enterprises Inc. | DRP-11394 | Mar 8, 2027 | |
OmesanOmeprazole (as sodium) | 40 mg Powder for Solution for injection (IV)10mL USP Type I Amber glass vial + 10ml Ampoule diluent (Box of 1's) | Rx | Scott Edil Pharmacia Ltd.India | Sanreich Healthcare, Inc.Importer: I.E. Medica, Inc.Trader: I-Care Formulations | DRP-8557-04 | Oct 6, 2027 | |
OmesarOmeprazole | 20 mg CapsuleFoil Strip x 10's (Box of 100's) | Rx | J.M. Tolmann Laboratories, Inc.Philippines | Dhan-Czar MarketingTrader: Interhealthcare Pharmaceuticals Inc. | DRP-1623-05 | Mar 10, 2028 | |
OmesenzOmeprazole (as sodium) | 40mg Lyophilized Powder for Injection (IV)10 mL Type II Transparent Amber color Tubular Glass Vial Sealed with Grey Butyl Rubber Stopper and Flip- Off Seal Cap x 1's (Box 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Pharmaessence, Inc. | DRP-13545 | Mar 8, 2028 | |
Omestop IIOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl rubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | OM Biomedic Pvt. Ltd.India | Jackson Pharmaceuticals Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15495-06 | Jul 26, 2029 | |
OmetanOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I Amber Glass Vial (active) + USP Type I Clear Glass Ampoule x 10 mL (diluent) (Box of 1's) | Rx | Gufic Biosciences Ltd.India | SRS Life Sciences Inc. | DRP-5669 | Jul 8, 2028 | |
OmetiftOmeprazole | 20 mg Delayed Released CapsuleAlu/Alu Strip Foil x 10’s (Box of 100's) | Rx | Kopran LimitedIndia | Triple Tact Import & Export Corp. | DRP-6949 | Dec 14, 2031 | |
OmetorOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (IV)Kit contains: Low Borosilicate Glass Vial with blue-colored flip-off seal; Water for Injection 10 mL Box of 5's and Box of 1's | Rx | Cisen Pharmaceutical Co., Ltd.China | Endure Medical Inc. | DR-XY43602 | Aug 6, 2029 | |
OmetrolOmeprazole | 20 mg CapsuleAlu/Alu Strip Foil x 10’s (Box of 100’s) | Rx | Umedica Laboratories Pvt. Ltd.India | Suhitas Pharmaceuticals Inc. | DRP-2931 | Apr 19, 2029 | |
OmevarozOmeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | Varoz MarketingImporter: Ambica International Corporation | DRP-2725-05 | Jan 17, 2028 | |
OmevexOMEPRAZOLE (AS SODIUM) | 40 mg Lyophillized Powder for IV infusionLow Borosilicate Glass Vial (Box of 5's and 10's) | Rx | Livzon(Group) Pharmaceutical FactoryZhuhai Guangdong China | Sannovex Pharmaceutical Distributor | DRP-2822 | Mar 2, 2031 | |
OmevinOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Tubular Glass Vial with Gray Bromobutyl Rubber Stopper and Purple Aluminum Flip-Off Seal Cap x 10 mL + 10 mL Sterile Water for Injection in White Polyethylene (PE) Plastic Form-Fill-Seal (FFS) Ampoule (Box of 1's) | Rx | Jodas Expoim Pvt. Ltd.India | Vintel Med EnterprisesImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-11492-07 | Mar 17, 2027 | |
OmevinOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl tubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | OM Biomedic Pvt. Ltd.India | Vintel Med EnterprisesImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-15496-13 | Jul 26, 2029 | |
OmexacOmeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10’s (Box of 100’s) | Rx | XL Laboratories Pvt. Ltd.India | D&G PharmaImporter: Ambica International Corporation | DRP-2725-20 | Jan 17, 2028 | |
Omexac-20Omeprazole | 20 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's Box of 30's and 100's | Rx | Stallion Laboratories Pvt. Ltd.India | D&G PharmaImporter: Ambica International Corporation | DRP-3047-04 | Jun 15, 2029 | |
Omexac-40Omeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)10 mL-capacity USP Type II amber glass vial with gray butyl rubber stopper and blue aluminum plastic caps + USP Type I transparent glass ampoule x 10 mL water for injection (diluent) [Box of 1's] | Rx | Reyoung Pharmaceutical Co. Ltd.China | D & G PharmaImporter: Ambicare Pharmaceuticals Inc. | DRP-13236-06 | Jan 6, 2028 | |
Omexac-40Omeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent (Box of 1 vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | D&G PharmaImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-31 | Dec 27, 2028 | |
OmeyouOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (IV)10 mL-capacity USP Type II amber glass vial with gray butyl rubber stopper and blue aluminum plastic caps + USP Type I transparent glass ampoule x 10 mL water for injection (diluent) [Box of 1's] | Rx | Reyoung Pharmaceutical Co. Ltd.China | Ambicare Pharmaceuticals Inc.Importer: Ambicare Pharmaceuticals, Inc. | DRP-13236 | Jan 6, 2028 | |
OmezarOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl rubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | Om Biomedic Pvt. Ltd.India | Sanzar Pharmaceuticals Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15495-02 | Jul 26, 2029 | |
OmezidOmeprazole | 20 mg CapsuleAlu-Alu Blister Pack x 8's (Box of 32's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Prosel Pharmaceuticals & Distributors, Inc. | DR-XY40682 | Feb 24, 2027 | |
Omezin-20Omeprazole | 20 mg Gastro-Resistant Capsule | Rx | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-17682 | Feb 18, 2031 | |
Omezin-40Omeprazole (as sodium) | 40 mg Lyophilized Powder for Solution for Injection (IV)10 mL-capacity clear low borosilicate glass vial with rubber stopper and aluminum white flip-off seal (Box of 1's) | Rx | Cisen Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-18470 | Jul 23, 2031 | |
OmezolOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (IV)USP Type I Amber Colored Glass Vial + 10 mL Polypropylene Ampoule (as diluent) [Box of 1's] | Rx | Swiss Parenterals Ltd.India | Endure Medical, Inc. | DR-XY39893 | Aug 10, 2028 | |
OMEZYN-20Omeprazole | 20 mg CapsuleAlu Strip Foil x 2's (Box of 14's); Alu Strip Foil x 10's (Box of 100's) | Rx | OMAN PHARMACEUTICAL PRODUCTS CO., LLCOman | MG PRIME PHARMACEUTICAL INC.Importer: ATLANTIC PHARMACEUTICALS, INC. | DRP-7434 | Dec 5, 2028 | |
Omi-Pearl 40Omeprazole (as sodium) | 40mg Powder for Solution for injection (IV)10mL USP Type I Amber glass vial + 10mL Ampoule diluent (Box of 1's) | Rx | Scoot-Edil Pharmacia LimitedIndia | I.E. Medica, Inc. | DRP-8557 | Oct 6, 2032 | |
OmigutOmeprazole (as sodium) | 40 mg Powder for Injection10 mL amber glass vial, with rubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | Skymap Healthcare Pvt. Ltd.India | Khriz Pharma Trading Inc. | DR-XY49535 | Oct 7, 2030 | |
OmipinOmeprazole | 20 mg Delayed-Release CapsuleAluminum Foil Strip x 10’s (Box of 100’s) | Rx | Brawn Laboratories LimitedIndia | Jjysrinn Trading Inc.Importer: Ambica International Corporation | DRP-4149 | Dec 18, 2027 | |
OmipraOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with Pink Flip-off Seal + 10 mL Sterile Water for Injection as Diluent Box of 1 Vial + Diluent | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Excelpharm CorporationImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-34 | Dec 27, 2028 | |
Omlek-40Omeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-2725-06 | Jan 17, 2028 | |
OmprazOmeprazole (as Sodium) | 40 mg Powder for Injection (IV)10mL USP Type I clear glass vial with rubber stopper and blue flip off seal with Water for Injection (Type I Clear Colorless Glass Ampoule x 10mL) (Box of 1's and 10’s) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Southmed Pharma CorporationImporter: AMB HK Enterprises Inc. | DRP-8396-07 | Nov 19, 2028 | |
OmprazomepOmeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-4887-03 | Nov 4, 2028 | |
OmprelexOmeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Fredun Pharmaceuticals LimitedIndia | Excelcare, Inc.Importer: AMB HK Enterprises Inc. | DRP-14809-02 | Feb 26, 2029 | |
OmrozOmeprazole | 40 mg Lyophilized Powder for Injection (I.V.)10 mL USP Type I Amber Vial with Rubber Stopper & Blue Flip-off Seal + 10 mL Clear Ampoule Sterile Water for Injection (Box of 1's) | Rx | Celon Laboratories Private LimitedIndia | Medethix, Inc.Importer: I.E. Medica, Inc. | DRP-1499-03 | Apr 23, 2031 | |
OmzolOmeprazole (as sodium) | 40mg Lyophilized Powder for Injection (I.V)USP Type I moulded Glass Vial with grey Butyl Rubber Stopper and Red Flip-Off Seal (Box of 1's) | Rx | Aspiro Pharma LimitedIndia | Camber Pharmaceuticals, Inc. | DRP-9510 | Feb 24, 2031 | |
Onesin-40Omeprazole | 40mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-14809 | Feb 26, 2029 | |
OpelOmeprazole | 20 mg CapsuleFoil Strip x 10’s (Box of 30's and 100’s) | Rx | Nabros Pharma Pvt. Ltd.India | Santemed Medical Equipment and Supplies TradingImporter: Ambica International Corporation | DRP-6303 | Dec 14, 2031 | |
OprazOmeprazole | 20mg CapsuleAluminum Foil Strip x 10's Box of 100's | Rx | Berlin Pharmaceuticals Industry Co., Ltd.Thailand | Littman Drug Corporation | DR-XY32461 | Oct 18, 2028 | |
OprexOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I tubular glass vial with rubber stopper and flip-off cap (Box of 10’s) | Rx | Reyoung Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-9122 | Sep 4, 2030 | |
OrazoOmeprazole | 40 mg Lyophilized Powder for Injection (IV)10 mL-capacity USP type I amber glass vial with bromo butyl rubber stopper and aluminum flip-off seal and FFS ampoule x 10 mL for sterile water for injection (diluent) [in one box] | Rx | Med Biopharm Pvt. Ltd.India | Elin Pharmaceuticals, Inc.Importer: Pors Pharma Trading | DRP-17355-04 | Oct 24, 2031 | |
OromepOmeprazole (as sodium) | 40 mg Lyophilized Powder for Intravenous Injection/Infusion10 mL Type I glass vial, with rubber stopper and flip-off seal (drug product) + 10 mL Type I glass ampoule (Sterile Water for Injection as diluent) (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Oro Sinai Pharma and General Merchandise, Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-11700-01 | Apr 25, 2027 | |
OvintOmeprazole Sodium | 40 mg Lyophilized Powder for InjectionUSP Type I Clear Glass Vial x 10 mL (Box of 1's) | Rx | FUREN PHARMACEUTICAL GROUP CO., LTD.China | VINTEL MED ENTERPRISESImporter: AGLOBAL CARE, INC. | DRP-5930-03 | Dec 5, 2028 | |
Ozolex 20Omeprazole | 20 mg CapsuleAlu/Alu Blister Pack x 7's (Box of 70's) | Rx | Hetero Labs Limited (Unit III)India | Camber Pharmaceuticals, Inc. | DRP-16532 | May 22, 2030 | |
Ozolex 40Omeprazole | 40 mg CapsuleAlu/Alu Blister Pack x 7's (Box of 70's) | Rx | Hetero Labs Limited (Unit III)India | Camber Pharmaceuticals, Inc. | DRP-16533 | May 22, 2030 | |
OzuprakOmeprazole | 20 mg CapsuleAlu/Alu Blister Pack x 7's (Box of 14's) . | Rx | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc. | DRP-16791 | Jul 11, 2030 | |
PepticureOmeprazole | 40mg (equivalent to 44.63mg Omeprazole sodium) Lyophilized Powder for Injection (I.V.)USP Type II Amber Tubular Vial x 10mL with Butyl Rubber Stopper and Flip-off Aluminum Seal (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Importer: Pharma-Surrey International, Inc. | DRP-11407 | Mar 9, 2027 | |
PeptinOmeprazole | 20 mg Delayed-Release CapsuleAluminum Foil Strip x 10’s (Box of 100’s) | Rx | Brawn Laboratories LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-4149-02 | Dec 18, 2027 | |
Peptisolv IVOmeprazole (as sodium) | 40 mg Lyophilized Powder for I.V. InjectionBox of 1 contains: 10 mL-Capacity Type I Colorless Glass Vial with Grey Bromobutyl Rubber Stopper and Blue Flip-off Cap and Water for Injection (as Diluent) in USP Type I Colorless Glass Ampoule x 10 mL | Rx | Centurion Ilac Sanayi Ve Ticaret A.S. Ankara SubesiTurkey | Justright Healthcare Inc.Importer: Ambicare Pharmaceuticals Inc. | DRP-12801-01 | Oct 12, 2027 | |
PeptoblocOmeprazole | 20 mg CapsuleAlu/Alu Foil Strip x 10's (Box of 100's) | Rx | Medico Remedies LimitedIndia | Vitalife Pharma & Medical Supply Inc.Importer: Medethix, Inc. | DRP-14049-01 | Jun 8, 2028 | |
PharzoleOmeprazole (As Sodium) | 40 mg Lyophilized Powder for I.V. Injection10 mL-capacity USP Type I amber glass vial with gray bromobutyl rubber stopper and aluminum seal with blue-colored polypropylene flip-off cap (Box of 1 vial) | Rx | Affy ParenteralsIndia | Pharmakon Biotec, Inc. | DRP-11590 | Mar 31, 2027 | |
PhilrazoOmeprazole (as Sodium) | 40 mg Powder for Injection (IV)10 mL USP Type I Clear Glass Vial with Rubber Stopper and Red Flip-off Seal + Water for injection (Type I Clear Colorless Glass Ampoule x 10 mL) (Box of 1's and 10's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-8396-09 | Nov 19, 2028 | |
PibitorOmeprazole | 20 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | 228 Pharma TradingImporter: Ambica International Corporation | DRP-3047-07 | Jun 15, 2029 | |
PillprazoleOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)10 mL-Capacity USP Type II amber glass vial with gray butyl rubber stopper and blue aluminum plastic caps + USP Type I transparent glass ampoule x 10 mL water for Injection (diluent) [Box of 1's] | Rx | Reyoung Pharmaceutical Co. Ltd.China | Diafarm Inc.Importer: Ambicare Pharmaceuticals Inc. | DRP-13236-08 | Jan 6, 2028 | |
PorsomeOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)10 mL-capacity USP Type I amber glass vial with rubber stopper and aluminum flip-off seal (Box of 10's) | Rx | Med Biopharm Pvt. Ltd.India | Pors Pharma Trading | DRP-16938 | Dec 10, 2029 | |
Pracid-40Omeprazole (as sodium) | 40 mg Powder for Solution for Injection (IV)In a box, 10 mL-capacity amber glass vial with rubber stopper and aluminum white flip-off seal + LDPE plastic ampoule x 10 mL for sterile water for injection (as diluent) | Rx | Skymap Healthcare Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-18397 | Jul 1, 2031 | |
PralecOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I Clear and Colorless Glass Vial (for the lyophilized powder) + 10 mL USP Type I Clear and Colorless Glass Ampoule [Diluent (0.9% Sodium Chloride)] in Aluminum PVC Blister Pack (Box of 1's) | Rx | Drug International LimitedBangladesh | Stratmed PharmaImporter: Jazmark Pharmaceutical | DRP-6422-07 | Apr 5, 2031 | |
PramepOmeprazole (as sodium) | 40 mg Powder for Injection (I.V.)10 mL-capacity USP Type II amber colored Clear Glass Vial with Gray Butyl Rubber stopper and blue aluminum plastic cap x 10 mL (Box of 1's) | Rx | Reyoung Pharmaceutical Co. Ltd.China | Blue Medceuticals Marketing Corp.Importer: Medinova Pharmaceutical Inc. | DRP-12554-04 | Sep 1, 2027 | |
PramizOmeprazole | 20 mg CapsuleAluminum Foil Strip x 10’s (Box of 30’s) | Rx | Zim Laboratories LimitedIndia | Suhitas Pharmaceuticals Inc. | DRP-526 | Nov 17, 2028 | |
PraxejanOmeprazole | 20 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Jjysrinn Trading Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Ltd. | DRP-5904-02 | Dec 17, 2029 | |
PraxidOmeprazole | 10 mg Delayed Release CapsulePET/Alu/PE Foil Strip x 4's (Box of 100's) | Rx | Interphil Laboratories, Inc.Philippines | — | DRP-4934 | Nov 20, 2028 | |
PraxidOmeprazole | 20 mg Delayed Release CapsulePET/Alu/PE Foil Strip x 4's (Box of 100's) | Rx | Interphil Laboratories, Inc.Philippines | — | DRP-4935 | Nov 18, 2028 | |
PraxolOmeprazole | 10 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 8's (Box of 16's, 24's and 80's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-6638 | Apr 12, 2031 | |
PraxolOmeprazole | 20 mg Delayed-release CapsuleAlu/Alu Blister Pack x 8's (Box of 16's, 24's and 80's) | Rx | Azarias Pharmaceutical Laboratories, Inc.Philippines | — | DRP-6639 | Apr 12, 2031 | |
PrazocapOmeprazole | 40 mg CapsuleFoil Strip x 10's Box of 30's | Rx | Lloyd Laboratories, Inc.Philippines | TGP Pharma, Inc.Trader: DB Manix International, Inc. | DRP-6946 | Aug 3, 2029 | |
PrazoCareOmeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 7's (Box of 70's) | Rx | Medisure Laboratories Pakistan (Pvt.) LimitedPakistan | Medcare PharmaceuticalsImporter: Accesspoint International Trading Inc. | DRP-6027-05 | Feb 27, 2030 | |
PRAZOCOMOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I Tubular Glass Vial with Butyl Rubber Stopper and Flip-Off Cap (Box of 10's) | Rx | Reyoung Pharmaceutical Co., LtdChina | Compharm, Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-8747-04 | Feb 20, 2030 | |
PrazomeOmeprazole | 20 mg Delayed Release CapsuleAlu/Alu Blister Pack x 7's (Box of 14's) | Rx | Magbro Healthcare Pvt. Ltd.India | Importer: Pharmakon Biotec, Inc. | DRP-12448 | Aug 9, 2027 | |
PrazotamOmeprazole (as sodium monohydrate) | 40mg Lyophilized Powder for Injection (I.V.)10mL amber and transparent USP Type II glass tubular vials sealed with gray butyl rubber stopper and blue aluminum plastic cap + 10mL USP Type I glass transparent colorless ampoule (Water for Injection as diluent) (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Tamiga Pharmaceuticals SupplyImporter: GPC Geo Pharma Corporation | DRP-12424-01 | Aug 4, 2027 | |
PremioOmeprazole (as sodium) | 40 mg Lyophilized Powder for I.V. InfusionUSP Type I Clear Glass Vial with Light Pink Flip-Off Seal + Clear Colorless Ampoule x 5 mL (Diluent Sodium Chloride 0.9% Injection) (Box of 1's) | Rx | Bosch Pharmaceuticals (Pvt.) Ltd.Pakistan | Nueva Sunshine Phils., Inc.Importer: Sahar International Trading, Inc. | DRP-13676-01 | Jul 9, 2029 | |
PromeprazoleOmeprazole (as Sodium) | 40 mg Powder for Injection (I.V.)10 mL colorless USP Type III Vial and Diluent 10 mL Sterile Water for Injection in plastic FFS Not Applicable | Rx | Gufic Biosciences LimitedIndia | Providencia Medica Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-1570-10 | Aug 11, 2031 | |
PromeprazoleOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with Pink Flip-off Seal + 10 mL Sterile Water for Injection as Diluent Box of 1 Vial + Diluent | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Providencia Medica Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-35 | Dec 27, 2028 | |
Promeprazole-20Omeprazole | 20 mg CapsuleFoil Strip x 10's (Box of 100's) | Rx | J.M. Tolmann Laboratories, Inc.Philippines | Providencia Medica Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1623-08 | Mar 10, 2028 | |
ProsecOmeprazole | 20 mg CapsuleAlu/Alu Blister Pack x 4's (Box of 20's) | Rx | The ACME Laboratories LimitedBangladesh | Bell-Kenz Pharma Inc.Importer: Euro Generics International Phils., Inc. | DRP-742-01 | Aug 17, 2029 | |
ProsecOmeprazole (as sodium) | 40 mg Powder for Injection (IV)Clear colorless glass vial + 10 mL clear colorless glass ampoule (diluent) in a sealed plastic tray per box | Rx | The ACME Laboratories LimitedBangladesh | Bell-Kenz Pharma Inc.Importer: Euro Generics International Phils., Inc. | DRP-5657 | Nov 21, 2027 | |
ProtonblockOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL Type III Amber Glass Vial with Pink Flip-Off Seal + 10 mL Sterile Water for Injection as diluent (Box of 1 vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | JWK Enterprises, Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-23 | Dec 27, 2028 | |
ProtonfreeOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Tubular Glass Vial with Gray Bromobutyl Rubbert Stopper and Blue Aluminum Flip-off Seal Cap x 10 mL + 10 mL Sterile Water for Injection in White Polyethylene (PE) Plastic Form-Fill-Seal (FFS) Ampoule (Box of 1's) | Rx | Jodas Expoim Pvt. Ltd.India | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-11492-08 | Mar 17, 2027 | |
ProtonfreeOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl rubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | Om Biomedic Pvt. Ltd.India | Afree Pharmaceutical Distribution and Consultancy Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15496-03 | Jul 26, 2029 | |
ProtosanOmeprazole (as sodium) | 40 mg Lyophilized Powder for Intravenous Injection/Infusion10 mL Type I glass vial with rubber stopper and flip off seal (drug product) +10 mL Type I glass ampoule (Sterile Water for Injection as diluent) (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Compharm, Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-11700-07 | Apr 25, 2027 | |
ProzalacOmeprazole | 20 mg CapsuleAlu/Alu Blister Pack x 8's (Box of 24's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Philippine Home Pharmaceutical | DR-XY42535 | Sep 6, 2028 | |
ProzalacOmeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 8's (Box of 24's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Philippine Home Pharmaceuticals | DR-XY45496 | Jul 5, 2031 | |
PuroxelOmeprazole | 20 mg CapsuleFoil Strip x 10's (Box of 20's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Vitalink Health Products, Inc. | DRP-716 | Dec 13, 2029 | |
PuroxelOmeprazole | 40 mg CapsuleAlu/Alu Blister Pack x 8's (Box of 24's) | Rx | Lloyd Laboratories, Inc.Philippines | Lunarmed Pharma TradingTrader: Vitalink Health Products, Inc. | DRP-6378 | Sep 23, 2028 | |
QerdOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)10 mL Type II Transparent Amber color Tubular Glass Vial Sealed with grey Butyl Rubber Stopper and Flip-off Seal Cap x 1's (Box of 10's) | Rx | Reyoung Pharmaceutical Co., LtdChina | Ellebasy Medicale Group Inc.Importer: Pharmaessence Inc. | DRP-13545-01 | Mar 8, 2028 | |
QmeprazoleOmeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Jiangxi Xierkangtai Pharmaceutical Co., Ltd.China | QUAD-GEN PHARMACEUTICALSImporter: PHILRX PHARMA INC. | DRP-9420-01 | Dec 5, 2028 | |
QmeprazoleOmeprazole (as Sodium) | 40 mg Powder for Injection (IV)10 mL USP Type I clear glass vial with rubber stopper and blue flip off seal with Water for Injection (Type I Clear Colorless Glass Ampoule x 10 mL) (Box of 1's and 10's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Quad-Gen PharmaceuticalsImporter: AMB HK Enterprises Inc. | DRP-8396-05 | Nov 19, 2028 | |
RamezoleOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (I.V.)10 mL USP Type I clear and colorless glass vial + 10 mL USP Type I clear and colorless glass ampoule (0.9% sodium chloride as diluent) (Box of 1's) | Rx | Aristopharma Ltd.Bangladesh | Amson PharmaceuticalsImporter: Sahar International Trading, Inc. | DRP-5041-01 | Jun 27, 2028 | |
RanzoleOmeprazole | 20 mg CapsuleAlu/Alu Blister Pack x 10 (Box of 100's) | Rx | Fredun Pharmaceuticals Limited.India | PhilRx Pharma Inc. | DRP-16739 | Jul 15, 2030 | |
RanzoleOmeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Jiangxi Xierkangtai Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc. | DRP-9420 | Dec 5, 2028 | |
RanzoleOmeprazole (as Sodium) | 40 mg Powder for Injection (IV)Borosilicate Tube Vial with Rubber Stopper and Blue Flip-Off Seal (Box of 10's) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | PhilRx Pharma, Inc.Importer: AMB HK Enterprises Inc. | DRP-3590-02 | Jul 14, 2028 | |
RanzoleOmeprazole | 40mg Enteric Coated CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-16731 | Jul 1, 2030 | |
RaqzoleOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)Type I Clear Glass Vial Sealed with Bromobutyl Rubber topper and Aluminum Flip-Off Seal Cap x 1's +5mL Sterile Water for Injection in Clear Glass Ampoule (Box of 1's and 10's) | Rx | Friends Pharma (Pvt.) Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-17100 | Sep 29, 2031 | |
RedacidOmeprazole | 40 mg capsuleAlu-Alu Blister Pack x 4's (Box of 40's) | Rx | Biopharma Laboratories LimitedBangladesh | Planetarium Enterprise, Inc.Importer: JF Draf Pharmaceuticals Corp. | DRP-1977-07 | Dec 1, 2029 | |
RedacidOmeprazole (as Sodium) | 40 mg Powder for Solution for Injection (IV)10 mL USP Type I Amber Glass Vial + 10 mL Ampoule Diluent (Box of 1's) | Rx | SCOTT EDIL PHARMACIA LTD.India | PLANETARIUM ENTERPRISE, INC.Importer: I.E. MEDICA, INC.Trader: ADI SOLUTIONS PTY. LTD. | DRP-8557-01 | Oct 6, 2027 | |
ReflucxidOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)10 mL Type II Amber Glass Vial Sealed with Gray Butyl Rubber Stopper and Blue Aluminum Plastic Cap + 10 mL Sterile Water for Injection in Type I Colorless and Transparent Glass Ampoule (Box of 1's) | Rx | Reyoung Pharmaceutical Group Co., Ltd.China | Asianmeds, Inc.Importer: Euro-Care Products Philippines | DRP-12583-08 | Sep 8, 2027 | |
RetamepOmeprazole (as sodium) | 40 mg Powder for Injection (I.V.)10 mL-capacity USP Type II amber colored Clear Glass Vial with Gray Butyl Rubber stopper and blue aluminum plastic cap x 10 mL (Box of 1's; Box of 10's) | Rx | Reyoung Pharmaceutical Co. Ltd.China | Reta DrugImporter: Medinova Pharmaceutical Inc. | DRP-12554-03 | Sep 1, 2027 | |
RetaprazOmeprazole Sodium | 40 mg Lyophilized Powder For InjectionUSP Type I Clear Glass Vial X 10 mL (Box of 1’s and 10’s); USP Type I Clear Glass Vial X 10 mL With 10 mL USP Type I Glass Ampoule containing Sterile Water for Injection (as Diluent) in a Box (Box of 1’s + Diluent) | Rx | FUREN PHARMACEUTICAL GROUP CO., LTD.China | RETA DRUGImporter: AGLOBAL CARE, INC. | DRP-5930-10 | Dec 5, 2028 | |
Retapraz-ROmeprazole (as sodium) | 40 mg Powder for Injection (I.V.)10 mL-capacity USP Type II amber glass vial with gray butyl rubber stopper and aluminum seal with blue plastic flip-off cap + USP Type I clear and colorless glass ampoule containing 10 mL Sterile Water for Injection as diluent (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Reta DrugImporter: Dreamax Incorporated | DRP-14850-02 | Jan 24, 2029 | |
RetaprezOmeprazole | 20mg Delayed-Release CapsuleAlu-Alu Foil Strip Pack x 10's (Box of 100's) | Rx | ACME Formulation Pvt. Ltd.India | Reta DrugImporter: Medinova Pharmaceutical Inc | DRP-10810-01 | Nov 26, 2026 | |
RetazoleOmeprazole (as sodium) | 40 mg Lyophilized Powder for Intravenous Injection/Infusion10 mL Type I glass vial, with rubber stopper and flip off seal (drug product) + 10 mL Type I glass ampoule (Sterile Water for Injection as diluent) (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Reta DrugImporter: Sanimed Pharmaceuticals Inc. | DRP-11700-04 | Apr 25, 2027 | |
RezoleOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I Clear and Colorless Glass Vial (for the lyophilized powder) + 10 mL USP Type I Clear and Colorless Glass Ampoule [Diluent (0.9% Sodium Chloride)] in Aluminum PVC Blister Pack (Box of 1's) | Rx | Drug International LimitedBangladesh | R.E. PharmaceuticalsImporter: Jazmark Pharmaceutical | DRP-6422-09 | Apr 5, 2031 | |
RisekOmeprazole | 20 mg Enteric-coated Pellets in CapsuleAlu/Alu Blister Pack x 7's/ (Box of 14's) | Rx | Getz Pharma (Pvt.) (Ltd.)Pakistan | Getz Pharma (Pvt.) (Ltd.) | DR-XY28643 | Jul 15, 2030 | |
RisekOmeprazole | 20 mg Enteric-coated Pellets in CapsuleAlu/Alu Blister Pack x 7's (Box of 14's) | Rx | Getz Pharma (Pvt.), Ltd.Pakistan | Importer: Getz Pharma (Phils.), Ltd. | DRP-16168 | May 14, 2028 | |
RisekOmeprazole (as sodium) | 40 mg/ vial Lyophilized Powder for Intravenous Injection and InfusionUSP Type II Amber Glass Vial (active) + 10 mL Clear Glass Ampoule (diluent) [Box of 1's] | Rx | Getz Pharma (Pvt.), Ltd.Pakistan | Importer: Getz Pharma (Phils.), Inc. | DRP-16187 | May 17, 2028 | |
RisekOmeprazole (as sodium) | 40 mg/vial Lyophilized Powder for Intravenous InjectionUSP Type II Amber Glass Vial (active) + 10 mL Clear Glass Ampoule (diluent) [Box of 1's] | Rx | Getz Pharma (Pvt.) Ltd.Pakistan | Getz Pharma (Phils.), Inc. | DR-XY31530 | Aug 15, 2030 | |
Risek 40Omeprazole | 40 mg Enteric-Coated Pellet in CapsuleAlu-Alu Blister Pack of 7's (Box of 14's) Alu/Alu Blister Pack of 1's Box of 1's (Physician Sample) | Rx | Getz Pharma Pvt. Ltd.Pakistan | Getz Pharma (Phils.), Inc. | DR-XY33622 | Jul 15, 2030 | |
Risek 40Omeprazole | 40mg CapsuleAlu/Alu Blister Pack x 7's (Box of 14's); Alu/Alu Blister Pack x 1’s (Box of 1’s) [Physician sample] | Rx | Getz Pharma (Pvt.), Ltd.Pakistan | Importer: Getz Pharma (Phils.), Inc. | DRP-16171 | Jul 12, 2027 | |
RobimepOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection/Infusion10 mL USP Type I Amber Glass Vial + 10 mL USP Type I Clear and Colorless Glass Ampoule containing Sterile Water for Injection (as diluent) Box of 1's | Rx | Gufic Biosciences LimitedIndia | Rx Global Sales and Mktg. Corp.Importer: Suhitas Pharmaceuticals Inc. | DRP-5882-05 | Dec 9, 2027 | |
ROMEP-40Omeprazole Sodium | 40 mg Lyophilized Powder for InjectionUSP Type I Clear Glass Vial x 10 mL with 10 mL USP Type I Glass Ampoule containing Sterile Water for Injection (as diluent) in a Box | Rx | FUREN PHARMACEUTICAL GROUP CO., LTD.China | RODAISE PHARMA DISTRIBUTOR CORPORATIONImporter: AGLOBAL CARE, INC. | DRP-5930-08 | Dec 5, 2028 | |
Seaprazole 40Omeprazole | 40 mg CapsuleAlu Strip Foil x 10's (Box of 100's) | Rx | Windlas Biotech LimitedIndia | MultiGro Healthcare Inc.Importer: Grovic Pharma Inc. | DRP-3016-01 | Jun 2, 2028 | |
SerocidOmeprazole (as Sodium) | 40mg Lyophilized Powder For IV InjectionBox of 1 contains: 10 mL-Capacity Type I Colorless Glass Vial with Grey Bromobutyl Rubber Stopper and Blue Flip-off Cap and Water for Injection (as Diluent) in USP Type I Colorless Glass Ampoule x 10 mL | Rx | Centurion Ilac Sanayi ve Ticaret A.S. Ankara SubesiTurkey | Stangen Pharmaceuticals Philippines | DRP-12801 | Oct 12, 2027 | |
SidprazoleOmeprazole (as sodium) | 40 mg Lyophilized Powder for I.V. InjectionUSP Type I Glass Vial (Box of 1's) | Rx | Harbin Pharmaceutical Group Bioengineering Co., Ltd.China | Sahar International Trading, Inc. | DRP-3943 | Apr 15, 2029 | |
Siti-OmepOmeprazole (as Sodium) | 40 mg Lyophilized Powder for IV InfusionUSP Type I Clear Glass Vial with Light Pink Flip-Off Seal + Clear Colorless Ampoule x 5 mL (Diluent Sodium Chloride 0.9% Injection) (Box of 1's) | Rx | Bosch Pharmaceuticals (Pvt.) Ltd.Pakistan | Sahar International Trading Inc. | DRP-13676 | Jul 9, 2029 | |
SomecidOmeprazole (as sodium) | 40 mg Powder for Injection (I.V.)10 mL colorless USP Type III vial & diluent 10 mL Sterile Water for Injection in plastic FFS | Rx | Gufic Biosciences LimitedIndia | Biotechnica Medical EnterprisesImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-1570 | May 21, 2031 | |
Somecid-20Omeprazole | 20 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-3047 | Jun 15, 2029 | |
SuprezolOmeprazole (as Sodium) | 40 mg Powder for Injection (I.V.)10 mL colorless USP Type III Vial and Diluent 10 mL Sterile Water for Injection in plastic FFS Not Applicable | Rx | Gufic Biosciences LimitedIndia | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-1570-09 | Jul 26, 2031 | |
SuprezolOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with Pink Flip-off Seal + 10 mL Sterile Water for Injection as diluent (Box of 1 vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Curasave PharmaImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-39 | Dec 27, 2028 | |
TansinelOmeprazole | 20 mg CapsuleAlu/Alu Blister Pack x 4's Box of 20's | Rx | The ACME Laboratories LimitedBangladesh | Euro Generics International Phils., Inc. | DRP-742 | Aug 17, 2029 | |
TechnozoleOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with pink flip-off seal + 10 mL Sterile Water for Injection as diluent (Box of 1 vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | One Technodrug Life Sciences Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-46 | Dec 27, 2028 | |
TerracidOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)10 mL Type II Amber Glass Vial Sealed with Gray Butyl Rubber Stopper and Blue Aluminum Plastic Cap + 10 mL Sterile Water for Injection in Type I Colorless and Transparent Glass Ampoule (Box of 1's) | Rx | Reyoung Pharmaeutical Co., Ltd.China | Santerra TradingImporter: Euro-Care Products Philippines | DRP-12583-01 | Sep 8, 2027 | |
TgprazolOmeprazole (as sodium) | 40 mg Powder for Injection (I.V.)10 mL-capacity USP Type II amber glass vial with gray butyl rubber stopper and aluminum seal with blue plastic flip-off cap + USP Type I clear and colorless glass ampoule containing 10 mL Sterile Water for Injection as diluent (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Tgif Pharmaceutical Trading Inc.Importer: Dreamax Incorporated | DRP-14850-01 | Jan 24, 2029 | |
TolprazOmeprazole (as sodium monohydrate) | 40 mg Lyophilized Powder for Injection (I.V.)10 mL amber and transparent USP Type II glass tubular vials sealed with gray butyl rubber stopper and blue aluminum plastic cap + 10 mL USP Type I glass transparent colorless ampoule (Water for Injection as diluent) [Box of 1's] | Rx | Reyoung Pharmaceutical Co., Ltd.China | Altor Pharmaceutical Product DistributionImporter: GPC Geo Pharma Corporation | DRP-12424-05 | Aug 4, 2027 | |
TriasopOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)10mL Type II Amber Glass Vial Sealed with Gray Butyl Rubber Stopper and Blue Aluminum Plastic Cap + 10mL sterile water for injection in Type I Colorless and Transparent glass ampoule (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | JPMR PharmaImporter: Euro-Care Products Philippines | DRP-12583-04 | Sep 8, 2027 | |
TrumeprazoleOmeprazole | 20 mg CapsuleAlu-Alu Blister Pack x 10's (Box of 100's) | Rx | Flamingo Pharmaceuticals Ltd.India | Trumed PharmaceuticalsImporter: Hexagon Pharmaceuticals | DRP-413-03 | Nov 13, 2027 | |
U-ZoleOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl tubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | OM Biomedic Pvt. Ltd.India | Universal MBF Pharma (UMP), Co.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15496-14 | Jul 26, 2029 | |
UlceracidOmeprazole (as sodium) | 40mg Lyophilized Powder For Injection (IV)10 mL-capacity USP type II amber glass vial with gray butyl rubber stopper and blue aluminum plastic cap (Box of 10’s) | Rx | Reyoung Pharmaceutical Co., Ltd.China | GPC Geo Pharma Corporation | DRP-13808 | Apr 26, 2028 | |
UlceraidOmeprazole | 20mg Delayed-Release CapsuleAlu-Alu Blister Strip x 10’s (Box of 30’s and 100’s) | Rx | Windlas Biotech Limited (Plant 2)India | Synergia Health Care & Life Sciences, Inc . | DRP-19058 | Oct 26, 2031 | |
UlcerateOmeprazole | 20 mg Delayed Release CapsuleAlu/Alu Strip Foil x 10’s Box of 100's | Rx | Kopran LimitedIndia | Guimhealth Pharmaceutical Distributor and DrugstoreImporter: Triple Tact Import & Export Corp. | DRP-6949-05 | Dec 14, 2031 | |
UlcomezOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (I.V.)10 mL Type 1 Amber Glass Vial with pink flip-top seal and rubber stopper Box of 1's | Rx | Naprod Life Sciences Pvt. Ltd.India | Importer: RiteMED Phils., Inc. | DR-XY38790 | Nov 30, 2027 | |
UlsekOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)Type I Boron-silicate colorless glass vial (Box of 1's + Diluent) | Rx | Standard Chem & Pharm Co., LtdChina | Phil Pharmawealth, Inc. | DR-XY29163 | Nov 18, 2028 | |
UlzolOmeprazole | 20 mg CapsuleFoil Strip x 10's (Box of 100's) | Rx | J.M. Tolmann Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1623 | Mar 10, 2028 | |
UMBRIVOOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Tubular Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 10 mL + 10 mL Sterile Water for Injection in White Polyethylene (PE) Plastic Form-Fill-Seal (FFS) Ampoule (Box of 1's) | Rx | Jodas Expoim Pvt. Ltd.India | Triple Tact Import & Export Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-11492-18 | Mar 17, 2027 | |
UnbrandedOmeprazole | 20 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Zim Laboratories LimitedIndia | Actimed, Inc.Importer: I.E. Medica, Inc. | DRP-13336 | Apr 26, 2031 | |
UnbrandedOmeprazole | 40 mg Capsule | Rx | Lloyd Laboratories, Inc. | Actimed, Inc.Trader: Innogen Pharmaceuticals, Inc. | DR-XY40330 | Nov 21, 2026 | |
UnbrandedOmeprazole | 40 mg CapsuleAlu/Alu Blister Pack x 8's (Box of 24's) | Rx | Lloyd Laboratories, Inc.Philippines | Actimed, Inc.Trader: Innogen Pharmaceuticals, Inc. | DRP-11761 | Nov 21, 2031 | |
UnbrandedOmeprazole | 40 mg CapsuleAlu/Alu Blister Pack x 8's (Box of 24's) | Rx | Lloyd Laboratories, Inc.Philippines | St. Joseph DrugstoreTrader: Innogen Pharmaceuticals, Inc. | DRP-11761-01 | Nov 21, 2031 | |
UnbrandedOmeprazole | 40 mg CapsuleAlu/Alu Blister Pack x 8's (Box of 24's) | Rx | Lloyd Laboratories, Inc.Philippines | Rose Pharmacy, IncorporatedTrader: Innogen Pharmaceuticals, Inc. | DRP-11761-02 | Nov 21, 2031 | |
UnbrandedOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)USP Type I Clear Glass Vial with Green Flip-Off Seal + Type I Clear Glass Ampoule (diluent) x 10 mL | Rx | Standard Chem. & Pharm. Co., LtdChina | Phil Pharmawealth, Inc. | DR-XY31035 | Sep 1, 2030 | |
UnomepOmeprazole | 40mg Lyophilized Powder for Injection (IV)10 mL-capacity USP type I amber glass vial with bromo butyl rubber stopper and aluminum flip-off seal and FFS ampoule x 10 mL for sterile water for injection (diluent) [in one box] (Box of 1's) | Rx | Med Biopharm Pvt. Ltd.India | One UP Pharmaceutical and Medical Supplies CorporationImporter: Pors Pharma Trading | DRP-17355-01 | Oct 24, 2031 | |
VALOMEZOmeprazole | 40 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 100’s) | Rx | Jiangxi Xierkangtai Pharmaceutical Co., Ltd.China | SwissPharmatech Co.Importer: PhilRx Pharma Inc. | DRP-9420-04 | Jul 1, 2030 | |
ViprazoleOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)Type III Clear Glass Vial Sealed with Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Mason PharmaIndia | Vios Integrated Projects (VIP) Inc.Importer: Finstad Inc. | DRP-11022-01 | Apr 29, 2027 | |
WilomOmeprazole | 40 mg capsuleWhite PVDC/Aluminum Blister Pack x 10's (Box of 50's) | Rx | Hizon Laboratories, Inc.Philippines | New Willore Pharma Corp. | DRP-945 | Jul 4, 2031 | |
XolepremeOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV InfusionUSP Type I flint tubular glass vial Box of 1's | Rx | Gufic Biosciences LimitedIndia | Ambica International CorporationTrader: Gufic Stridden Biopharma Pvt. Ltd. | DRP-8271 | Jul 25, 2029 | |
Xoprazole PlusOmeprazole | 40 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 70's and 100's) | Rx | Medisure Laboratories Pakistan (Pvt.) LimitedPakistan | Accesspoint International Trading, Inc. | DRP-6027 | Feb 26, 2030 | |
YumepraOmeprazole (as Sodium) | 40 mg Powder for Injection (IV)USP Type I Clear Glass Vial with Rubber Stopper and Blue Flip-off Seal x 10 mL (Box of 10's) | Rx | CSPC Ouyi Pharmaceutical (Shijiazhuang) Co.LtdChina | Clearvue PharmaceuticalImporter: AMB HK Enterprises | DRP-8396 | Aug 28, 2030 | |
ZefxonOmeprazole | 40 mg Lyophilized Powder for Injection (IV)Type I Colorless Glass Vial with Bromobutyl Rubber Stopper and White Flip-Off seal + Type I Glass Ampoule x 10 mL Solvent for Reconstitution Box of 1's | Rx | BIOLAB CO., LTD.Thailand | THE CATHAY DRUG CO., INC. | DR-XY35911 | Jun 11, 2029 | |
Zemo 20Omeprazole | 20 mg CapsuleAluminum Foil Strip x 10’s (Box of 100’s) | Rx | Agio Pharmaceuticals Ltd.India | Ambica International Corporation | DRP-4950 | Apr 29, 2029 | |
ZemomaxOmeprazole | 20 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Prodrom Nutritionals, IncorporatedImporter: Ambica International Corporation | DRP-3047-10 | Jun 15, 2029 | |
ZemomaxOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with Pink Flip-off Seal + 10 mL Sterile Water for Injection as diluent (Box of 1 vial + diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | Prodrom Nutritionals, IncorporatedImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-28 | Dec 27, 2028 | |
ZenomepOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)Type III Clear Glass Vial Sealed with Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Mason PharmaIndia | Genzen Pharmaceutical TradingImporter: Finstad Inc. | DRP-11022-03 | Apr 29, 2027 | |
ZertazoleOmeprazole | 40 mg Delayed Release CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | F.C. Andres Drug DistributorImporter: Ambica International Corporation | DRP-4887-02 | Nov 4, 2028 | |
ZolashOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)10 mL Type I Amber Glass Vial Sealed with Grey Bromobutyl Rubber Stopper and Magenta Aluminum Flip-Off Seal Cap x 1's (Box 1's) | Rx | Nitin Lifesciences Ltd. (Unit III)India | Medko Pharmaceuticals DistributorImporter: Pharmakon Biotec Inc. | DRP-13514-04 | Mar 2, 2028 | |
ZolecOmeprazole | 20 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Centurion Laboratories Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-1421 | Jul 10, 2028 | |
Zolec 40Omeprazole | 40 mg CapsuleAluminum Strip Foil x 6's (Box of 30's) | Rx | Hizon Laboratories, Inc.Philippines | Sigmamatic Co. Inc. | DRP-4769 | Jul 29, 2029 | |
ZolemedOmeprazole (as sodium) | 40mg Powder for Injection (IV.)10 mL-capacity USP Type II amber glass vial with gray glass vi butyl rubber stopper and aluminum seal with blue plastic flip-off cap (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Dreamax Incorporated | DRP-14851 | Jan 25, 2029 | |
Zolemed-WFIOmeprazole (as sodium) | 40mg Powder for Injection (I.V.10 mL-capacity USP Type II amber glass vial with gray butyl rubber stopper and aluminum seal with blue plastic flip-off cap + USP Type I clear and colorless glass ampoule containing 10 mL Sterile Water for Injection as diluent (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Dreamax Incorporated | DRP-14850 | Jan 24, 2029 | |
ZolemepOmeprazole (as sodium) | 40 mg Powder for Injection (IV)10 mL USP Type III Amber Glass Vial with Pink Flip-off Seal + 10 mL Sterile Water for Injection as Diluent (Box of 1 Vial + Diluent) | Rx | Shreechem Pharmaceuticals Pvt. Ltd.India | SH & S EnterprisesImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5025-13 | Dec 27, 2028 | |
ZolexcelOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (IV Infusion)10 mL Type II Amber Glass Vial Sealed with Gray Butyl Rubber Stopper and Blue Aluminum Plastic Cap + 10 mL Sterile Water for Injection in Type I Colorless and Transparent Glass Ampoule (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | MedRep Plus Pharmaceuticals Inc.Importer: Euro-Care Products Philippines | DRP-12583-03 | Sep 8, 2027 | |
ZolexempOmeprazole (as Sodium) | 40 mg Powder for Injection (I.V.)10 mL colorless USP Type III Vial and Diluent 10 mL Sterile Water for Injection in plastic FFS Not Applicable | Rx | Gufic Biosciences LimitedIndia | Excelpharm CorporationImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-1570-03 | Aug 11, 2031 | |
ZolfreeOmeprazole (as sodium) | 40 mg Lyophilized Powder for IV Injection10 mL USP type I amber glass vial with grey bromobutyl rubber stopper, aluminum seal and white flip-off cap (Box of 1's) | Rx | OM Biomedic Pvt. Ltd.India | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-15496-06 | Jul 26, 2029 | |
ZolnevarOmeprazole (As Sodium) | 40 mg Lyophilized Powder for I.V. InjectionUSP Type I Amber Glass Vial with Pink Flip-Off Seal (Box of 1's and 10's) | Rx | Lyka Labs, Ltd.India | Bansan Pharma DistributorImporter: Arvincare Pharma Inc. | DRP-2116-02 | Feb 24, 2037 | |
ZolphenOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (IV)10 mL Clear Colorless Type III Glass Vial with Rubber Stopper and Blue Flip-Off Seal in Individual Box (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Philgen Pharmaceuticals Inc. | DRP-1876 | Jan 7, 2029 | |
ZolppiOmeprazole | 20 mg Delayed-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Zim Laboratories Limited441501 India | I.E. Medica, Inc. | DRP-9685 | May 11, 2031 | |
ZomepOmeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection (I.V.)USP Type I Clear and Colorless Glass Vial (for the lyophilized powder) + 10 mL USP Type I Clear and Colorless Glass Ampoule [Diluent (0.9% Sodium Chloride)] in Aluminum PVC Blister Pack (Box of 1's) | Rx | Drug International LimitedBangladesh | ECE Pharmaceuticals, Inc.Importer: Jazmark Pharmaceutical | DRP-6422-10 | Apr 5, 2031 | |
ZopramepOmeprazole (as sodium) | 40 mg Powder for Injection (I.V.)10 mL capacity USP Type 1 amber glass vial (Box of 1's) | Rx | Swiss Parenterals Ltd..India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-7385-01 | Oct 9, 2027 | |
ZyomOmeprazole | 40 mg Lyophilized Powder for Injection (IV)USP Type I Amber Glass Vial + 10 mL FFS Ampoule (Box of 1's) | Rx | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines, Inc. | DRP-7373 | Sep 23, 2029 | |
ZypantOmeprazole (as sodium) | 40 mg Lyophilized Powder for Injection (IV)10 ml Type I Amber Glass Vial Sealed with Grey Bromobutyl Rubber Stopper and Magenta Aluminum Flip-Off Seal Cap x 1's (Box 1's) | Rx | Nitin Lifesciences Ltd. (Unit III)India | Greentech Life Sciences Inc.Importer: Pharmakon Biotec Inc. | DRP-13514-01 | Mar 2, 2028 | |
(no brand name)Omeprazole | 20 mg CapsuleAlu/Alu foil strip x 10's (Box of 100's) | Rx | Medico Remedies LimitedIndia | MedEthix, Inc. | DRP-14049 | Jun 8, 2028 | |
(no brand name)Omeprazole (As Sodium) | 20 mg Lyophilized Powder for Intravenous Injection/ Infusion10 mL Low borosilicate clear glass vial with bromobutyl rubber stopper, aluminum flip-off seal and plastic cap (Box of 1's) | Rx | Shandong Yuxin Pharmaceutical Co., Ltd.China | Luoxin Pharmaceuticals (PH) Corp. | DR-XY47933 | Apr 25, 2027 | |
(no brand name)Omeprazole (as sodium) | 40 mg Lyophilized Powder for I.V. Injection10 mL-capacity clear and colorless glass vial with rubber stopper and aluminum seal with plastic flip-off cap (box of 1 vial) | Rx | Steril-Gene Life Sciences Pvt. Ltd.India | Euro-Health Care Exponents, Inc. | DR-XY47874 | Mar 31, 2027 | |
(no brand name)Omeprazole (as Sodium) | 40 mg Lyophilized Powder for Injection for I.V. InfusionBorosilicate glass vial with brominated butyl rubber stopper and aluminum plastic cap (Box of l's and 10's) | Rx | Hainan Brilliant Pharmaceutical Co., Ltd.China | Philgen Pharmaceuticals Inc. | DRP-12568 | Sep 7, 2027 | |
(no brand name)Omeprazole (As Sodium) | 40 mg Lyophilized Powder for Intravenous Injection/ Infusion10 mL Low borosilicate clear glass vial with bromobutyl rubber stopper, aluminum flip-off seal and plastic cap (Box of 1's) | Rx | Shandong Yuxin Pharmaceutical Co., Ltd.China | Luoxin Pharmaceuticals (PH) Corp. | DR-XY47937 | Apr 25, 2027 | |
(no brand name)Omeprazole (As Sodium) | 40 mg Lyophilized Powder for Intravenous Injection/ Infusion10 mL Type I glass vial, with rubber stopper and flip off seal (drug product) + 10 mL Type I glass ampoule (Sterile Water for Injection as diluent) (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Sanimed Pharmaceuticals Inc. | DRP-11700 | Apr 25, 2027 | |
(no brand name)Omeprazole | 40 mg Sterile Lyophilized Powder for Injection (IV)Tubular Glass Vials Sealed with Rubber Stopper with Flip-off Cap x 10 mL (Box of 10's) | Rx | North China Pharmaceutical Co., Ltd.China | Euro-Med Laboratories Phil., Inc. | DR-XY49638 | Feb 11, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Omeprazole Delayed-Release Capsules, USP 10 mg are size ‘3’ two piece hard gelatin capsules with a light blue to blue body with “G” imprinted in black ink and an orange cap with “G230” imprinted in black ink. The capsules are filled with white to off-white pellets. Omeprazole Delayed-Release Capsules, USP 20 mg are size ‘2’ two piece hard gelatin capsules with a light blue to blue body with “G” imprinted in black ink and a light blue to blue cap with “G231” imprinted in black ink.
The capsules are filled with white to off-white pellets. Omeprazole Delayed-Release Capsules, USP 40 mg are size ‘1’ two piece hard gelatin capsules with an orange body with ‘G’ imprinted in black ink and a light blue to blue cap with ‘G232’ imprinted in black ink. The capsules are filled with white to off-white pellets.
Omeprazole Delayed-Release Capsules: 10 mg, 20 mg and 40 mg (3)
Warnings/Precautions
- Gastric Malignancy: In adults, symptomatic response does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing. (5.1)
- Acute Tubulointerstitial Nephritis: discontinue treatment and evaluate patients. (5.2)
- Clostridium difficile -Associated Diarrhea: PPI therapy may be associated with increased risk. (5.3)
- Bone Fracture: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine. (5.4)
- Severe Cutaneous Adverse Reactions: Discontinue at the first signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation. (5.5)
- Cutaneous and Systemic Lupus Erythematosus: Mostly cutaneous; new onset or exacerbation of existing disease; discontinue omeprazole and refer to specialist for evaluation. (5.6)
- Interaction with Clopidogrel: Avoid concomitant use of omeprazole. (5.7, 7) Cyanocobalamin (Vitamin B-12) Deficiency: Daily long-term use (e.g., longer than 3 years) may lead to malabsorption or a deficiency of cyanocobalamin. (5.8)
- Hypomagnesemia and Mineral Metabolism: Reported rarely with prolonged treatment with PPIs. (5.9)
- Interaction with St. John’s Wort or Rifampin: Avoid concomitant use of omeprazole. (5.10, 7) Interactions with Diagnostic Investigations for …
5.1 Presence of Gastric Malignancy
5.1 Presence of Gastric Malignancy In adults, symptomatic response to therapy with omeprazole does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with a PPI. In older patients, also consider an endoscopy.
5.2 Acute Tubulointerstitial Nephritis
5.2 Acute Tubulointerstitial Nephritis Acute tubulointerstitial nephritis (TIN) has been observed in patients taking PPIs and may occur at any point during PPI therapy. Patients may present with varying signs and symptoms from symptomatic hypersensitivity reactions to non-specific symptoms of decreased renal function (e.g., malaise, nausea, anorexia).
In reported case series, some patients were diagnosed on biopsy and in the absence of extra-renal manifestations (e.g., fever, rash or arthralgia). Discontinue omeprazole delayed-release capsules and evaluate patients with suspected acute TIN [see Contraindications (4)].
5.3 Clostridium difficile
5.3 Clostridium difficile -Associated Diarrhea Published observational studies suggest that PPI therapy like omeprazole may be associated with an increased risk of Clostridium difficile- associated diarrhea, especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve [see Adverse Reactions (6.2)].
Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Clostridium difficile- associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents. For more information specific to antibacterial agents (clarithromycin and amoxicillin) indicated for use in combination with omeprazole, refer to Warnings and Precautions sections of the corresponding prescribing information.
5.4 Bone Fracture
5.4 Bone Fracture Several published observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer).
Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to established treatment guidelines [see Dosage and Administration (2.1), Adverse Reactions (6.3)].
5.5 Severe Cutaneous Adverse Reactions
5.5 Severe Cutaneous Adverse Reactions Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) have been reported in association with the use of PPIs [see Adverse Reactions (6.2)]. Discontinue omeprazole at the first signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation.
5.6 Cutaneous and Systemic Lupus Erythematosus
5.6 Cutaneous and Systemic Lupus Erythematosus Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs, including omeprazole. These events have occurred as both new onset and an exacerbation of existing autoimmune disease. The majority of PPI-induced lupus erythematosus cases were CLE.
The most common form of CLE reported in patients treated with PPIs was subacute CLE (SCLE) and occurred within weeks to years after continuous drug therapy in patients ranging from infants to the elderly. Generally, histological findings were observed without organ involvement. Systemic lupus erythematosus (SLE) is less commonly reported than CLE in patients receiving PPIs.
PPI associated SLE is usually milder than non-drug induced SLE. Onset of SLE typically occurred within days to years after initiating treatment primarily in patients ranging from young adults to the elderly. The majority of patients presented with rash; however, arthralgia and cytopenia were also reported. Avoid administration of PPIs for longer than medically indicated.
If signs or symptoms consistent with CLE or SLE are noted in patients receiving omeprazole, discontinue the drug and refer the patient to the appropriate specialist for evaluation. Most patients improve with discontinuation of the PPI alone in 4 to 12 weeks. Serological testing (e.g., ANA) may be positive and elevated serological test results may take longer to resolve than clinical manifestations.
5.7 Interaction with Clopidogrel
5.7 Interaction with Clopidogrel Avoid concomitant use of omeprazole with clopidogrel. Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by use with concomitant medications, such as omeprazole, that inhibit CYP2C19 activity.
Concomitant use of clopidogrel with 80 mg omeprazole reduces the pharmacological activity of clopidogrel, even when administered 12 hours apart. When using omeprazole, consider alternative anti-platelet therapy [see Drug Interactions (7) and Clinical Pharmacology (12.3)].
5.8 Cyanocobalamin (Vitamin B-12) Deficiency
5.8 Cyanocobalamin (Vitamin B-12) Deficiency Daily treatment with any acid-suppressing medications over a long period of time (e.g., longer than 3 years) may lead to malabsorption of cyanocobalamin (vitamin B-12) caused by hypo- or achlorhydria. Rare reports of cyanocobalamin deficiency occurring with acid-suppressing therapy have been reported in the literature.
This diagnosis should be considered if clinical symptoms consistent with cyanocobalamin deficiency are observed in patients treated with omeprazole.
5.9 Hypomagnesemia and Mineral Metabolism
5.9 Hypomagnesemia and Mineral Metabolism Hypomagnesemia,symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy. Serious adverse events include tetany, arrhythmias, and seizures. Hypomagnesemia may lead to hypocalcemia and/or hypokalemia and may exacerbate underlying hypocalcemia in at-risk patients.
In most patients, treatment of hypomagnesemia required magnesium replacement and discontinuation of the PPI. For patientsexpected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2)].
Consider monitoringmagnesium and calcium levels prior to initiation of omeprazole and periodically while on treatment in patients with a preexisting risk of hypocalcemia (e.g., hypoparathyroidism). Supplement with magnesium and/or calcium, as necessary. If hypocalcemia is refractory to treatment, consider discontinuing the PPI.
5.10 Interaction with St
5.10 Interaction with St. John's Wort or Rifampin Drugs which induce CYP2C19 or CYP3A4 (such as St. John’s Wort or rifampin) can substantially decrease omeprazole concentrations [see Drug Interactions (7)]. Avoid concomitant use of omeprazole with St. John’s Wort or rifampin.
5.11 Interactions with Diagnostic Investigations for Neuroendocrine Tumors
5.11 Interactions with Diagnostic Investigations for Neuroendocrine Tumors Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors. Healthcare providers should temporarily stop omeprazole treatment at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high.
If serial tests are performed (e.g., for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary [see Drug Interactions (7)].
5.12 Interaction with Methotrexate
5.12 Interaction with Methotrexate Literature suggests that concomitant use of PPIs with methotrexate (primarily at high dose) may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. In high-dose methotrexate administration a temporary withdrawal of the PPI may be considered in some patients [see Drug Interactions (7)].
5.13 Fundic Gland Polyps
5.13 Fundic Gland Polyps PPI use is associated with an increased risk of fundic gland polyps that increases with long-term use, especially beyond one year. Most PPI users who developed fundic gland polyps were asymptomatic and fundic gland polyps were identified incidentally on endoscopy. Use the shortest duration of PPI therapy appropriate to the condition being treated.
Drug interactions
Drug interactions (US label) US FDA label
7 DRUG INTERACTIONS Tables 3 and 4 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with omeprazole and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs.
Table 3: Clinically Relevant Interactions Affecting Drugs Co-Administered with Omeprazole and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology (12.3)].
Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with omeprazole may increase toxicity [see Clinical Pharmacology (12.3)]. There are other antiretroviral drugs which do not result in clinically relevant interactions with omeprazole. Intervention: Rilpivirine-containing products: Concomitant use with omeprazole is contraindicated [see Contraindications (4)].
Atazanavir: Avoid concomitant use with omeprazole. See prescribing information for atazanavir for dosing information. Nelfinavir: Avoid concomitant use with omeprazole. See prescribing information for nelfinavir. Saquinavir: See the prescribing information for saquinavir for monitoring of potential saquinavir-related toxicities.
Other antiretrovirals: See prescribing information for specific antiretroviral drugs. Warfarin Clinical Impact: Increased INR and prothrombin time in patients receiving PPIs, including omeprazole, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Intervention: Monitor INR and prothrombin time and adjust the dose of warfarin, if needed, to maintain target INR range.
Methotrexate Clinical Impact: Concomitant use of omeprazole with methotrexate (primarily at high dose) may elevate and prolong serum concentrations of methotrexate and/or its metabolite hydroxymethotrexate, possibly leading to methotrexate toxicities. No formal drug interaction studies of high-dose methotrexate with PPIs have been conducted [see Warnings and Precautions (5.12)].
Intervention: A temporary withdrawal of omeprazole may be considered in some patients receiving high-dose methotrexate. CYP2C19 Substrates (e.g., clopidogrel, citalopram, cilostazol, phenytoin, diazepam) Clopidogrel Clinical Impact: Concomitant use of omeprazole 80 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition [see Clinical Pharmacology (12.3)].
There are no adequate combination studies of a lower dose of omeprazole or a higher dose of clopidogrel in comparison with the approved dose of clopidogrel. Intervention: Avoid concomitant use with omeprazole. Consider use of alternative anti-platelet therapy [see Warnings and Precautions (5.7)]. Citalopram Clinical Impact: Increased exposure of citalopram leading to an increased risk of QT prolongation [see Clinical Pharmacology (12.3)].
Intervention: Limit the dose of citalopram to a maximum of 20 mg per day. See prescribing information for citalopram. Cilostazol Clinical Impact: Increased exposure of one of the active metabolites of cilostazol (3,4-dihydro-cilostazol) [see Clinical Pharmacology (12.3)]. Intervention: Reduce the dose of cilostazol to 50 mg twice daily.
See prescribing information for cilostazol. Phenytoin Clinical Impact: Potential for increased exposure of phenytoin. Intervention: Monitor phenytoin serum concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations. See prescribing information for phenytoin. Diazepam Clinical Impact: Increased exposure of diazepam [see Clinical Pharmacology (12.3)].
Intervention: Monitor patients for increased sedation and reduce the dose of diazepam as needed. Digoxin Clinical Impact: Potential for increased exposure of digoxin [see Clinical Pharmacology (12.3)]. Intervention: Monitor digoxin concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations. See digoxin prescribing information.
Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.
The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving omeprazole and MMF. Use omeprazole with caution in transplant patients receiving MMF [see Clinical Pharmacology (12.3)]. See the prescribing information for other drugs dependent on gastric pH for absorption.
Combination Therapy with Clarithromycin and Amoxicillin Clinical Impact: Concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions, including potentially fatal arrhythmias, and are contraindicated. Amoxicillin also has drug interactions. Intervention: See Contraindications, Warnings and Precautions in prescribing information for clarithromycin.
See Drug Interactions in prescribing information for amoxicillin. Tacrolimus Clinical Impact: Potential for increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19. Intervention: Monitor tacrolimus whole blood concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations.
See prescribing information for tacrolimus. Interactions with Investigations of Neuroendocrine Tumors Clinical Impact: Serum chromogranin A (CgA) levels increase secondary to PPI-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors [see Warnings and Precautions (5.11), Clinical Pharmacology (12.2)].
Intervention: Temporarily stop omeprazole treatment at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g., for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary. Interaction with Secretin Stimulation Test Clinical Impact: Hyper-response in gastrin secretion in response to secretin stimulation test, falsely suggesting gastrinoma.
Intervention: Temporarily stop omeprazole treatment at least 14 days before assessing to allow gastrin levels to return to baseline [see Clinical Pharmacology (12.2)]. False Positive Urine Tests for THC Clinical Impact: There have been reports of false positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving PPIs.
Intervention: An alternative confirmatory method should be considered to verify positive results. Other Clinical Impact: There have been clinical reports of interactions with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram). Intervention: Monitor patients to determine if it is necessary to adjust the dosage of these other drugs when taken concomitantly with omeprazole.
Table 4: Clinically Relevant Interactions Affecting Omeprazole When Co-Administered with Other Drugs CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of omeprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3)]. Intervention: St. John’s Wort, rifampin: Avoid concomitant use with omeprazole [see Warnings and Precautions (5.10)].
Ritonavir-containing products: see prescribing information for specific drugs. CYP2C19 or CYP3A4 Inhibitors Clinical Impact: Increased exposure of omeprazole [see Clinical Pharmacology (12.3)]. Intervention: Voriconazole: Dose adjustment of omeprazole is not normally required. However, in patients with Zollinger-Ellison syndrome, who may require higher doses, dose adjustment may be considered.
See prescribing information for voriconazole. See full prescribing information for a list of clinically important drug interactions. (7)
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
12.3 Pharmacokinetics Omeprazole is a time-dependent inhibitor of CYP2C19, resulting in autoinhibition and nonlinear pharmacokinetics.
The major part of its metabolism is dependent on the polymorphically expressed CYP2C19, responsible for the formation of hydroxyomeprazole, the major metabolite in plasma.
The remaining part is dependent on another specific isoform, CYP3A4, responsible for the formation of omeprazole sulphone.
Drug Interaction Studies Effect of Omeprazole on Other Drugs Omeprazole is a time-dependent inhibitor of CYP2C19 and can increase the systemic exposure of co-administered drugs that are CYP2C19 substrates.
Cilostazol Omeprazole acts as an inhibitor of CYP2C19.
Effect of Other Drugs on Omeprazole Voriconazole Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure.
CYP2C19 Substrates (e.g., clopidogrel, citalopram, cilostazol, phenytoin, diazepam) Clopidogrel Clinical Impact: Concomitant use of omeprazole 80 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition [see Clinical Pharmacology ( 12.3 )].
Tacrolimus Clinical Impact: Potential for increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19 .
Adverse reactions
- The following serious adverse reactions are described below and elsewhere in labeling: Acute Tubulointerstitial Nephritis [see Warnings and Precautions (5.2)] Clostridium difficile -Associated Diarrhea [see Warnings and Precautions (5.3)] Bone Fracture [see Warnings and Precautions (5.4)] Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.5)]. Cutaneous and Systemic Lupus Erythematosus [see Warnings and Precautions (5.6)] Cyanocobalamin (Vitamin B-12) Deficiency [see Warnings and Precautions (5.8)] Hypomagnesemia and Mineral Metabolism [see Warnings and Precautions (5.9)] Fundic Gland Polyps [see Warnings and Precautions (5.13)] Adults: Most common adverse reactions in adults (incidence ≥2%) are Headache, abdominal pain, nausea, diarrhea, vomiting, and flatulence. (6) Pediatric patients (2 to 16 years of age): Safety profile similar to that in adults, except that respiratory system events and fever were the most frequently reported reactions in pediatric studies. (8.4)
- To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience with Omeprazole Monotherapy
6.1 Clinical Trials Experience with Omeprazole Monotherapy Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety data described below reflects exposure to omeprazole delayed-release capsules in 3096 patients from worldwide clinical trials (465 patients from US studies and 2,631 patients from international studies).
Indications clinically studied in US trials included duodenal ulcer, resistant ulcer, and Zollinger-Ellison syndrome. The international clinical trials were double blind and open-label in design. The most common adverse reactions reported (i.e., with an incidence rate ≥2%) from omeprazole-treated patients enrolled in these studies included headache (7%), abdominal pain (5%), nausea (4%), diarrhea (4%), vomiting (3%), and flatulence (3%).
Additional adverse reactions that were reported with an incidence ≥1% included acid regurgitation (2%), upper respiratory infection (2%), constipation (2%), dizziness (2%), rash (2%), asthenia (1%), back pain (1%), and cough (1%). The clinical trial safety profile in patients greater than 65 years of age was similar to that in patients 65 years of age or less.
The clinical trial safety profile in pediatric patients who received omeprazole delayed-release capsules was similar to that in adult patients. Unique to the pediatric population, however, adverse reactions of the respiratory system were frequently reported in the 2 to 16 year age group (19%). In addition, accidental injuries were frequently reported in the 2 to 16 year age group (4%) [see Use in Specific Populations (8.4)].
6.2 Clinical Trials Experience with Omeprazole in Combination Therapy for H
6.2 Clinical Trials Experience with Omeprazole in Combination Therapy for H. pylori Eradication In clinical trials using either dual therapy with omeprazole and clarithromycin, or triple therapy with omeprazole, clarithromycin, and amoxicillin, no adverse reactions unique to these drug combinations were observed. Adverse reactions observed were limited to those previously reported with omeprazole, clarithromycin, or amoxicillin alone.
Dual Therapy (omeprazole/clarithromycin) Adverse reactions observed in controlled clinical trials using combination therapy with omeprazole and clarithromycin (n = 346) that differed from those previously described for omeprazole alone were taste perversion (15%), tongue discoloration (2%), rhinitis (2%), pharyngitis (1%) and flu-syndrome (1%). (For more information on clarithromycin, refer to the clarithromycin prescribing information, Adverse Reactions section.) Triple Therapy (omeprazole/clarithromycin/amoxicillin) The most frequent adverse reactions observed in clinical trials using combination therapy with omeprazole, clarithromycin, and amoxicillin (n = 274) were diarrhea (14%), taste perversion (10%), and headache (7%).
None of these occurred at a higher frequency than that reported by patients taking antimicrobial agents alone. (For more information on clarithromycin or amoxicillin, refer to the respective prescribing information, Adverse Reactions sections.)
6.3 Postmarketing Experience
6.3 Postmarketing Experience The following adverse reactions have been identified during post-approval use of omeprazole. Because these reactions are voluntarily reported from a population of uncertain size, it is not always possible to reliably estimate their actual frequency or establish a causal relationship to drug exposure.
Body As a Whole: Hypersensitivity reactions including anaphylaxis, anaphylactic shock, angioedema, bronchospasm, interstitial nephritis, urticaria, (see also Skin below); fever; pain; fatigue; malaise; systemic lupus erythematosus Cardiovascular: Chest pain or angina, tachycardia, bradycardia, palpitations, elevated blood pressure, peripheral edema Endocrine: Gynecomastia Gastrointestinal: Pancreatitis (some fatal), anorexia, irritable colon, fecal discoloration, esophageal candidiasis, mucosal atrophy of the tongue, stomatitis, abdominal swelling, dry mouth, microscopic colitis, fundic gland polyps. Gastroduodenal carcinoids have been reported in patients with ZE syndrome on long-term treatment with omeprazole.
This finding is believed to be a manifestation of the underlying condition, which is known to be associated with such tumors. Hepatic: Liver disease including hepatic failure (some fatal), liver necrosis (some fatal), hepatic encephalopathy hepatocellular disease, cholestatic disease, mixed hepatitis, jaundice, and elevations of liver function tests [ALT, AST, GGT, alkaline phosphatase, and bilirubin] Infections and Infestations: Clostridium difficile- associated diarrhea Metabolism and Nutritional disorders: Hypoglycemia, hypomagnesemia, with or without hypocalcemia and/or hypokalemia [see Warnings and Precautions (5.9)], hyponatremia, weight gain Musculoskeletal: Muscle weakness, myalgia, muscle cramps, joint pain, leg pain, bone fracture Nervous System/Psychiatric: Psychiatric and sleep disturbances including depression, agitation, aggression, hallucinations, confusion, insomnia, nervousness, apathy, somnolence, anxiety, and dream abnormalities; tremors, paresthesia; vertigo Respiratory: Epistaxis, pharyngeal pain Skin: Severe generalized skin reactions including toxic epidermal necrolysis (some fatal), Stevens-Johnson syndrome, cutaneous lupus erythematosus and erythema multiforme; photosensitivity; urticaria; rash; skin inflammation; pruritus; petechiae; purpura; alopecia; dry skin; hyperhidrosis Special Senses: Tinnitus, taste perversion Ocular: Optic atrophy, anterior ischemic optic neuropathy, optic neuritis, dry eye syndrome, ocular irritation, blurred vision, double vision Urogenital: Interstitial nephritis, hematuria, proteinuria, elevated serum creatinine, microscopic pyuria, urinary tract infection, glycosuria, urinary frequency, testicular pain, erectile dysfunction Hematologic: Agranulocytosis (some fatal), hemolytic anemia, pancytopenia, neutropenia, anemia, thrombocytopenia, leukopenia, leukocytosis
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with omeprazole in pregnant women. Available epidemiologic data fail to demonstrate an increased risk of major congenital malformations or other adverse pregnancy outcomes with first trimester omeprazole use. Reproduction studies in rats and rabbits resulted in dose-dependent embryo-lethality at omeprazole doses that were approximately 3.4 to 34 times an oral human dose of 40 mg (based on a body surface area for a 60 kg person).
Teratogenicity was not observed in animal reproduction studies with administration of oral esomeprazole (an enantiomer of omeprazole) magnesium in rats and rabbits during organogenesis with doses about 68 times and 42 times, respectively, an oral human dose of 40 mg esomeprazole or 40 mg omeprazole (based on body surface area for a 60 kg person). Changes in bone morphology were observed in offspring of rats dosed through most of pregnancy and lactation at doses equal to or greater than approximately 34 times an oral human dose of 40 mg esomeprazole or 40 mg omeprazole.
When maternal administration was confined to gestation only, there were no effects on bone physeal morphology in the offspring at any age [see Data]. The estimated background risks of major birth defects and miscarriage for the indicated population are unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Human Data Four published epidemiological studies compared the frequency of congenital abnormalities among infants born to women who used omeprazole during pregnancy with the frequency of abnormalities among infants of women exposed to H 2 -receptor antagonists or other controls.
A population-based retrospective cohort epidemiological study from the Swedish Medical Birth Registry, covering approximately 99% of pregnancies, from 1995 to 99, reported on 955 infants (824 exposed during the first trimester with 39 of these exposed beyond first trimester, and 131 exposed after the first trimester) whose mothers used omeprazole during pregnancy. The number of infants exposed in utero to omeprazole that had any malformation, low birth weight, low Apgar score, or hospitalization was similar to the number observed in this population.
The number of infants born with ventricular septal defects and the number of stillborn infants was slightly higher in the omeprazole-exposed infants than the expected number in this population. A population-based retrospective cohort study covering all live births in Denmark from 1996 to 2009, reported on 1,800 live births whose mothers used omeprazole during the first trimester of pregnancy and 837,317 live births whose mothers did not use any proton pump inhibitor.
The overall rate of birth defects in infants born to mothers with first trimester exposure to omeprazole was 2.9% and 2.6% in infants born to mothers not exposed to any proton pump inhibitor during the first trimester. A retrospective cohort study reported on 689 pregnant women exposed to either H 2 -blockers or omeprazole in the first trimester (134 exposed to omeprazole) and 1,572 pregnant women unexposed to either during the first trimester.
The overall malformation rate in offspring born to mothers with first trimester exposure to omeprazole, an H 2 -blocker, or were unexposed was 3.6%, 5.5%, and 4.1% respectively. A small prospective observational cohort study followed 113 women exposed to omeprazole during pregnancy (89% with first trimester exposures). The reported rate of major congenital malformations was 4% in the omeprazole group, 2% in controls exposed to non-teratogens, and 2.8% in disease-paired controls.
Rates of spontaneous and elective abortions, preterm deliveries, gestational age at delivery, and mean birth weight were similar among the groups. Several studies have reported no apparent adverse short-term effects on the infant when single dose oral or intravenous omeprazole was administered to over 200 pregnant women as premedication for cesarean section under general anesthesia.
Animal Data Omeprazole Reproductive studies conducted with omeprazole in rats at oral doses up to 138 mg/kg/day (about 34 times an oral human dose of 40 mg on a body surface area basis) and in rabbits at doses up to 69.1 mg/kg/day (about 34 times an oral human dose of 40 mg on a body surface area basis) during organogenesis did not disclose any evidence for a teratogenic potential of omeprazole. In rabbits, omeprazole in a dose range of 6.9 to 69.1 mg/kg/day (about 3.4 to 34 times an oral human dose of 40 mg on a body surface area basis) administered during organogenesis produced dose-related increases in embryo-lethality, fetal resorptions, and pregnancy disruptions.
In rats, dose-related embryo/fetal toxicity and postnatal developmental toxicity were observed in offspring resulting from parents treated with omeprazole at 13.8 to 138 mg/kg/day (about 3.4 to 34 times an oral human doses of 40 mg on a body surface area basis), administered prior to mating through the lactation period. Esomeprazole The data described below was generated from studies using esomeprazole, an enantiomer of omeprazole.
The animal to human dose multiples are based on the assumption of equal systemic exposure to esomeprazole in humans following oral administration of either 40 mg esomeprazole or 40 mg omeprazole. No effects on embryo-fetal development were observed in reproduction studies with esomeprazole magnesium in rats at oral doses up to 280 mg/kg/day (about 68 times an oral human dose of 40 mg on a body surface area basis) or in rabbits at oral doses up to 86 mg/kg/day (about 42 times an oral human dose of 40 mg esomeprazole or 40 mg omeprazole on a body surface area basis) administered during organogenesis.
A pre- and postnatal developmental toxicity study in rats with additional endpoints to evaluate bone development was performed with esomeprazole magnesium at oral doses of 14 to 280 mg/kg/day (about 3.4 to 68 times an oral human dose of 40 mg esomeprazole or 40 mg omeprazole on a body surface area basis). Neonatal/early postnatal (birth to weaning) survival was decreased at doses equal to or greater than 138 mg/kg/day (about 34 times an oral human dose of 40 mg esomeprazole or 40 mg omeprazole on a body surface area basis).
Body weight and body weight gain were reduced and neurobehavioral or general developmental delays in the immediate post-weaning timeframe were evident at doses equal to or greater than 69 mg/kg/day (about 17 times an oral human dose of 40 mg esomeprazole or 40 mg omeprazole on a body surface area basis). In addition, decreased femur length, width and thickness of cortical bone, decreased thickness of the tibial growth plate and minimal to mild bone marrow hypocellularity were noted at doses equal to or greater than 14 mg/kg/day (about 3.4 times an oral human dose of 40 mg esomeprazole or 40 mg omeprazole on a body surface area basis).
Physeal dysplasia in the femur was observed in offspring of rats treated with oral doses of esomeprazole magnesium at doses equal to or greater than 138 mg/kg/day (about 34 times an oral human dose of 40 mg esomeprazole or 40 mg omeprazole on a body surface area basis). Effects on maternal bone were observed in pregnant and lactating rats in the pre- and postnatal toxicity study when esomeprazole magnesium was administered at oral doses of 14 to 280 mg/kg/day (about 3.4 to 68 times an oral human dose of 40 mg esomeprazole or 40 mg omeprazole on a body surface area basis).
When rats were dosed from gestational day 7 through weaning on postnatal day 21, a statistically significant decrease in maternal femur weight of up to 14% (as compared to placebo treatment) was observed at doses equal to or greater than 138 mg/kg/day (about 34 times an oral human dose of 40 mg esomeprazole or 40 mg omeprazole on a body surface area basis). A pre- and postnatal development study in rats with esomeprazole strontium (using equimolar doses compared to esomeprazole magnesium study) produced similar results in dams and pups as described above.
A follow up developmental toxicity study in rats with further time points to evaluate pup bone development from postnatal day 2 to adulthood was performed with esomeprazole magnesium at oral doses of 280 mg/kg/day (about 68 times an oral human dose of 40 mg on a body surface area basis) where esomeprazole administration was from either gestational day 7 or gestational day 16 until parturition. When maternal administration was confined to gestation only, there were no effects on bone physeal morphology in the offspring at any age.
Mechanism of action
12.1 Mechanism of Action Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H + /K + ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production.
This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Antisecretory Activity After oral administration, the onset of the antisecretory effect of omeprazole occurs within one hour, with the maximum effect occurring within two hours. Inhibition of secretion is about 50% of maximum at 24 hours and the duration of inhibition lasts up to 72 hours. The antisecretory effect thus lasts far longer than would be expected from the very short (less than one hour) plasma half-life, apparently due to prolonged binding to the parietal H + /K + ATPase enzyme.
When the drug is discontinued, secretory activity returns gradually, over 3 to 5 days. The inhibitory effect of omeprazole on acid secretion increases with repeated once-daily dosing, reaching a plateau after four days. Results from numerous studies of the antisecretory effect of multiple doses of 20 mg and 40 mg of omeprazole in healthy subjects and patients are shown below.
The “max” value represents determinations at a time of maximum effect (2 to 6 hours after dosing), while “min” values are those 24 hours after the last dose of omeprazole. Table 5: Range of Mean Values from Multiple Studies of the Mean Antisecretory Effects of Omeprazole After Multiple Daily Dosing Omeprazole 20 mg Omeprazole 40 mg Parameter Max Min Max Min % Decrease in Basal Acid Output 78 1 58 to 80 94 1 80 to 93 % Decrease in Peak Acid Output 79 1 50 to 59 88 1 62 to 68 % Decrease in 24-hr.
Intragastric Acidity 80 to 97 92 to 94 1 Single Studies Single daily oral doses of omeprazole ranging from a dose of 10 mg to 40 mg have produced 100% inhibition of 24-hour intragastric acidity in some patients. Serum Gastrin Effects In studies involving more than 200 patients, serum gastrin levels increased during the first 1 to 2 weeks of once-daily administration of therapeutic doses of omeprazole in parallel with inhibition of acid secretion.
No further increase in serum gastrin occurred with continued treatment. In comparison with histamine H 2 -receptor antagonists, the median increases produced by 20 mg doses of omeprazole were higher (1.3 to 3.6 fold vs. 1.1 to 1.8 fold increase). Gastrin values returned to pretreatment levels, usually within 1 to 2 weeks after discontinuation of therapy.
Increased gastrin causes enterochromaffin-like cell hyperplasia and increased serum Chromogranin A (CgA) levels. The increased CgA levels may cause false positive results in diagnostic investigations for neuroendocrine tumors [see Warnings and Precautions (5.11)]. Enterochromaffin-like (ECL) Cell Effects Human gastric biopsy specimens have been obtained from more than 3000 patients (both children and adults) treated with omeprazole in long-term clinical trials.
The incidence of ECL cell hyperplasia in these studies increased with time; however, no case of ECL cell carcinoids, dysplasia, or neoplasia has been found in these patients. However, these studies are of insufficient duration and size to rule out the possible influence of long-term administration of omeprazole on the development of any premalignant or malignant conditions.
Other Effects Systemic effects of omeprazole in the CNS, cardiovascular and respiratory systems have not been found to date. Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
No effect on gastric emptying of the solid and liquid components of a test meal was demonstrated after a single dose of omeprazole 90 mg. In healthy subjects, a single intravenous dose of omeprazole (0.35 mg/kg) had no effect on intrinsic factor secretion. No systematic dose-dependent effect has been observed on basal or stimulated pepsin output in humans.
However, when intragastric pH is maintained at 4 or above, basal pepsin output is low, and pepsin activity is decreased. As do other agents that elevate intragastric pH, omeprazole administered for 14 days in healthy subjects produced a significant increase in the intragastric concentrations of viable bacteria. The pattern of the bacterial species was unchanged from that commonly found in saliva.
All changes resolved within three days of stopping treatment. The course of Barrett’s esophagus in 106 patients was evaluated in a U.S. double-blind controlled study of omeprazole 40 mg twice daily for 12 months followed by 20 mg twice daily for 12 months or ranitidine 300 mg twice daily for 24 months. No clinically significant impact on Barrett’s mucosa by antisecretory therapy was observed.
Although neosquamous epithelium developed during antisecretory therapy, complete elimination of Barrett’s mucosa was not achieved. No significant difference was observed between treatment groups in development of dysplasia in Barrett’s mucosa and no patient developed esophageal carcinoma during treatment. No significant differences between treatment groups were observed in development of ECL cell hyperplasia, corpus atrophic gastritis, corpus intestinal metaplasia, or colon polyps exceeding 3 mm in diameter.
Pharmacokinetics
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
Excretion Following single dose oral administration of a buffered solution of omeprazole, little if any unchanged drug was excreted in urine.
The majority of the dose (about 77%) was eliminated in urine as at least six metabolites.
This implies a significant biliary excretion of the metabolites of omeprazole.
The plasma clearance of omeprazole was 250 mL/min (about half that of young volunteers) and its plasma half-life averaged one hour, about twice that of young healthy volunteers.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Omeprazole is a time-dependent inhibitor of CYP2C19, resulting in autoinhibition and nonlinear pharmacokinetics. The systemic exposure increases in a more than dose proportional manner after multiple oral doses of omeprazole. Compared to the first dose, the systemic exposure (C max and AUC 0-24h) at steady state following once a day dosing increased by 61% and 62%, respectively, compared to after the first dose for the 20 mg dose of omeprazole delayed-release capsules and increased by 118% and 175%, respectively, for the 40 mg dose of omeprazole delayed-release capsules.
Absorption Omeprazole delayed-release capsules contain an enteric-coated granule formulation of omeprazole (because omeprazole is acid-labile), so that absorption of omeprazole begins only after the granules leave the stomach. Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
Peak plasma concentrations of omeprazole and AUC are approximately proportional to doses up to 40 mg, but because of a saturable first-pass effect, a greater than linear response in peak plasma concentration and AUC occurs with doses greater than 40 mg. Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min. Based on a relative bioavailability study, the AUC and C max of omeprazole for delayed-release oral suspension were 87% and 88% of those for omeprazole delayed-release capsules, respectively. The bioavailability of omeprazole increases slightly upon repeated administration of omeprazole delayed-release capsules.
The systemic exposure (C max and AUC) are similar when a 40 mg omeprazole delayed-release capsule is administered with and without applesauce. However, administration of a 20 mg omeprazole delayed-release capsule with applesauce, results in a mean 25% reduction in C max without a significant change in AUC compared to administration without applesauce.
The clinical relevance of this finding is unknown. Distribution Protein binding is approximately 95%. Elimination Metabolism Omeprazole is extensively metabolized by the cytochrome P450 (CYP) enzyme system. The major part of its metabolism is dependent on the polymorphically expressed CYP2C19, responsible for the formation of hydroxyomeprazole, the major metabolite in plasma.
The remaining part is dependent on another specific isoform, CYP3A4, responsible for the formation of omeprazole sulphone. Excretion Following single dose oral administration of a buffered solution of omeprazole, little if any unchanged drug was excreted in urine. The majority of the dose (about 77%) was eliminated in urine as at least six metabolites.
Two were identified as hydroxyomeprazole and the corresponding carboxylic acid. The remainder of the dose was recoverable in feces. This implies a significant biliary excretion of the metabolites of omeprazole. Three metabolites have been identified in plasma the sulfide and sulfone derivatives of omeprazole, and hydroxyomeprazole.
These metabolites have very little or no antisecretory activity. Combination Therapy with Antimicrobials Omeprazole 40 mg daily was given in combination with clarithromycin 500 mg every 8 hours to healthy adult male subjects. The steady state plasma concentrations of omeprazole were increased (C max, AUC 0-24, and T 1/2 increases of 30%, 89% and 34% respectively) by the concomitant administration of clarithromycin.
The observed increases in omeprazole plasma concentration were associated with the following pharmacological effects. The mean 24‑hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when co-administered with clarithromycin. The plasma concentrations of clarithromycin and 14-hydroxy-clarithromycin were increased by the concomitant administration of omeprazole.
For clarithromycin, the mean C max was 10% greater, the mean C min was 27% greater, and the mean AUC 0-8 was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone. Similar results were seen for 14-hydroxy-clarithromycin, the mean C max was 45% greater, the mean C min was 57% greater, and the mean AUC 0-8 was 45% greater.
Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole. Table 6: Clarithromycin Tissue Concentrations 2 hours after Dose 1 Tissue Clarithromycin Clarithromycin + Omeprazole Antrum 10.48 ± 2.01 (n = 5) 19.96 ± 4.71 (n = 5) Fundus 20.81 ± 7.64 (n = 5) 24.25 ± 6.37 (n = 5) Mucus 4.15 ± 7.74 (n = 4) 39.29 ± 32.79 (n = 4) 1 Mean ± SD (mcg/g) Specific Populations Age: Geriatric Population The elimination rate of omeprazole was somewhat decreased in the elderly, and bioavailability was increased.
Omeprazole was 76% bioavailable when a single 40 mg oral dose of omeprazole (buffered solution) was administered to healthy elderly volunteers, versus 58% in young volunteers given the same dose. Nearly 70% of the dose was recovered in urine as metabolites of omeprazole and no unchanged drug was detected. The plasma clearance of omeprazole was 250 mL/min (about half that of young volunteers) and its plasma half-life averaged one hour, about twice that of young healthy volunteers.
Age: Pediatric Population 2 to 16 Years of Age The pharmacokinetics of omeprazole have been investigated in pediatric patients 2 to 16 years of age: Table 7: Pharmacokinetic Parameters of Omeprazole Following Single and Repeated Oral Administration in Pediatric Populations Compared with Adults Single or Repeated Oral Dosing/Parameter Children 1 ≤ 20 kg 2 to 5 years 10 mg Children 1 > 20 kg 6 to 16 years 20 mg Adults 2 (mean 76 kg) 23 to 29 years (n=12) Single Dosing C max 3 (ng/mL) 288 (n=10) 495 (n=49) 668 AUC 3 (ng h/mL) 511 (n=7) 1140 (n=32) 1220 Repeated Dosing C max 3 (ng/mL) 539 (n=4) 851 (n=32) 1458 AUC 3 (ng h/mL) 1179 (n=2) 2276 (n=23) 3352 1 Data from single and repeated dose studies. Doses of 10, 20 and 40 mg omeprazole as enteric-coated granules. 2 Data from a single and repeated dose study.
Doses of 10, 20 and 40 mg omeprazole as enteric-coated granules. 3 Plasma concentration adjusted to an oral dose of 1 mg/kg. Following comparable mg/kg doses of omeprazole, younger children (2 to 5 years of age) have lower AUCs than children 6 to 16 years of age or adults; AUCs of the latter two groups did not differ [see Dosage and Administration (2)].
Race/Ethnicity [See Clinical Pharmacology (12.5)]. Renal Impairment In patients with chronic renal impairment (creatinine clearance between 10 and 62 mL/min/1.73 m²), the disposition of omeprazole was very similar to that in healthy subjects, although there was a slight increase in bioavailability. Because urinary excretion is a primary route of excretion of omeprazole metabolites, their elimination slowed in proportion to the decreased creatinine clearance.
This increase in bioavailability is not considered to be clinically meaningful. Hepatic Impairment In patients with chronic hepatic disease classified as Child-Pugh Class A (n=3), B (n=4) and C (n=1), the bioavailability increased to approximately 100% compared to healthy subjects, reflecting decreased first-pass effect, and the plasma half- life of the drug increased to nearly 3 hours compared with the half-life in healthy subjects of 0.5 to 1 hour.
Plasma clearance averaged 70 mL/min, compared with a value of 500 to 600 mL/min in healthy subjects [see Dosage and Administration (2.1), Use in Specific Populations (8.6)]. Drug Interaction Studies Effect of Omeprazole on Other Drugs Omeprazole is a time-dependent inhibitor of CYP2C19 and can increase the systemic exposure of co-administered drugs that are CYP2C19 substrates.
In addition, administration of omeprazole increases intragastric pH and can alter the systemic exposure of certain drugs that exhibit pH-dependent solubility. Antiretrovirals For some antiretroviral drugs, such as rilpivirine, atazanavir and nelfinavir, decreased serum concentrations have been reported when given together with omeprazole [see Drug Interactions (7)].
Rilpivirine: Following multiple doses of rilpivirine (150 mg, daily) and omeprazole (20 mg, daily), AUC was decreased by 40%, C max by 40%, and C min by 33% for rilpivirine. Nelfinavir: Following multiple doses of nelfinavir (1250 mg, twice daily) and omeprazole (40 mg daily), AUC was decreased by 36% and 92%, C max by 37% and 89% and C min by 39% and 75% respectively for nelfinavir and M8.
Atazanavir: Following multiple doses of atazanavir (400 mg, daily) and omeprazole (40 mg, daily, 2 hours before atazanavir), AUC was decreased by 94%, C max by 96%, and C min by 95%. Saquinavir: Following multiple dosing of saquinavir/ritonavir (1000/100 mg) twice daily for 15 days with omeprazole 40 mg daily co-administered days 11 to 15.
AUC was increased by 82%, C max by 75%, and C min by 106%. The mechanism behind this interaction is not fully elucidated. Therefore, clinical and laboratory monitoring for saquinavir toxicity is recommended during concurrent use with omeprazole. Clopidogrel In a crossover clinical study, 72 healthy subjects were administered clopidogrel (300 mg loading dose followed by 75 mg per day) alone and with omeprazole (80 mg at the same time as clopidogrel) for 5 days.
The exposure to the active metabolite of clopidogrel was decreased by 46% (Day 1) and 42% (Day 5) when clopidogrel and omeprazole were administered together. Results from another crossover study in healthy subjects showed a similar pharmacokinetic interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and omeprazole 80 mg daily when co-administered for 30 days.
Exposure to the active metabolite of clopidogrel was reduced by 41% to 46% over this time period. In another study, 72 healthy subjects were given the same doses of clopidogrel and 80 mg omeprazole but the drugs were administered 12 hours apart; the results were similar, indicating that administering clopidogrel and omeprazole at different times does not prevent their interaction [see Warnings and Precautions (5.7), Drug Interactions (7)].
Mycophenolate Mofetil Administration of omeprazole 20 mg twice daily for 4 days and a single 1000 mg dose of MMF approximately one hour after the last dose of omeprazole to 12 healthy subjects in a cross-over study resulted in a 52% reduction in the C max and 23% reduction in the AUC of MPA [see Drug Interactions (7)]. Cilostazol Omeprazole acts as an inhibitor of CYP2C19.
Omeprazole, given in doses of 40 mg daily for one week to 20 healthy subjects in cross-over study, increased C max and AUC of cilostazol by 18% and 26% respectively. The C max and AUC of one of the active metabolites, 3,4- dihydro-cilostazol, which has 4 to 7 times the activity of cilostazol, were increased by 29% and 69%, respectively.
Co-administration of cilostazol with omeprazole is expected to increase concentrations of cilostazol and the above mentioned active metabolite [see Drug Interactions (7)]. Diazepam Concomitant administration of omeprazole 20 mg once daily and diazepam 0.1 mg/kg given intravenously resulted in 27% decrease in clearance and 36% increase in diazepam half-life [see Drug Interactions (7)].
Digoxin Concomitant administration of omeprazole 20 mg once daily and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (30% in two subjects) [see Drug Interactions (7)]. Effect of Other Drugs on Omeprazole Voriconazole Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure.
When voriconazole (400 mg every 12 hours for one day, followed by 200 mg once daily for 6 days) was given with omeprazole (40 mg once daily for 7 days) to healthy subjects, the steady-state C max and AUC 0-24 of omeprazole significantly increased: an average of 2 times (90% CI: 1.8, 2.6) and 4 times (90% CI: 3.3, 4.4), respectively, as compared to when omeprazole was given without voriconazole [see Drug Interactions (7)].
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Omeprazole 20 mg Capsule | ₱0.68–₱12.00Reference ₱0.81 | per capsule | DPRI procurement range |
| Omeprazole 40 mg Capsule | ₱2.20–₱28.00Reference ₱4.23 | per capsule | DPRI procurement range |
| Omeprazole 40 mg powder vial + 10 mL solvent Ampule | ₱21.00–₱335.00Reference ₱24.78 | per ampule | DPRI procurement range |
| 20 mg capsule | ₱19.00 | per capsule | PhilHealth GAMOT fixed fee |
| 40 mg capsule | ₱27.50 | per capsule | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Omeprazole |
| PNF listing | Oral: 20 mg and 40 mg capsule |
| PNF listing | Inj.: powder, 40 mg vial + 10 mL solvent ampul/vial (IV) |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Omeprazole · Unit Dose Solutions, Inc. [US FDA-approved label, version 1, June 30, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=557d4c2c-5541-3a51-e063-6394a90ad278
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .
